{"PMC3539885": [["BackgroundIn Australia in 2009, an outstanding feature of the arrival of pandemic influenza caused by the A(H1N1)pdm09 virus was an apparently strong need for intensive care services among patients infected with the virus[1].", [["influenza", "DISEASE", 82, 91], ["A(H1N1)pdm09 virus", "ORGANISM", 106, 124], ["patients", "ORGANISM", 189, 197], ["H1N1)pdm09 virus", "SPECIES", 108, 124], ["patients", "SPECIES", 189, 197], ["A(H1N1)pdm09 virus", "SPECIES", 106, 124], ["pandemic influenza", "PROBLEM", 73, 91], ["the A(H1N1)pdm09 virus", "PROBLEM", 102, 124], ["intensive care services", "TREATMENT", 159, 182]]], ["A large number of reports have described the characteristics of intensive care patients with pandemic influenza both in Australasia[1-3] and internationally[4-6], but there has been little examination of the relative impact of the pandemic and seasonal influenza strains on use of intensive care.BackgroundIn the state of New South Wales (NSW), Australia (population 7 million) the 2009 epidemic associated with A(H1N1)pdm09 influenza subtype occurred during the usual winter influenza season, and had a single distinct peak[3].", [["influenza", "DISEASE", 102, 111], ["pandemic", "DISEASE", 231, 239], ["influenza", "DISEASE", 253, 262], ["influenza", "DISEASE", 425, 434], ["influenza", "DISEASE", 476, 485], ["patients", "ORGANISM", 79, 87], ["A(H1N1)pdm09", "ORGANISM", 412, 424], ["patients", "SPECIES", 79, 87], ["pandemic influenza", "PROBLEM", 93, 111], ["little examination", "TEST", 182, 200], ["the pandemic", "PROBLEM", 227, 239], ["seasonal influenza strains", "PROBLEM", 244, 270], ["intensive care", "TREATMENT", 281, 295], ["A(H1N1)pdm09 influenza subtype", "PROBLEM", 412, 442], ["large", "OBSERVATION_MODIFIER", 2, 7], ["New", "OBSERVATION_MODIFIER", 322, 325]]], ["Of 225 people admitted to intensive care in NSW with confirmed infection, 87% were aged under 65 years, and included 16 pregnant women and 14 Aboriginal people[3].", [["infection", "DISEASE", 63, 72], ["people", "ORGANISM", 7, 13], ["women", "ORGANISM", 129, 134], ["people", "ORGANISM", 153, 159], ["people", "SPECIES", 7, 13], ["women", "SPECIES", 129, 134], ["people", "SPECIES", 153, 159], ["infection", "PROBLEM", 63, 72], ["infection", "OBSERVATION", 63, 72]]], ["In 2009, there was also a high level of severe illness, as evidenced by the development of acute respiratory distress syndrome (ARDS), and the need for extracorporeal membrane oxygenation (ECMO)[9].BackgroundMost studies have focused on laboratory confirmed or suspected influenza A(H1N1)pdm09 infection, while no studies have attempted to estimate the overall contribution of influenza to use of intensive care over time.", [["respiratory", "ANATOMY", 97, 108], ["extracorporeal membrane", "ANATOMY", 152, 175], ["illness", "DISEASE", 47, 54], ["acute respiratory distress syndrome", "DISEASE", 91, 126], ["ARDS", "DISEASE", 128, 132], ["influenza A(H1N1)pdm09 infection", "DISEASE", 271, 303], ["influenza", "DISEASE", 377, 386], ["influenza A(H1N1)pdm09", "ORGANISM", 271, 293], ["influenza A(H1N1)pdm09", "SPECIES", 271, 293], ["severe illness", "PROBLEM", 40, 54], ["acute respiratory distress syndrome", "PROBLEM", 91, 126], ["ARDS", "PROBLEM", 128, 132], ["extracorporeal membrane oxygenation", "TREATMENT", 152, 187], ["influenza A(H1N1)pdm09 infection", "PROBLEM", 271, 303], ["studies", "TEST", 314, 321], ["influenza", "PROBLEM", 377, 386], ["intensive care", "TREATMENT", 397, 411], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["illness", "OBSERVATION", 47, 54], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory distress syndrome", "OBSERVATION", 97, 126], ["influenza", "OBSERVATION", 377, 386]]], ["Patients with influenza who require hospitalisation tend not to present with classic influenza-like illness (ILI), therefore relying on ILI presentations to identify patients suffering serious influenza infections or influenza-related complications is inadequate[10].", [["influenza", "DISEASE", 14, 23], ["influenza-like illness", "DISEASE", 85, 107], ["ILI", "DISEASE", 109, 112], ["influenza infections", "DISEASE", 193, 213], ["influenza", "DISEASE", 217, 226], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 166, 174], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 166, 174], ["influenza", "PROBLEM", 14, 23], ["classic influenza", "PROBLEM", 77, 94], ["serious influenza infections", "PROBLEM", 185, 213], ["influenza", "PROBLEM", 217, 226], ["related complications", "PROBLEM", 227, 248], ["influenza", "OBSERVATION", 85, 94]]], ["A substantial proportion of patients admitted to intensive care with pneumonia or respiratory infection are found to be positive for influenza, if an appropriate test is performed in a timely manner[11].", [["respiratory", "ANATOMY", 82, 93], ["pneumonia", "DISEASE", 69, 78], ["respiratory infection", "DISEASE", 82, 103], ["influenza", "DISEASE", 133, 142], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["pneumonia", "PROBLEM", 69, 78], ["respiratory infection", "PROBLEM", 82, 103], ["influenza", "PROBLEM", 133, 142], ["an appropriate test", "TEST", 147, 166], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["proportion", "OBSERVATION_MODIFIER", 14, 24], ["pneumonia", "OBSERVATION", 69, 78], ["respiratory", "ANATOMY", 82, 93], ["infection", "OBSERVATION", 94, 103]]], ["Broader definitions of influenza-associated illness are therefore required to estimate the full impact of influenza-related illness on health care utilisation[12,13].BackgroundFor the years 2007 to 2010, we used a population database of all hospital admissions in NSW, to estimate and compare the impact of recent seasonal and pandemic influenza epidemics on admissions to intensive care in the general population, in pregnant women, and in Aboriginal people.Data ::: MethodsThe NSW Admitted Patients Data Collection (APDC) consists of routinely collected data on all hospital separations (discharges, transfers and deaths) from all NSW public and private sector hospitals and day procedure centres.", [["influenza-associated illness", "DISEASE", 23, 51], ["influenza", "DISEASE", 106, 115], ["illness", "DISEASE", 124, 131], ["influenza", "DISEASE", 336, 345], ["deaths", "DISEASE", 616, 622], ["women", "ORGANISM", 427, 432], ["people", "ORGANISM", 452, 458], ["Patients", "ORGANISM", 492, 500], ["women", "SPECIES", 427, 432], ["people", "SPECIES", 452, 458], ["Patients", "SPECIES", 492, 500], ["influenza-associated illness", "PROBLEM", 23, 51], ["influenza", "PROBLEM", 106, 115], ["recent seasonal and pandemic influenza epidemics", "PROBLEM", 307, 355], ["Methods", "TREATMENT", 468, 475], ["influenza", "OBSERVATION", 23, 32], ["influenza", "OBSERVATION", 106, 115]]], ["The data include patient demographics, service referred to on separation, up to 50 primary and co-morbid diagnoses and up to 50 procedures applied during the admission episode.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["The diagnoses are recorded using the Australian modification of the International Statistical Classification of Diseases and Related Problems, 10th revision (ICD 10-AM).", [["Diseases", "PROBLEM", 112, 120], ["Related Problems", "PROBLEM", 125, 141], ["10th revision (ICD", "TREATMENT", 143, 161], ["Diseases", "OBSERVATION", 112, 120]]], ["All admissions in the APDC with an unplanned admission to an intensive care unit (ICU) during 2007 through 2010 inclusive were extracted for analysis.", [["analysis", "TEST", 141, 149]]], ["No identifiable information was used for this study and so ethics approval was not required.Outcomes ::: MethodsUsing diagnoses recorded for each admission, we considered three outcomes to assess the impact of influenza on intensive care admissions: influenza alone (ICD-10-AM J09 to J11), influenza or pneumonia (ICD-10-AM J09 to J18), and any respiratory illness (ICD-10-AM J00 to J99).", [["respiratory", "ANATOMY", 345, 356], ["influenza", "DISEASE", 210, 219], ["influenza", "DISEASE", 250, 259], ["influenza", "DISEASE", 290, 299], ["pneumonia", "DISEASE", 303, 312], ["ICD-10-AM J09 to J18", "DISEASE", 314, 334], ["respiratory illness", "DISEASE", 345, 364], ["this study", "TEST", 41, 51], ["ethics approval", "TREATMENT", 59, 74], ["influenza", "PROBLEM", 210, 219], ["influenza", "PROBLEM", 250, 259], ["ICD", "TEST", 267, 270], ["influenza", "PROBLEM", 290, 299], ["pneumonia", "PROBLEM", 303, 312], ["ICD", "TEST", 314, 317], ["any respiratory illness", "PROBLEM", 341, 364], ["ICD", "TEST", 366, 369], ["influenza", "OBSERVATION", 210, 219], ["pneumonia", "OBSERVATION", 303, 312], ["respiratory", "ANATOMY", 345, 356], ["illness", "OBSERVATION", 357, 364]]], ["To identify influenza and pneumonia, we used all primary and additional diagnoses.", [["influenza", "DISEASE", 12, 21], ["pneumonia", "DISEASE", 26, 35], ["influenza", "PROBLEM", 12, 21], ["pneumonia", "PROBLEM", 26, 35], ["influenza", "OBSERVATION", 12, 21], ["pneumonia", "OBSERVATION", 26, 35]]], ["The all respiratory category included all influenza and pneumonia diagnoses, as well as a primary diagnosis of any other respiratory illness.", [["respiratory", "ANATOMY", 121, 132], ["influenza", "DISEASE", 42, 51], ["pneumonia", "DISEASE", 56, 65], ["respiratory illness", "DISEASE", 121, 140], ["all influenza", "PROBLEM", 38, 51], ["pneumonia", "PROBLEM", 56, 65], ["any other respiratory illness", "PROBLEM", 111, 140], ["respiratory category", "OBSERVATION", 8, 28], ["influenza", "OBSERVATION", 42, 51], ["pneumonia", "OBSERVATION", 56, 65], ["respiratory", "ANATOMY", 121, 132], ["illness", "OBSERVATION", 133, 140]]], ["Pregnant/postpartum women were identified by the ICD-10 codes O09 to O99, and Z33 to Z37 in any primary or additional diagnosis.", [["women", "ORGANISM", 20, 25], ["women", "SPECIES", 20, 25]]], ["Greater than 95% of the NSW Indigenous population identify as Aboriginal.Outcomes ::: MethodsTo further assess the impact on intensive care, we determined the number of admissions with markers of severe illness, including respiratory failure, acute respiratory distress syndrome (ARDS), mechanical ventilation and extracorporeal membrane oxygenation (ECMO).", [["respiratory", "ANATOMY", 222, 233], ["respiratory", "ANATOMY", 249, 260], ["extracorporeal membrane", "ANATOMY", 314, 337], ["illness", "DISEASE", 203, 210], ["respiratory failure", "DISEASE", 222, 241], ["acute respiratory distress syndrome", "DISEASE", 243, 278], ["ARDS", "DISEASE", 280, 284], ["Methods", "TREATMENT", 86, 93], ["severe illness", "PROBLEM", 196, 210], ["respiratory failure", "PROBLEM", 222, 241], ["acute respiratory distress syndrome", "PROBLEM", 243, 278], ["ARDS", "PROBLEM", 280, 284], ["mechanical ventilation", "TREATMENT", 287, 309], ["extracorporeal membrane oxygenation", "TREATMENT", 314, 349], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["illness", "OBSERVATION", 203, 210], ["respiratory failure", "OBSERVATION", 222, 241], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["respiratory distress", "OBSERVATION", 249, 269], ["mechanical ventilation", "OBSERVATION", 287, 309], ["extracorporeal membrane oxygenation", "OBSERVATION", 314, 349]]], ["Respiratory failure (ICD-10-AM J96) and ARDS (ICD-10-AM J80) were identified using all diagnoses.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory failure", "DISEASE", 0, 19], ["ARDS", "DISEASE", 40, 44], ["Respiratory failure", "PROBLEM", 0, 19], ["ICD", "TREATMENT", 21, 24], ["ARDS", "PROBLEM", 40, 44], ["ICD", "TREATMENT", 46, 49], ["failure", "OBSERVATION", 12, 19], ["ARDS", "OBSERVATION", 40, 44]]], ["Mechanical ventilation and ECMO were identified using ACHI codes 13822\u201300, 13882\u201301, 13882\u201302, 13857\u201300 and 13879\u201300 for mechanical ventilation and 90225\u201300 for ECMO.", [["Mechanical ventilation", "TREATMENT", 0, 22], ["ECMO", "TREATMENT", 27, 31], ["mechanical ventilation", "TREATMENT", 121, 143], ["ECMO", "TREATMENT", 161, 165], ["ventilation", "OBSERVATION", 11, 22]]], ["The median hours spent in intensive care and the proportion of patients who died during their ICU stay were also determined, using information recorded in the hospitalisation data.Data analysis ::: MethodsAnalysis was restricted to NSW residents only.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Data analysis", "TEST", 180, 193]]], ["Weekly counts of intensive care admissions for all outcomes were calculated for the study period, and weekly rates were then calculated using estimated resident populations linearly interpolated from mid-year estimates[14] and from year end projections for Aboriginal people[15].", [["people", "SPECIES", 268, 274], ["the study", "TEST", 80, 89]]], ["To estimate the population of pregnant/postpartum women at risk during each influenza period, first the number of women who were pregnant in a year was calculated by multiplying the total number of confinements in that year[16] by 40/52, as an average pregnancy lasts 40 weeks.", [["women", "ORGANISM", 50, 55], ["women", "ORGANISM", 114, 119], ["women", "SPECIES", 50, 55], ["women", "SPECIES", 114, 119]]], ["Second, to determine the number of women at risk during a given week in that year, this number was divided by 52.", [["women", "ORGANISM", 35, 40], ["women", "SPECIES", 35, 40]]], ["The resulting weekly rates were summed over the length of the influenza season to give estimated rates over the entire season.Data analysis ::: MethodsEach influenza period was defined as the period when the number of respiratory specimens that tested positive for influenza type A and B combined exceeded 3%, which is the lowest value that gave a distinct, single epidemic period in each year.", [["respiratory specimens", "ANATOMY", 218, 239], ["influenza", "DISEASE", 265, 274], ["B", "GENE_OR_GENE_PRODUCT", 286, 287], ["Data analysis", "TEST", 126, 139], ["MethodsEach influenza period", "TREATMENT", 144, 172], ["respiratory specimens", "TEST", 218, 239], ["influenza type A", "PROBLEM", 265, 281]]], ["Excess intensive care admissions were estimated using a Serfling-type approach[17] to account for the baseline or underlying seasonality that occurs even when influenza epidemics are absent.", [["influenza", "DISEASE", 159, 168], ["a Serfling-type approach", "TREATMENT", 54, 78], ["underlying seasonality", "PROBLEM", 114, 136], ["influenza epidemics", "PROBLEM", 159, 178]]], ["A regression model was fit using robust regression (SAS ROBUSTREG), which limits the influence of outliers caused by influenza epidemics and other short term changes in mortality and thus does not require removal of the influenza periods to estimate the baseline, which is the traditional approach.", [["influenza", "DISEASE", 117, 126], ["A regression model", "PROBLEM", 0, 18], ["robust regression (SAS ROBUSTREG", "TREATMENT", 33, 65], ["influenza epidemics", "PROBLEM", 117, 136], ["other short term changes in mortality", "PROBLEM", 141, 178], ["removal", "TREATMENT", 205, 212], ["the influenza periods", "PROBLEM", 216, 237], ["influenza", "OBSERVATION", 117, 126], ["short term", "OBSERVATION_MODIFIER", 147, 157], ["influenza", "OBSERVATION", 220, 229]]], ["This method has been used previously to estimate excess mortality due to influenza epidemics[18,19].", [["influenza", "DISEASE", 73, 82], ["influenza epidemics", "PROBLEM", 73, 92]]], ["The traditional approach was not used as it is sensitive to the time period chosen to be excluded for estimation of the baseline.", [["The traditional approach", "TREATMENT", 0, 24]]], ["The two methods have been shown to give similar results, with the robust regression approach giving more conservative estimates[18].Data analysis ::: MethodsThe model was specified asData analysis ::: MethodsExpectedY=\u03b20+\u03b21t+\u03b22t2+\u03b23t3+\u03b24sin2\u03c0t52.2+\u03b25cos2\u03c0t52.2Data analysis ::: Methodswhere Y represents the weekly rate of intensive care admission and t is the week number. t, t2 and t3 were included to account for linear and non-linear trends, while the sine and cosine terms account for the amplitude and phase of the annual seasonal wave.Data analysis ::: MethodsTo estimate the overall contribution of influenza-related illness to the rates of intensive care admission during each influenza epidemic period, the difference between the observed and baseline predicted admission rates in each week were calculated and then summed over all weeks of the influenza period.", [["influenza", "DISEASE", 607, 616], ["illness", "DISEASE", 625, 632], ["t3", "DNA", 384, 386], ["Data analysis", "TEST", 132, 145], ["Methods", "TREATMENT", 150, 157], ["MethodsExpectedY=\u03b20+\u03b21t+\u03b22t2+\u03b23t3+\u03b24sin2\u03c0t52.2+\u03b25cos2\u03c0t52.2Data analysis", "TEST", 201, 273], ["linear and non-linear trends", "PROBLEM", 416, 444], ["Data analysis", "TEST", 542, 555], ["Methods", "TREATMENT", 560, 567], ["influenza", "PROBLEM", 607, 616], ["influenza", "OBSERVATION", 607, 616]]], ["The 95% confidence limits for the rate differences were also calculated in a similar fashion by using the upper and lower confidence limit of each weekly estimate of the baseline as the reference from which to calculate the difference between the observed admission rates and the lower and upper confidence limits of the predicted admission rates.", [["the rate differences", "PROBLEM", 30, 50], ["upper", "ANATOMY_MODIFIER", 106, 111], ["lower", "ANATOMY_MODIFIER", 280, 285], ["upper", "ANATOMY_MODIFIER", 290, 295]]], ["Excess admission counts and their 95% confidence limits were estimated by applying the rate difference to the population estimates for that year.", [["Excess admission counts", "TEST", 0, 23]]], ["A negative difference indicates that there were fewer admissions than expected, while a positive difference indicates that there were more admissions than expected, when compared to the seasonal baseline.Data analysis ::: MethodsFor outcomes or procedures that were rare outside of the influenza epidemic periods, or which did not have a distinct seasonal background pattern, we assumed a constant rate during the non-influenza period, which was estimated by calculating the average weekly rate over the study period excluding the influenza epidemic periods.Data analysis ::: MethodsThe fit of the model for estimating the baseline was assessed by checking the robust residuals outside of the influenza seasons.", [["influenza", "DISEASE", 531, 540], ["influenza", "DISEASE", 693, 702], ["Data analysis", "TEST", 204, 217], ["Methods", "TREATMENT", 222, 229], ["procedures", "TREATMENT", 245, 255], ["the influenza epidemic periods", "PROBLEM", 282, 312], ["a distinct seasonal background pattern", "PROBLEM", 336, 374], ["the study", "TEST", 500, 509], ["the influenza epidemic periods", "PROBLEM", 527, 557], ["Data analysis", "TEST", 558, 571], ["Methods", "TREATMENT", 576, 583], ["the influenza seasons", "PROBLEM", 689, 710], ["negative", "OBSERVATION", 2, 10], ["influenza epidemic", "OBSERVATION", 531, 549]]], ["Autocorrelation plots of the residuals were also constructed.", [["Autocorrelation plots", "TEST", 0, 21], ["the residuals", "TEST", 25, 38]]], ["All analyses were performed using SAS V9.2.ResultsBetween 1 January 2007 and 31 December 2010 in NSW, there were 75,154 unplanned ICU admissions in NSW, or an average of 18,789 (266/100,000 population) per year.ResultsThe time series of the observed weekly rate of influenza-related intensive care admission by age group are shown in Figure1.", [["influenza", "DISEASE", 265, 274], ["All analyses", "TEST", 0, 12], ["influenza", "PROBLEM", 265, 274]]], ["The observed and predicted seasonal baseline weekly rate of influenza and pneumonia-related intensive care admission and all unplanned respiratory intensive care admissions are presented by age group in Figures2 and3.", [["influenza", "DISEASE", 60, 69], ["pneumonia", "DISEASE", 74, 83], ["influenza", "PROBLEM", 60, 69], ["pneumonia", "PROBLEM", 74, 83], ["influenza", "OBSERVATION", 60, 69], ["pneumonia", "OBSERVATION", 74, 83]]], ["Overall, the 2008 and 2010 influenza periods had little obvious impact on admissions to intensive care, compared with 2007 and 2009.ResultsCompared with other years, influenza was much more commonly included as part of an intensive care admission diagnosis in 2009 (Table1, Figure1).", [["influenza", "DISEASE", 27, 36], ["influenza", "DISEASE", 166, 175], ["influenza", "PROBLEM", 166, 175]]], ["In the 2009 pandemic period, there were 182 (95% CI 180 to 185) excess, unplanned ICU admissions that received a diagnosis of influenza, compared with a maximum of 28 in other epidemic periods, which was observed in 2010.", [["influenza", "DISEASE", 126, 135], ["CI", "TEST", 49, 51], ["influenza", "PROBLEM", 126, 135], ["influenza", "OBSERVATION", 126, 135]]], ["By contrast, when using the broader influenza/pneumonia and all respiratory diagnosis categories, the estimated impact of influenza on intensive care admissions for all ages was greater in 2007 than in 2009 (Table1).ResultsThe 2007 and 2009 influenza epidemics affected very different age groups.", [["influenza", "DISEASE", 36, 45], ["pneumonia", "DISEASE", 46, 55], ["influenza", "DISEASE", 122, 131], ["influenza", "DISEASE", 241, 250], ["the broader influenza", "PROBLEM", 24, 45], ["pneumonia", "PROBLEM", 46, 55], ["all respiratory diagnosis categories", "PROBLEM", 60, 96], ["influenza", "PROBLEM", 122, 131], ["influenza epidemics affected", "PROBLEM", 241, 269], ["influenza", "OBSERVATION", 36, 45], ["pneumonia", "OBSERVATION", 46, 55]]], ["In 2009, the weekly rate of respiratory ICU admission in those aged 17 to 64 years peaked at 1.7 per 100,000 people in the week ending July 11 (Figure3).", [["people", "SPECIES", 109, 115]]], ["By contrast, older people (65 years and older) were most affected in 2007, with a peak weekly rate of 6.7 per 100,000 people in the week ending July 21 (Figure3).", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25], ["people", "SPECIES", 118, 124], ["a peak weekly rate", "TEST", 80, 98]]], ["In 2009, the estimated impact of influenza on respiratory intensive care admissions in older people was negative, indicating that the observed intensive care admission rate in that age group was lower than the estimated seasonal baseline (Table1).ResultsConsidering all respiratory intensive care admissions, pregnant/postpartum women were markedly more affected in 2009 (Table2, Figure4) with a rate of respiratory admission per 100,000 of 14.4 (95% CI 12.5 to 16.2), as were Aboriginal people with a rate of respiratory admission per 100,000 of 17.0 (95% CI 14.4 to 19.6) (Table2, Figure5).", [["influenza", "DISEASE", 33, 42], ["people", "ORGANISM", 93, 99], ["women", "ORGANISM", 329, 334], ["people", "ORGANISM", 488, 494], ["people", "SPECIES", 93, 99], ["women", "SPECIES", 329, 334], ["people", "SPECIES", 488, 494], ["influenza", "PROBLEM", 33, 42], ["CI", "TEST", 451, 453], ["CI", "TEST", 557, 559], ["influenza", "OBSERVATION", 33, 42]]], ["These compare to rates of 8.5 per 100,000 (95% CI 7.0 to 9.9) and 3.1 per 100,000 (95% CI 1.1 to 5.2) respectively for pregnant women and Aboriginal people in 2007.", [["women", "ORGANISM", 128, 133], ["people", "ORGANISM", 149, 155], ["women", "SPECIES", 128, 133], ["people", "SPECIES", 149, 155], ["rates", "TEST", 17, 22], ["CI", "TEST", 47, 49], ["CI", "TEST", 87, 89]]], ["Both pregnant women and Aboriginal people have a younger age distribution than the general population, and when compared to the excess respiratory rate in 17 to 64 year olds, the excess rate in pregnant women was nearly 5 times larger, while the excess rate in Aboriginal people was nearly 6 times larger.", [["women", "ORGANISM", 14, 19], ["people", "ORGANISM", 35, 41], ["women", "ORGANISM", 203, 208], ["people", "ORGANISM", 272, 278], ["women", "SPECIES", 14, 19], ["people", "SPECIES", 35, 41], ["women", "SPECIES", 203, 208], ["people", "SPECIES", 272, 278], ["the excess respiratory rate", "PROBLEM", 124, 151]]], ["This compares to differences of 6 times and 2 times, respectively, in 2007 (Table2).ResultsIn terms of severity, while respiratory failure and mechanical ventilation were more common in 2007, 2009 saw the greatest number of diagnoses of ARDS and the greatest number of admissions where the patient required ECMO, with an excess of 34 diagnoses (95% CI 21 to 46) and 21 admissions (95% CI 20 to 23) respectively (Table3, Figure6).", [["respiratory", "ANATOMY", 119, 130], ["respiratory failure", "DISEASE", 119, 138], ["ARDS", "DISEASE", 237, 241], ["patient", "ORGANISM", 290, 297], ["patient", "SPECIES", 290, 297], ["severity", "PROBLEM", 103, 111], ["respiratory failure", "PROBLEM", 119, 138], ["mechanical ventilation", "TREATMENT", 143, 165], ["ARDS", "PROBLEM", 237, 241], ["ECMO", "TREATMENT", 307, 311], ["CI", "TEST", 349, 351], ["CI", "TEST", 385, 387], ["respiratory failure", "OBSERVATION", 119, 138], ["mechanical ventilation", "OBSERVATION", 143, 165], ["ARDS", "OBSERVATION", 237, 241]]], ["No other year experienced an excess of ARDS diagnoses, while the next highest excess number of admissions where the patient required ECMO was observed in 2010, with an excess of 3 admissions (95% CI 2 to 4).", [["ARDS", "DISEASE", 39, 43], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["ARDS diagnoses", "PROBLEM", 39, 53], ["ECMO", "TREATMENT", 133, 137], ["CI", "TEST", 196, 198], ["ARDS", "OBSERVATION", 39, 43]]], ["Overall, in 2009 the median time spent in ICU in patients with respiratory illness and influenza/pneumonia were 77 hours and 96 hours respectively, which are similar to other years (Table4).", [["respiratory", "ANATOMY", 63, 74], ["respiratory illness", "DISEASE", 63, 82], ["influenza", "DISEASE", 87, 96], ["pneumonia", "DISEASE", 97, 106], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["respiratory illness", "PROBLEM", 63, 82], ["influenza", "PROBLEM", 87, 96], ["pneumonia", "PROBLEM", 97, 106], ["respiratory", "ANATOMY", 63, 74], ["illness", "OBSERVATION", 75, 82], ["pneumonia", "OBSERVATION", 97, 106]]], ["People under 65 years with influenza/pneumonia tended to have a longer stay in intensive care on average in 2009, while people 65 years and older had shorter stays (Table4).", [["influenza/pneumonia", "DISEASE", 27, 46], ["People", "ORGANISM", 0, 6], ["people", "ORGANISM", 120, 126], ["People", "SPECIES", 0, 6], ["people", "SPECIES", 120, 126], ["influenza", "PROBLEM", 27, 36], ["pneumonia", "PROBLEM", 37, 46], ["pneumonia", "OBSERVATION", 37, 46]]], ["In 2009 the percentage of respiratory patients who died while in intensive care was the lowest of all 4 years (16%) (Table5).DiscussionIn NSW, when the entire influenza period is considered for each year and the age distribution of influenza-related illness is ignored, the population rate of influenza-associated respiratory admissions to intensive care was greater during seasonal influenza in 2007 than in pandemic influenza in 2009, despite the well-documented severe pandemic influenza-related illness in 2009.", [["influenza", "DISEASE", 159, 168], ["influenza", "DISEASE", 232, 241], ["illness", "DISEASE", 250, 257], ["influenza", "DISEASE", 293, 302], ["influenza", "DISEASE", 383, 392], ["influenza", "DISEASE", 418, 427], ["influenza", "DISEASE", 481, 490], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["influenza", "PROBLEM", 232, 241], ["related illness", "PROBLEM", 242, 257], ["influenza", "PROBLEM", 293, 302], ["intensive care", "TREATMENT", 340, 354], ["seasonal influenza", "PROBLEM", 374, 392], ["pandemic influenza", "PROBLEM", 409, 427], ["severe pandemic influenza", "PROBLEM", 465, 490], ["influenza", "OBSERVATION", 232, 241], ["severe", "OBSERVATION_MODIFIER", 465, 471], ["pandemic", "OBSERVATION_MODIFIER", 472, 480], ["influenza", "OBSERVATION", 481, 490]]], ["The perception of 2009 as a more severe influenza year than 2007 could be due to a number of factors, including the rapid progression of the epidemic of influenza A(H1N1)pdm09 in Australia, the intense media attention and uncharacteristic reporting of counts of confirmed cases and deaths, and the apparent increase in incidence of clearly influenza-related severe acute respiratory distress in younger adults compared with seasonal influenza epidemics.", [["respiratory", "ANATOMY", 371, 382], ["influenza", "DISEASE", 40, 49], ["influenza A(H1N1)pdm09", "DISEASE", 153, 175], ["deaths", "DISEASE", 282, 288], ["influenza", "DISEASE", 340, 349], ["acute respiratory distress", "DISEASE", 365, 391], ["influenza", "DISEASE", 433, 442], ["influenza A(H1N1)pdm09", "ORGANISM", 153, 175], ["a more severe influenza", "PROBLEM", 26, 49], ["influenza", "PROBLEM", 153, 162], ["pdm09", "PROBLEM", 170, 175], ["influenza", "PROBLEM", 340, 349], ["severe acute respiratory distress", "PROBLEM", 358, 391], ["seasonal influenza epidemics", "PROBLEM", 424, 452], ["increase", "OBSERVATION_MODIFIER", 307, 315], ["influenza", "OBSERVATION", 340, 349], ["severe", "OBSERVATION_MODIFIER", 358, 364], ["acute", "OBSERVATION_MODIFIER", 365, 370], ["respiratory distress", "OBSERVATION", 371, 391]]], ["The rapid increase of the 2009 epidemic was followed by an equally rapid decline, thus tempering the final impact.", [["an equally rapid decline", "PROBLEM", 56, 80], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["equally", "OBSERVATION_MODIFIER", 59, 66], ["rapid", "OBSERVATION_MODIFIER", 67, 72], ["decline", "OBSERVATION", 73, 80]]], ["In seasonal influenza years such as 2007, in which older persons were at greater risk of poor outcomes of influenza infection, the role of influenza may be less clear.", [["influenza", "DISEASE", 12, 21], ["influenza infection", "DISEASE", 106, 125], ["influenza", "DISEASE", 139, 148], ["persons", "ORGANISM", 57, 64], ["persons", "SPECIES", 57, 64], ["influenza infection", "PROBLEM", 106, 125], ["influenza", "PROBLEM", 139, 148], ["influenza", "OBSERVATION_MODIFIER", 106, 115], ["infection", "OBSERVATION", 116, 125]]], ["A large proportion of patients hospitalised with seasonal influenza have symptoms uncharacteristic of a classic influenza syndrome[20,21].DiscussionIn 2009, there is some evidence that patients who required intensive care due to influenza-related illness were more severely ill, with a large number of patients diagnosed with ARDS or who received ECMO.", [["influenza", "DISEASE", 58, 67], ["influenza syndrome", "DISEASE", 112, 130], ["influenza", "DISEASE", 229, 238], ["ARDS", "DISEASE", 326, 330], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 302, 310], ["seasonal influenza", "PROBLEM", 49, 67], ["symptoms", "PROBLEM", 73, 81], ["a classic influenza syndrome", "PROBLEM", 102, 130], ["intensive care", "TREATMENT", 207, 221], ["influenza", "PROBLEM", 229, 238], ["severely ill", "PROBLEM", 265, 277], ["ARDS", "PROBLEM", 326, 330], ["ECMO", "TREATMENT", 347, 351], ["large", "OBSERVATION_MODIFIER", 2, 7], ["influenza syndrome", "OBSERVATION", 112, 130], ["large", "OBSERVATION_MODIFIER", 286, 291], ["ARDS", "OBSERVATION", 326, 330]]], ["Further, while younger patients had a longer median stay in intensive care in 2009 than in other years, these figures should be interpreted with caution as only a small proportion of admissions would be truly due to influenza, and variation in other, non-influenza causes may have explained the differences.DiscussionIn Australia, 2007 was considered a moderate to severe influenza season, which was attributed to antigenic drift in both the H1N1 and H3N2 influenza strains which may have compromised the effectiveness of that year's Southern Hemisphere influenza vaccine[22].", [["influenza", "DISEASE", 216, 225], ["influenza", "DISEASE", 372, 381], ["influenza", "DISEASE", 456, 465], ["patients", "ORGANISM", 23, 31], ["H3N2 influenza strains", "ORGANISM", 451, 473], ["patients", "SPECIES", 23, 31], ["H3N2 influenza", "SPECIES", 451, 465], ["influenza", "PROBLEM", 216, 225], ["a moderate to severe influenza season", "PROBLEM", 351, 388], ["antigenic drift", "PROBLEM", 414, 429], ["the H1N1", "PROBLEM", 438, 446], ["H3N2 influenza strains", "PROBLEM", 451, 473], ["influenza vaccine", "TREATMENT", 554, 571], ["influenza", "OBSERVATION", 216, 225], ["moderate", "OBSERVATION_MODIFIER", 353, 361], ["severe", "OBSERVATION_MODIFIER", 365, 371], ["influenza", "OBSERVATION", 372, 381]]], ["Even so, the 2009 period was highly unusual in that increases in influenza-associated intensive care admissions were observed only in people under 65 years.", [["influenza", "DISEASE", 65, 74], ["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["influenza", "PROBLEM", 65, 74], ["increases", "OBSERVATION_MODIFIER", 52, 61], ["influenza", "OBSERVATION", 65, 74]]], ["Older people were relatively protected, compared to normal seasonal influenza epidemic periods.", [["influenza", "DISEASE", 68, 77], ["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["seasonal", "OBSERVATION_MODIFIER", 59, 67], ["influenza", "OBSERVATION", 68, 77]]], ["Studies both in Australia and internationally have found that older populations tended to have a high prevalence of pre-existing cross-reacting influenza A(H1N1)pdm09 antibodies, while few younger people had such protection[23-25].", [["influenza A(H1N1)pdm09", "ORGANISM", 144, 166], ["people", "ORGANISM", 197, 203], ["influenza A(H1N1)pdm09 antibodies", "PROTEIN", 144, 177], ["people", "SPECIES", 197, 203], ["Studies", "TEST", 0, 7], ["older populations", "PROBLEM", 62, 79], ["pre-existing cross-reacting influenza A(H1N1)pdm09 antibodies", "PROBLEM", 116, 177], ["influenza", "OBSERVATION", 144, 153]]], ["Hence, the all ages excess rate in 2009 was small when compared to 2007, as the increased rate in younger people was offset by the unusually low rate in older people.", [["people", "ORGANISM", 106, 112], ["people", "ORGANISM", 159, 165], ["people", "SPECIES", 106, 112], ["people", "SPECIES", 159, 165], ["small", "OBSERVATION_MODIFIER", 44, 49], ["increased", "OBSERVATION_MODIFIER", 80, 89]]], ["A study from Denmark examining all influenza-associated hospital admissions also did not find an increase during the first epidemic of influenza A(H1N1)pdm09 virus compared with seasonal influenza, except in people younger than 65 years[26].", [["influenza", "DISEASE", 35, 44], ["influenza", "DISEASE", 135, 144], ["influenza", "DISEASE", 187, 196], ["influenza A(H1N1)pdm09 virus", "ORGANISM", 135, 163], ["people", "ORGANISM", 208, 214], ["H1N1)pdm09 virus", "SPECIES", 147, 163], ["people", "SPECIES", 208, 214], ["influenza A(H1N1)pdm09 virus", "SPECIES", 135, 163], ["A study", "TEST", 0, 7], ["influenza A(H1N1)pdm09 virus", "PROBLEM", 135, 163], ["seasonal influenza", "PROBLEM", 178, 196], ["increase", "OBSERVATION", 97, 105]]], ["Our findings are consistent with those of a study in a US hospital that found that patients at greatest risk of complications from seasonal influenza tend to be older, with a mean age of 75 years[27].", [["influenza", "DISEASE", 140, 149], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["a study", "TEST", 42, 49], ["complications", "PROBLEM", 112, 125], ["seasonal influenza", "PROBLEM", 131, 149], ["consistent with", "UNCERTAINTY", 17, 32], ["complications", "OBSERVATION", 112, 125]]], ["The 2010 epidemic, the first season following the arrival of pandemic influenza continued to be dominated by the pandemic strain.", [["influenza", "DISEASE", 70, 79], ["pandemic influenza", "PROBLEM", 61, 79], ["the pandemic strain", "PROBLEM", 109, 128], ["pandemic strain", "OBSERVATION", 113, 128]]], ["This season was characterised by low influenza activity and very low influenza-related ICU use.DiscussionFor 2009, we estimated the rate of influenza-related respiratory ICU admission among Aboriginal people to be more than 6 times the highest rate in any single age group of the population overall.", [["influenza", "DISEASE", 69, 78], ["influenza", "DISEASE", 140, 149], ["people", "ORGANISM", 201, 207], ["people", "SPECIES", 201, 207], ["low influenza activity", "PROBLEM", 33, 55], ["very low influenza", "PROBLEM", 60, 78], ["influenza", "PROBLEM", 140, 149], ["low", "OBSERVATION_MODIFIER", 33, 36], ["influenza activity", "OBSERVATION", 37, 55]]], ["In 2009, it was recognised that Indigenous people around the world experienced a greater risk of infection with the pandemic influenza virus and more severe outcomes[28-30] although a Canadian study found no increased risk of intensive care admission or death among the Canadian Aboriginal populations[31].", [["infection", "DISEASE", 97, 106], ["influenza", "DISEASE", 125, 134], ["death", "DISEASE", 254, 259], ["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["pandemic influenza virus", "SPECIES", 116, 140], ["pandemic influenza virus", "SPECIES", 116, 140], ["infection", "PROBLEM", 97, 106], ["the pandemic influenza virus", "PROBLEM", 112, 140], ["a Canadian study", "TEST", 182, 198], ["death", "PROBLEM", 254, 259], ["infection", "OBSERVATION", 97, 106]]], ["A more recent study of Australian Aboriginal and Torres Strait Islander people found that a younger age distribution and a higher prevalence of underlying chronic conditions are a possible explanation for the apparent increased risk of influenza-related hospitalisation[32].", [["influenza", "DISEASE", 236, 245], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["underlying chronic conditions", "PROBLEM", 144, 173], ["influenza", "PROBLEM", 236, 245], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["influenza", "OBSERVATION", 236, 245]]], ["Improvements in the recording of Aboriginal status in hospitalisation data in NSW could affect the comparability of rates over time.DiscussionThe younger risk profile of 2009 pandemic influenza may also at least partly explain the higher rate of influenza-related ICU admission among pregnant women compared with the overall population.", [["influenza", "DISEASE", 184, 193], ["influenza", "DISEASE", 246, 255], ["women", "ORGANISM", 293, 298], ["women", "SPECIES", 293, 298], ["pandemic influenza", "PROBLEM", 175, 193], ["influenza", "PROBLEM", 246, 255], ["influenza", "OBSERVATION", 246, 255]]], ["However, in all years the risk of admission was greater in pregnant women than in the general population, indicating that seasonal influenza can also pose a strong risk to pregnant women.DiscussionThe use of administrative data in this study has both strengths and limitations.", [["influenza", "DISEASE", 131, 140], ["women", "ORGANISM", 68, 73], ["women", "ORGANISM", 181, 186], ["women", "SPECIES", 68, 73], ["women", "SPECIES", 181, 186], ["seasonal influenza", "PROBLEM", 122, 140], ["administrative data", "TEST", 208, 227], ["this study", "TEST", 231, 241]]], ["The main strength of this study is that it is population based which allows complete capture of all intensive care admissions in NSW residents.", [["this study", "TEST", 21, 31], ["main", "OBSERVATION_MODIFIER", 4, 8], ["strength", "OBSERVATION_MODIFIER", 9, 17]]], ["However, there is certainly some difficulty in accurately and consistently identifying admissions associated with influenza infection over time.", [["influenza infection", "DISEASE", 114, 133], ["influenza infection", "PROBLEM", 114, 133], ["influenza", "OBSERVATION_MODIFIER", 114, 123], ["infection", "OBSERVATION", 124, 133]]], ["There are many non-influenza causes of respiratory illness, both infectious and non-infectious.", [["respiratory", "ANATOMY", 39, 50], ["respiratory illness", "DISEASE", 39, 58], ["respiratory illness", "PROBLEM", 39, 58], ["non-infectious", "PROBLEM", 80, 94], ["respiratory illness", "OBSERVATION", 39, 58], ["infectious", "OBSERVATION_MODIFIER", 65, 75], ["non-infectious", "OBSERVATION_MODIFIER", 80, 94]]], ["Other viruses, such as respiratory syncytial virus, may have also been circulating during the influenza periods.", [["respiratory syncytial virus", "DISEASE", 23, 50], ["respiratory syncytial virus", "ORGANISM", 23, 50], ["respiratory syncytial virus", "SPECIES", 23, 50], ["respiratory syncytial virus", "SPECIES", 23, 50], ["Other viruses", "PROBLEM", 0, 13], ["respiratory syncytial virus", "PROBLEM", 23, 50], ["the influenza periods", "PROBLEM", 90, 111], ["viruses", "OBSERVATION", 6, 13], ["syncytial virus", "OBSERVATION", 35, 50]]], ["We controlled for these non-influenza factors using the Serfling method.", [["non-influenza factors", "PROTEIN", 24, 45], ["these non-influenza factors", "PROBLEM", 18, 45], ["the Serfling method", "TREATMENT", 52, 71]]], ["However, a limitation of the Serfling method is that it generates a rigid expectation of non-influenza seasonal illness.", [["non-influenza seasonal illness", "PROBLEM", 89, 119]]], ["While the sinusoidal model follows the background seasonal pattern, some variation in non-influenza causes of illness from year-to-year could lead to some over- or underestimation in some years.", [["illness", "DISEASE", 110, 117], ["illness", "PROBLEM", 110, 117], ["sinusoidal model", "OBSERVATION", 10, 26], ["some", "OBSERVATION_MODIFIER", 68, 72], ["variation", "OBSERVATION_MODIFIER", 73, 82]]], ["Other time series methods for estimating influenza-attributable health outcomes are available, such as a combined Serfling-Poisson model that incorporates virology data, but these have been shown to produce broadly similar results[33,34].", [["estimating influenza-attributable health outcomes", "PROBLEM", 30, 79]]], ["The lack of a gold standard for assessing the accuracy of these estimates remains a barrier for objectively comparing methods.DiscussionManagement of ECMO services was coincidentally altered in NSW in 2009 prior to the emergence of the pandemic influenza strain.", [["influenza", "DISEASE", 245, 254], ["ECMO services", "TREATMENT", 150, 163], ["the pandemic influenza strain", "PROBLEM", 232, 261], ["influenza", "OBSERVATION", 245, 254]]], ["The aim was to increase the mobility of ECMO services to allow wider geographic application.", [["ECMO services", "TREATMENT", 40, 53], ["wider geographic application", "TREATMENT", 63, 91]]], ["This may also have contributed to the apparent increase in use of ECMO associated with the 2009 epidemic.", [["ECMO", "TREATMENT", 66, 70], ["increase", "OBSERVATION_MODIFIER", 47, 55]]], ["In addition, this increased use may reflect the younger age distribution in 2009, given that clinicians may be more likely to use extreme measures on younger patients.DiscussionSince there is no generally accepted definition of an influenza season, we used a threshold of 3% of respiratory samples testing positive for influenza to define the seasons.", [["respiratory samples", "ANATOMY", 278, 297], ["influenza", "DISEASE", 319, 328], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["an influenza season", "PROBLEM", 228, 247], ["respiratory samples testing", "TEST", 278, 305], ["influenza", "PROBLEM", 319, 328], ["no generally", "UNCERTAINTY", 192, 204]]], ["While different thresholds can give slightly different results[35], the 2009 season as defined by our method is consistent with other estimates[3,36].DiscussionThis study highlights the challenge of identifying influenza-related illness.", [["influenza-related illness", "DISEASE", 211, 236], ["This study", "TEST", 160, 170], ["influenza", "PROBLEM", 211, 220], ["consistent with", "UNCERTAINTY", 112, 127], ["influenza", "OBSERVATION", 211, 220]]], ["Had we only included ICU admissions where influenza was recorded as a diagnosis, we would have concluded that there was a much greater use of influenza-related intensive care during 2009 than 2007.", [["influenza", "DISEASE", 42, 51], ["influenza", "DISEASE", 142, 151], ["influenza", "PROBLEM", 42, 51], ["influenza", "PROBLEM", 142, 151]]], ["Prior to 2009 specific testing for influenza in ICUs was uncommon, and during 2009 we believe that pandemic awareness amongst clinicians promoted testing for influenza, and increased the likelihood that influenza was recorded as part of the diagnosis, as evidenced by Figure1.", [["influenza", "DISEASE", 35, 44], ["influenza", "DISEASE", 158, 167], ["influenza", "DISEASE", 203, 212], ["Figure1", "PROTEIN", 268, 275], ["specific testing", "TEST", 14, 30], ["influenza", "PROBLEM", 35, 44], ["influenza", "PROBLEM", 158, 167], ["influenza", "PROBLEM", 203, 212]]], ["As well, a shift between 2007 and 2009 from the use of immunofluorescence for the detection of influenza to the more sensitive nucleic acid testing may have contributed to the increased rate of influenza diagnosis in 2009.DiscussionIncluding all respiratory admissions is a more sensitive method of estimating the impact of influenza.", [["influenza", "DISEASE", 95, 104], ["nucleic acid", "CHEMICAL", 127, 139], ["influenza", "DISEASE", 194, 203], ["influenza", "DISEASE", 324, 333], ["immunofluorescence", "TEST", 55, 73], ["influenza", "PROBLEM", 95, 104], ["nucleic acid testing", "TEST", 127, 147], ["the increased rate of influenza diagnosis", "PROBLEM", 172, 213], ["influenza", "PROBLEM", 324, 333], ["increased", "OBSERVATION_MODIFIER", 176, 185], ["influenza", "OBSERVATION", 324, 333]]], ["The influence of influenza during 2007 may have been more evident in the broader respiratory diagnosis group due to the older age of those most at risk of influenza complications in 2007.", [["influenza", "DISEASE", 17, 26], ["influenza", "DISEASE", 155, 164], ["influenza", "PROBLEM", 17, 26], ["influenza complications", "PROBLEM", 155, 178], ["influenza", "OBSERVATION", 155, 164]]], ["Older people have more complex and chronic illnesses which could mask the recognition of influenza's role in the illness and lead to more frequent diagnoses of alternative conditions such as pneumonia and respiratory failure/end-stage respiratory disease that could be secondary respiratory complications of primary influenza infection[11,37].ConclusionsWhile influenza was diagnosed more frequently and peak use of intensive care was higher in 2009, a broader assessment of respiratory admissions to intensive care indicates that 2007 seasonal influenza resulted in a higher rate of excess admissions to ICU than 2009 pandemic influenza.", [["respiratory", "ANATOMY", 205, 216], ["respiratory", "ANATOMY", 235, 246], ["respiratory", "ANATOMY", 279, 290], ["influenza", "DISEASE", 89, 98], ["pneumonia", "DISEASE", 191, 200], ["respiratory failure", "DISEASE", 205, 224], ["end-stage respiratory disease", "DISEASE", 225, 254], ["primary influenza infection", "DISEASE", 308, 335], ["influenza", "DISEASE", 360, 369], ["influenza", "DISEASE", 545, 554], ["influenza", "DISEASE", 628, 637], ["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["chronic illnesses", "PROBLEM", 35, 52], ["influenza", "PROBLEM", 89, 98], ["alternative conditions", "PROBLEM", 160, 182], ["pneumonia", "PROBLEM", 191, 200], ["respiratory failure", "PROBLEM", 205, 224], ["end-stage respiratory disease", "PROBLEM", 225, 254], ["respiratory complications", "PROBLEM", 279, 304], ["primary influenza infection", "PROBLEM", 308, 335], ["influenza", "PROBLEM", 360, 369], ["a broader assessment", "TEST", 451, 471], ["seasonal influenza", "PROBLEM", 536, 554], ["pandemic influenza", "PROBLEM", 619, 637], ["more complex", "OBSERVATION_MODIFIER", 18, 30], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["illnesses", "OBSERVATION", 43, 52], ["pneumonia", "OBSERVATION", 191, 200], ["respiratory failure", "OBSERVATION", 205, 224], ["stage", "OBSERVATION_MODIFIER", 229, 234], ["respiratory disease", "OBSERVATION", 235, 254], ["respiratory complications", "OBSERVATION", 279, 304], ["primary", "OBSERVATION_MODIFIER", 308, 315], ["influenza infection", "OBSERVATION", 316, 335]]], ["Thus, the role of seasonal influenza epidemics on intensive care use may have previously been under-recognised.", [["influenza", "DISEASE", 27, 36], ["seasonal influenza epidemics", "PROBLEM", 18, 46], ["intensive care", "TREATMENT", 50, 64]]], ["In 2009, relatively high use of intensive care among young to middle-aged adults was offset by low use among adults aged over 65 years.", [["adults", "ORGANISM", 74, 80], ["intensive care", "TREATMENT", 32, 46]]], ["Compared with seasonal influenza, the pandemic virus in 2009 was associated with some increase in markers of disease severity, but no overall increase in hospital mortality.ConclusionsPandemic influenza in 2009 had a far greater impact on Aboriginal people and pregnant women compared both with the overall population in 2009 and with seasonal influenza in other years.", [["seasonal influenza", "DISEASE", 14, 32], ["Pandemic influenza", "DISEASE", 184, 202], ["influenza", "DISEASE", 344, 353], ["people", "ORGANISM", 250, 256], ["women", "ORGANISM", 270, 275], ["people", "SPECIES", 250, 256], ["women", "SPECIES", 270, 275], ["seasonal influenza", "PROBLEM", 14, 32], ["the pandemic virus", "PROBLEM", 34, 52], ["disease severity", "PROBLEM", 109, 125], ["Pandemic influenza", "PROBLEM", 184, 202], ["seasonal influenza", "PROBLEM", 335, 353], ["influenza", "OBSERVATION", 23, 32], ["some", "OBSERVATION_MODIFIER", 81, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["disease", "OBSERVATION", 109, 116], ["no", "UNCERTAINTY", 131, 133], ["overall", "OBSERVATION_MODIFIER", 134, 141], ["increase", "OBSERVATION_MODIFIER", 142, 150]]], ["Future pandemic planning should place a priority on prevention of serious illness in these groups.Key messagesExcess intensive care admission rates for respiratory illness associated with pandemic influenza in 2009 were lower than that during the influenza season of 2007.", [["respiratory illness", "DISEASE", 152, 171], ["influenza", "DISEASE", 197, 206], ["Future pandemic planning", "TREATMENT", 0, 24], ["serious illness in these groups", "PROBLEM", 66, 97], ["respiratory illness", "PROBLEM", 152, 171], ["pandemic influenza", "PROBLEM", 188, 206]]], ["Thus, the role of seasonal influenza on use of intensive care services may have previously been under-recognised.Key messagesElderly persons accounted for much of the influenza-associated intensive care use from seasonal influenza, while young to middle-aged adults accounted for the majority of the pandemic influenza-related use.Key messagesAboriginal people and pregnant women were substantially over-represented among intensive care admissions during pandemic influenza in 2009.", [["influenza", "DISEASE", 27, 36], ["influenza", "DISEASE", 167, 176], ["influenza", "DISEASE", 221, 230], ["influenza", "DISEASE", 309, 318], ["influenza", "DISEASE", 464, 473], ["persons", "ORGANISM", 133, 140], ["adults", "ORGANISM", 259, 265], ["people", "ORGANISM", 354, 360], ["women", "ORGANISM", 374, 379], ["persons", "SPECIES", 133, 140], ["people", "SPECIES", 354, 360], ["women", "SPECIES", 374, 379], ["seasonal influenza", "PROBLEM", 18, 36], ["intensive care services", "TREATMENT", 47, 70], ["seasonal influenza", "PROBLEM", 212, 230], ["the pandemic influenza", "PROBLEM", 296, 318], ["pandemic influenza", "PROBLEM", 455, 473]]], ["A priority in influenza pandemic planning should be prevention of serious illness in these groups.AbbreviationsCI: Confidence interval; ICU: Intensive care unit; NSW: New South Wales; APDC: Admitted Patients Data Collection; ICD-10-AM: International Classification of Diseases, 10th Revision.", [["influenza pandemic", "DISEASE", 14, 32], ["Patients", "SPECIES", 199, 207], ["influenza pandemic planning", "TREATMENT", 14, 41], ["serious illness in these groups", "PROBLEM", 66, 97], ["ICD", "TEST", 225, 228], ["Diseases", "PROBLEM", 268, 276], ["10th Revision", "TREATMENT", 278, 291], ["Diseases", "OBSERVATION", 268, 276], ["Revision", "OBSERVATION", 283, 291]]], ["Australian Modification; ACHI: Australian Classification of Health Interventions; ECMO: Extracorporeal membrane oxygenation; ARDS: Acute respiratory distress syndrome.Competing interestsThe authors declare that they have no competing interests.Authors\u2019 contributionsDM, ST and RG conceived the study.", [["Extracorporeal membrane", "ANATOMY", 88, 111], ["ARDS", "DISEASE", 125, 129], ["Acute respiratory distress syndrome", "DISEASE", 131, 166], ["Extracorporeal membrane oxygenation", "TREATMENT", 88, 123], ["ARDS", "PROBLEM", 125, 129], ["Acute respiratory distress syndrome", "PROBLEM", 131, 166], ["the study", "TEST", 290, 299], ["ARDS", "OBSERVATION", 125, 129], ["Acute", "OBSERVATION_MODIFIER", 131, 136], ["respiratory distress", "OBSERVATION", 137, 157], ["syndrome", "OBSERVATION", 158, 166]]], ["AS, DM, ST and MC designed the study.", [["DM", "DISEASE", 4, 6], ["DM", "PROBLEM", 4, 6], ["the study", "TEST", 27, 36]]], ["AS carried out the data analysis.", [["the data analysis", "TEST", 15, 32]]], ["AS and DM drafted the manuscript.", [["DM", "PROBLEM", 7, 9]]], ["All authors have read and approved the final manuscript.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication historyhttp://www.biomedcentral.com/1471-2458/12/869/prepub", [["Pre-publication", "DISEASE", 56, 71], ["pre-publication", "DISEASE", 83, 98], ["Pre-publication", "DISEASE", 143, 158]]]], "56a11bae6ac6ab6e9c6aa5de3d7ecb37fbd3cdb9": [["Clinical and conceptual comments on \"Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis\"To the Editor, Currently research on COVID-19 has been prioritised globally with a high frequency of the articles being published in the literature.", [["COVID", "TEST", 173, 178]]], ["The incidence of false-negative tests for \"happy hypoxia\" in asymptomatic patients, evolving epidemiological characteristics, and the universal risk of infection in every single age group with unpredictable capricious outcomes, explains the need to explore the risk factors associated with the novel coronavirus.", [["hypoxia", "DISEASE", 49, 56], ["infection", "DISEASE", 152, 161], ["coronavirus", "DISEASE", 300, 311], ["patients", "ORGANISM", 74, 82], ["coronavirus", "ORGANISM", 300, 311], ["patients", "SPECIES", 74, 82], ["false-negative tests", "TEST", 17, 37], ["\"happy hypoxia", "PROBLEM", 42, 56], ["infection", "PROBLEM", 152, 161], ["unpredictable capricious outcomes", "PROBLEM", 193, 226], ["the risk factors", "PROBLEM", 257, 273], ["the novel coronavirus", "PROBLEM", 290, 311], ["false", "OBSERVATION", 17, 22], ["infection", "OBSERVATION", 152, 161]]], ["The systematic review and meta-analysis on COVID-19 by Zheng et al. contribute to this global research output, and attempts to inform clinical decision making during this crisis 1 .", [["The systematic review", "TEST", 0, 21], ["meta-analysis", "TEST", 26, 39], ["COVID", "TEST", 43, 48], ["this global research output", "PROBLEM", 82, 109]]], ["Few additional risk factors missing in the study: The epidemiology and clinical pattern of paediatric COVID 19 has a unique spectrum with infants and young children \u2264 5 years more likely to succumb to severe clinical symptoms of COVID19 than older children (i.e., \u2265 6 years).", [["COVID", "DISEASE", 102, 107], ["infants", "ORGANISM", 138, 145], ["children", "ORGANISM", 156, 164], ["children", "ORGANISM", 248, 256], ["infants", "SPECIES", 138, 145], ["children", "SPECIES", 156, 164], ["children", "SPECIES", 248, 256], ["severe clinical symptoms", "PROBLEM", 201, 225], ["risk factors", "OBSERVATION", 15, 27]]], ["The immaturity of the immune system is cited as a plausible explanation 1 .", [["immune system", "ANATOMY", 22, 35], ["immaturity", "OBSERVATION", 4, 14]]], ["Children can swiftly progress to acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 39, 50], ["acute respiratory distress syndrome", "DISEASE", 33, 68], ["ARDS", "DISEASE", 70, 74], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["acute respiratory distress syndrome", "PROBLEM", 33, 68], ["ARDS", "PROBLEM", 70, 74], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory distress", "OBSERVATION", 39, 59], ["ARDS", "OBSERVATION", 70, 74]]], ["They may also have shock, encephalopathy, myocardial injury or heart failure, coagulation dysfunction, and acute kidney injury.Clinical and conceptual comments on \"Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis\"The forgotten \"Cancer\": The unprecedented outbreak of COVID-19 has caused a substantial risk for cancer patients who are immunocompromised due to the disease and its treatment 2 .Fixed effect model of meta-analysis:We noted that the authors used the fixed-effect model to perform the meta-analysis.", [["myocardial", "ANATOMY", 42, 52], ["heart", "ANATOMY", 63, 68], ["kidney", "ANATOMY", 113, 119], ["cancer", "ANATOMY", 360, 366], ["shock", "DISEASE", 19, 24], ["encephalopathy", "DISEASE", 26, 40], ["myocardial injury", "DISEASE", 42, 59], ["heart failure", "DISEASE", 63, 76], ["coagulation dysfunction", "DISEASE", 78, 101], ["acute kidney injury", "DISEASE", 107, 126], ["Cancer", "DISEASE", 278, 284], ["COVID-19", "CHEMICAL", 317, 325], ["cancer", "DISEASE", 360, 366], ["myocardial", "MULTI-TISSUE_STRUCTURE", 42, 52], ["heart", "ORGAN", 63, 68], ["kidney", "ORGAN", 113, 119], ["Cancer", "CANCER", 278, 284], ["cancer", "CANCER", 360, 366], ["patients", "ORGANISM", 367, 375], ["patients", "SPECIES", 367, 375], ["shock", "PROBLEM", 19, 24], ["encephalopathy", "PROBLEM", 26, 40], ["myocardial injury", "PROBLEM", 42, 59], ["heart failure", "PROBLEM", 63, 76], ["coagulation dysfunction", "PROBLEM", 78, 101], ["acute kidney injury", "PROBLEM", 107, 126], ["cancer", "PROBLEM", 360, 366], ["immunocompromised", "PROBLEM", 384, 401], ["the disease", "PROBLEM", 409, 420], ["its treatment", "TREATMENT", 425, 438], ["the fixed-effect model", "TREATMENT", 509, 531], ["the meta-analysis", "TEST", 543, 560], ["shock", "OBSERVATION", 19, 24], ["encephalopathy", "OBSERVATION", 26, 40], ["myocardial", "ANATOMY", 42, 52], ["injury", "OBSERVATION", 53, 59], ["heart", "ANATOMY", 63, 68], ["failure", "OBSERVATION", 69, 76], ["coagulation dysfunction", "OBSERVATION", 78, 101], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["kidney", "ANATOMY", 113, 119], ["injury", "OBSERVATION", 120, 126], ["Cancer", "OBSERVATION", 278, 284], ["cancer", "OBSERVATION", 360, 366], ["disease", "OBSERVATION", 413, 420]]], ["The fixed-effects model is practically applied when the studies across which the data is being pooled have, similar study parameters, and are devoid of any major heterogeneity.", [["the studies", "TEST", 52, 63], ["similar study parameters", "TEST", 108, 132], ["any major heterogeneity", "PROBLEM", 152, 175], ["fixed", "OBSERVATION_MODIFIER", 4, 9], ["major", "OBSERVATION_MODIFIER", 156, 161], ["heterogeneity", "OBSERVATION", 162, 175]]], ["Hence, this model is often used to assess cohorts within a singular larger study.", [["a singular larger study", "TEST", 57, 80]]], ["Nevertheless, the meta-analysis by Zhang et al., where multiple different studies are used, are inherently predisposed to heterogeneity due to the differential protocols and parameters of individual study.", [["multiple different studies", "TEST", 55, 81], ["the differential protocols", "TEST", 143, 169], ["individual study", "TEST", 188, 204]]], ["We propose the \"random effects model\" for this study.", [["this study", "TEST", 42, 52]]], ["3, 4 .Fixed effect model of meta-analysis:Analysis of heterogeneity: Furthermore, although the analysis of heterogeneity was conducted using the commonly used I 2 statistic, it may not have sufficient power by itself to determine between-study heterogeneity.", [["the analysis", "TEST", 91, 103]]], ["The I 2 statistic has shown to be limited in its application; nonetheless we recommend the authors also asses heterogeneity via the Cochran\"s Q statistic and the Tau 2 statistic, which would add redundancy and robustness in the analysis of heterogeneity in this study 5 .", [["Tau 2", "GENE_OR_GENE_PRODUCT", 162, 167], ["this study", "TEST", 257, 267], ["heterogeneity", "OBSERVATION", 240, 253]]]], "1e7eb016764aeb8502c65f290752e6e57b0ba647": [["Gangliosides are sialic acid-containing glycosphingolipids that are ubiquitous components of the mammalian plasma membrane.", [["plasma membrane", "ANATOMY", 107, 122], ["Gangliosides", "SIMPLE_CHEMICAL", 0, 12], ["sialic acid-containing glycosphingolipids", "SIMPLE_CHEMICAL", 17, 58], ["plasma membrane", "CELLULAR_COMPONENT", 107, 122], ["Gangliosides", "TREATMENT", 0, 12], ["sialic acid-containing glycosphingolipids", "TREATMENT", 17, 58], ["sialic", "ANATOMY_MODIFIER", 17, 23], ["acid-containing glycosphingolipids", "OBSERVATION", 24, 58], ["ubiquitous", "OBSERVATION_MODIFIER", 68, 78], ["components", "OBSERVATION_MODIFIER", 79, 89], ["mammalian plasma membrane", "OBSERVATION", 97, 122]]], ["They are assumed to play important roles in the interaction of cells with their environment, and are apparently involved in the regulation of many cellular events (Hakomori, 1990 (Hakomori, , 1991 Kopitz, 1996) .", [["cells", "ANATOMY", 63, 68], ["cellular", "ANATOMY", 147, 155], ["cells", "CELL", 63, 68], ["cellular", "CELL", 147, 155]]], ["Since the carbohydrate part of naturally occurring gangliosides can be modified, e.g., by 9-0acetylation of sialic acids (Reuter and Schauer, 1987) , the presence of such alterations prompts evaluation of their structural impact on conformation and molecular recognition.", [["9-0acetylation", "CHEMICAL", 90, 104], ["sialic acids", "CHEMICAL", 108, 120], ["carbohydrate", "CHEMICAL", 10, 22], ["sialic acids", "CHEMICAL", 108, 120], ["gangliosides", "SIMPLE_CHEMICAL", 51, 63], ["sialic acids", "SIMPLE_CHEMICAL", 108, 120], ["sialic acids", "TREATMENT", 108, 120], ["such alterations", "PROBLEM", 166, 182], ["evaluation", "TEST", 191, 201]]], ["Following this reasoning, we have focused in the present study on G DU and its 9-O-acetylated derivative G D , a ( e Neu5,9Ac 2 ) carrying the A'-acetyl-9-O-acetylneuraminic acid exclusively linked to the terminal galactose moiety of the tetrasaccharide backbone Galpl-3GalNAc(31tGlc, whereas the internal galactose residue is substituted by /V-acetylneuraminic acid (Gowda et ai, 1984) .", [["DU", "CHEMICAL", 68, 70], ["acetyl-9-O-acetylneuraminic acid", "CHEMICAL", 146, 178], ["galactose", "CHEMICAL", 214, 223], ["Galpl-3GalNAc", "CHEMICAL", 263, 276], ["31tGlc", "CHEMICAL", 277, 283], ["galactose", "CHEMICAL", 306, 315], ["V-acetylneuraminic acid", "CHEMICAL", 343, 366], ["9-O", "CHEMICAL", 79, 82], ["A'-acetyl-9-O-acetylneuraminic acid", "CHEMICAL", 143, 178], ["galactose", "CHEMICAL", 214, 223], ["tetrasaccharide", "CHEMICAL", 238, 253], ["Galpl-3GalNAc", "CHEMICAL", 263, 276], ["Glc", "CHEMICAL", 280, 283], ["galactose", "CHEMICAL", 306, 315], ["V-acetylneuraminic acid", "CHEMICAL", 343, 366], ["G DU", "SIMPLE_CHEMICAL", 66, 70], ["9-O-acetylated derivative G D", "SIMPLE_CHEMICAL", 79, 108], ["e Neu5,9Ac 2", "SIMPLE_CHEMICAL", 115, 127], ["A'-acetyl-9-O-acetylneuraminic acid", "SIMPLE_CHEMICAL", 143, 178], ["galactose", "SIMPLE_CHEMICAL", 214, 223], ["Galpl-3GalNAc", "SIMPLE_CHEMICAL", 263, 276], ["31tGlc", "SIMPLE_CHEMICAL", 277, 283], ["V-acetylneuraminic acid", "SIMPLE_CHEMICAL", 343, 366], ["acetylated derivative G D", "TREATMENT", 83, 108], ["a ( e Neu5,9Ac", "TREATMENT", 111, 125], ["the A'-acetyl", "TREATMENT", 139, 152], ["O-acetylneuraminic acid", "TREATMENT", 155, 178], ["the tetrasaccharide backbone Galpl", "TEST", 234, 268], ["Glc", "TEST", 280, 283], ["the internal galactose residue", "TEST", 293, 323], ["galactose residue", "OBSERVATION", 306, 323]]], ["A schematic representation of the oligosaccharide part of G DU ( e Neu5,9Ac 2 ), denoted as fragment IV in the text, is shown in Figure 1 .", [["G DU", "SIMPLE_CHEMICAL", 58, 62], ["fragment IV", "PROTEIN", 92, 103], ["G DU ( e Neu5,9Ac", "TREATMENT", 58, 75]]]], "7c027d3fd824b9dc9a8dbc8700873d16f7930a99": [["IntroductionOn March 11 th , 2020, the World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) a pandemic.", [["coronavirus disease", "DISEASE", 80, 99], ["coronavirus", "ORGANISM", 80, 91], ["coronavirus disease", "PROBLEM", 80, 99], ["COVID", "TEST", 104, 109], ["a pandemic", "PROBLEM", 114, 124], ["coronavirus disease", "OBSERVATION", 80, 99]]], ["Currently, more than 2,314,621 people across all the world have been infected by this virus, and more than 157,847 people have died [1] .IntroductionThe rapid increase in this contagion have forced all area hospitals to transform rapidly from general or specialized care facilities to dedicated -COVID structures\u2016.", [["people", "ORGANISM", 31, 37], ["people", "ORGANISM", 115, 121], ["people", "SPECIES", 31, 37], ["people", "SPECIES", 115, 121], ["this virus", "PROBLEM", 81, 91], ["infected", "OBSERVATION", 69, 77], ["rapid", "OBSERVATION_MODIFIER", 153, 158], ["increase", "OBSERVATION_MODIFIER", 159, 167]]], ["All elective procedures have been postponed and only emergency care has continued.", [["All elective procedures", "TREATMENT", 0, 23], ["emergency care", "TREATMENT", 53, 67]]], ["Emergency rooms are filled with patients coming in for respiratory distress and fever, and the number of contagions increases daily [2] .", [["respiratory", "ANATOMY", 55, 66], ["respiratory distress", "DISEASE", 55, 75], ["fever", "DISEASE", 80, 85], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["respiratory distress", "PROBLEM", 55, 75], ["fever", "PROBLEM", 80, 85], ["fever", "OBSERVATION", 80, 85]]], ["On March 14 th , 2020, a State of Emergency (implementation of stringent lockdown measures for the population) was declared in Spain, and this has persisted to this date [3] .", [["stringent lockdown measures", "TREATMENT", 63, 90]]], ["There were and are no longer any subdivisions in our work [4] .IntroductionHospitals' work regimes have been re-prioritized.", [["IntroductionHospitals' work regimes", "TREATMENT", 63, 98], ["no longer", "UNCERTAINTY", 19, 28]]], ["However, even though coronavirus infection must be a priority, this pandemic does not cause other health emergencies, including orthopaedic and other trauma, to disappear [5] .", [["coronavirus infection", "DISEASE", 21, 42], ["trauma", "DISEASE", 150, 156], ["coronavirus", "ORGANISM", 21, 32], ["coronavirus infection", "PROBLEM", 21, 42], ["orthopaedic and other trauma", "PROBLEM", 128, 156], ["coronavirus", "OBSERVATION_MODIFIER", 21, 32], ["infection", "OBSERVATION", 33, 42]]], ["Orthopaedic surgery and trauma staff is the largest surgical department in most hospitals around the world.", [["trauma", "DISEASE", 24, 30], ["Orthopaedic surgery", "TREATMENT", 0, 19]]], ["Although most traumatologists are not fighting on the front line against Covid-19, we must guarantee treatment for orthopaedic and trauma patients and, in the meantime, protect healthcare workers and patients from Covid-19 infection [6] .", [["trauma", "DISEASE", 131, 137], ["infection", "DISEASE", 223, 232], ["traumatologists", "CANCER", 14, 29], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 200, 208], ["Covid-19", "ORGANISM", 214, 222], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 200, 208], ["Covid", "TEST", 73, 78]]], ["Many different strategies have been proposed and implemented worldwide in an attempt to contain this pandemic, some more successful than others [7] .", [["this pandemic", "PROBLEM", 96, 109]]], ["Each decision requires an individualized risk/benefit assessment, with the aims of protecting healthcare personal and patients, helping hospitals deal with Covid-19 lines, and not compromising the assessment and outcomes of our patients.", [["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 228, 236], ["benefit assessment", "TEST", 46, 64], ["Covid-19 lines", "TREATMENT", 156, 170], ["the assessment", "TEST", 193, 207]]], ["We cannot provide specific guidance, because resources and coronavirus infection curves are different between countries, cities, and hospitals.", [["coronavirus infection", "DISEASE", 59, 80], ["coronavirus", "ORGANISM", 59, 70], ["coronavirus infection curves", "PROBLEM", 59, 87]]], ["Nonetheless, we can share our experiences and outcomes during the first month of the Covid-19 pandemic, based on the strategies recommended and the strategies we have implemented.", [["the strategies", "TREATMENT", 113, 127], ["the strategies", "TREATMENT", 144, 158]]], ["We think this is important because, despite guidance via expert opinions [6] [7] [8] [9] [10] , no published outcome experiences are based on the strategies applied.", [["the strategies", "TREATMENT", 142, 156]]], ["Furthermore, that guides do not explain how orthopaedic and trauma staff can help and be part of the solution of this outbreak.Methods and MaterialsOur experience comes from our work at a referral hospital within the Spanish National Health System.", [["trauma", "DISEASE", 60, 66]]], ["Specific records have been kept since March 14 th , 2020, when a State of Emergency (implementation of stringent lockdown measures for the population) was declared in Spain.", [["stringent lockdown measures", "TREATMENT", 103, 130]]], ["Our hospital is one of the orthopaedic and trauma referral centers in Spain.", [["trauma", "DISEASE", 43, 49]]], ["We perform all kinds of elective and emergency surgery in trauma and orthopaedics, 8000 surgeries per year.", [["trauma", "DISEASE", 58, 64], ["elective and emergency surgery", "TREATMENT", 24, 54]]], ["Since the emergence of the COVID-19 outbreak, local orthopaedics and trauma practices have been markedly affected.Methods and MaterialsChanges to clinical practice have largely been guided by the current evidence and four main principles: (1) patient and health-care worker protection, (2) uninterrupted necessary care, (3) conservation of health-care resources, (4) uninterrupted formation for residents.", [["trauma", "DISEASE", 69, 75], ["patient", "ORGANISM", 243, 250], ["patient", "SPECIES", 243, 250], ["the COVID", "TEST", 23, 32], ["local orthopaedics", "TREATMENT", 46, 64], ["trauma practices", "TREATMENT", 69, 85], ["markedly", "OBSERVATION_MODIFIER", 96, 104]]], ["Based on these principles, changes in the service organization, elective clinical visits, emergency visits, surgical procedures, and inpatient and outpatient care have been tailored, as will be described later.Minimizing Risk.Daily information on the status of Covid-19 positive patients at our institution was presented via telematics.Minimizing Risk.On April 02 nd , 707 Covid-19 patients were admitted, among whom 165 were considered critical and requiring intensive care unit (ICU).", [["patients", "ORGANISM", 279, 287], ["patients", "ORGANISM", 382, 390], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 382, 390], ["surgical procedures", "TREATMENT", 108, 127], ["Covid", "TEST", 261, 266]]], ["A policy of avoiding all wearing of street clothes and street shoes in the hospital was implemented, as was the mandatory use of surgical masks and gloves throughout the hospital.", [["surgical masks", "TREATMENT", 129, 143], ["gloves", "TREATMENT", 148, 154]]], ["In the emergency room and in surgery rooms, wearing a N95 mask, FFP 2 mask, or FFP 3 mask was mandated.Organization.Separate Teams (A&B) work in separate weeks.", [["a N95 mask", "TREATMENT", 52, 62], ["FFP 2 mask", "TREATMENT", 64, 74], ["FFP 3 mask", "TREATMENT", 79, 89]]], ["Only people essential to the delivery of healthcare services are encouraged to go to the hospital.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["In our service, there are 10 units, which include a hip unit, knee unit, ankle and foot unit, shoulder and elbow unit, hand and microsurgery unit, spine unit, tumor unit, septic pathology and bone reconstruction unit, trauma unit, and orthopaedics and childhood trauma unit.", [["knee", "ANATOMY", 62, 66], ["shoulder", "ANATOMY", 94, 102], ["hand", "ANATOMY", 119, 123], ["spine", "ANATOMY", 147, 152], ["tumor", "ANATOMY", 159, 164], ["bone", "ANATOMY", 192, 196], ["tumor", "DISEASE", 159, 164], ["septic", "DISEASE", 171, 177], ["trauma", "DISEASE", 218, 224], ["trauma", "DISEASE", 262, 268], ["ankle", "ORGANISM_SUBDIVISION", 73, 78], ["shoulder", "ORGANISM_SUBDIVISION", 94, 102], ["tumor", "CANCER", 159, 164], ["bone", "TISSUE", 192, 196], ["a hip unit, knee unit, ankle and foot unit, shoulder and elbow unit", "TREATMENT", 50, 117], ["septic pathology", "PROBLEM", 171, 187], ["hip", "ANATOMY", 52, 55], ["knee", "ANATOMY", 62, 66], ["ankle", "ANATOMY", 73, 78], ["foot", "ANATOMY", 83, 87], ["shoulder", "ANATOMY", 94, 102], ["elbow", "ANATOMY", 107, 112], ["hand", "ANATOMY", 119, 123], ["spine", "ANATOMY", 147, 152], ["tumor", "OBSERVATION", 159, 164], ["septic", "OBSERVATION", 171, 177], ["bone", "ANATOMY", 192, 196]]], ["The teams were constructed so that one person from each unit is always present or on call.", [["person", "SPECIES", 39, 45]]], ["Likewise, an attempt was made to exclude elderly healthcare providers (over 60 years old) from the service, as well as those with newly-born children, so that such individuals may avoid going to the hospital unless absolutely essential.Organization.Daily telematics reunions between the chief of the service and chiefs of the individual units occur.", [["children", "ORGANISM", 141, 149], ["individuals", "ORGANISM", 164, 175], ["children", "SPECIES", 141, 149]]], ["Personnel have been organized to support the Covid-19 units, to cover trauma care (emergency clinical visits and emergent surgeries), operating rooms (delayed fracture emergencies) and clinical consultations (general and specialized consultations via telemedicine).", [["trauma", "DISEASE", 70, 76], ["fracture", "DISEASE", 159, 167], ["trauma care", "TREATMENT", 70, 81], ["emergent surgeries", "TREATMENT", 113, 131]]], ["Morning meetings have included information on the number of patients admitted the previous day for emergency care and a morning teaching session for the residents.Help to COVID areas and hospital beds.In our hospitals, we have 120 beds for trauma and orthopaedics patients, divided between three floors.", [["trauma", "DISEASE", 240, 246], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 264, 272], ["emergency care", "TREATMENT", 99, 113], ["hospital beds", "TREATMENT", 187, 200]]], ["Two floors are currently being used for COVID patients, while one floor is used for non-COVID patients.", [["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 94, 102], ["COVID patients", "TREATMENT", 40, 54]]], ["Also, a new ICU was constructed on one floor of the orthopaedics building, consisting of 80 intensive care unit beds, and this unit is partially covered by orthopaedics and trauma faculty and residents.Elective Clinical Visits.The adoption of telemedicine was improved.", [["trauma", "DISEASE", 173, 179]]], ["At our intuition, we have 70 weekly clinics, each with between 20 and 30 patients.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81]]], ["Fifty of these clinics are for orthopaedics and trauma specialties and 20 for general trauma and orthopaedic consultations.", [["trauma", "DISEASE", 48, 54], ["trauma", "DISEASE", 86, 92]]], ["Each doctor was responsible for their own patients' telephone visits.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50]]], ["General clinic schedules were distributed among the older specialists and those with newborn children.", [["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101]]], ["Only one daily consultation clinic remains, with a maximum of 10 patients, with an attending physician available to see patients whose visit could not be postponed.", [["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 120, 128]]], ["Also, two weekly general clinics for fracture patients who require follow-up were left open (maximum of 15 patients).Emergency Clinical Visits.For the implementation of stringent lockdown measures for the population, emergency clinical visits were reduced.", [["fracture", "DISEASE", 37, 45], ["patients", "ORGANISM", 46, 54], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 107, 115], ["fracture", "PROBLEM", 37, 45], ["stringent lockdown measures", "TREATMENT", 169, 196], ["fracture", "OBSERVATION", 37, 45]]], ["Consequently, the trauma emergency team was reduced to a minimum, consisting only of two traumatologists and orthopaedic surgeons and three traumatologists and orthopaedic residents.Emergency Clinical Visits.In the beginning, a real-time reverse transcription-polymerase chain reaction (RT-PCR) for Covid-19 was only requested if the patients had symptoms or had pathological chest x-ray evaluated by a radiologist, our biggest mistake.", [["trauma", "DISEASE", 18, 24], ["patients", "ORGANISM", 334, 342], ["patients", "SPECIES", 334, 342], ["polymerase chain reaction", "PROBLEM", 260, 285], ["RT-PCR", "TEST", 287, 293], ["Covid", "TEST", 299, 304], ["symptoms", "PROBLEM", 347, 355], ["pathological chest x-ray", "TEST", 363, 387], ["chest", "ANATOMY", 376, 381]]], ["Due to the increase of the pandemic outbreak and for the protection of health workers, we improved the protocol.", [["the pandemic outbreak", "PROBLEM", 23, 44], ["the protocol", "TREATMENT", 99, 111], ["increase", "OBSERVATION_MODIFIER", 11, 19]]], ["Currently, all patients that need visit wear gloves and mask, also all patients who need hospital admission undergo a RT-PCR test for Covid-19 and have a chest x-ray ( Figure 1 ).Orthopaedics and Trauma Surgery.Elective surgical cases have been postponed to permit hospitals to free up beds for the treatment of patients with either confirmed or suspected Covid-19.", [["Trauma", "DISEASE", 196, 202], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 312, 320], ["mask", "TREATMENT", 56, 60], ["a RT-PCR test", "TEST", 116, 129], ["Covid", "TEST", 134, 139], ["a chest x-ray", "TEST", 152, 165], ["Trauma Surgery", "TREATMENT", 196, 210], ["Elective surgical cases", "TREATMENT", 211, 234], ["the treatment", "TREATMENT", 295, 308], ["Covid", "TEST", 356, 361], ["chest", "ANATOMY", 154, 159]]], ["For emergent and urgent surgical cases, two different surgical areas have been created, each on a different floor: one a COVID-positive surgical area and the other a COVID-negative surgical area.", [["emergent and urgent surgical cases", "TREATMENT", 4, 38], ["two different surgical areas", "PROBLEM", 40, 68], ["a COVID-positive surgical area", "PROBLEM", 119, 149], ["different", "OBSERVATION_MODIFIER", 44, 53], ["surgical", "OBSERVATION", 54, 62], ["positive", "OBSERVATION_MODIFIER", 127, 135], ["surgical area", "OBSERVATION", 136, 149], ["negative", "OBSERVATION", 172, 180], ["surgical area", "OBSERVATION", 181, 194]]], ["RT-PCR tests for Covid-19 and chest x-rays are performed the night before or the same day that patients undergo surgery.Orthopaedics and Trauma Surgery.The description of personal protective equipment (PPE) in surgery rooms was performed in Table 1 , and is shown on figure 2 .", [["Trauma", "DISEASE", 137, 143], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["RT-PCR tests", "TEST", 0, 12], ["Covid", "TEST", 17, 22], ["chest x-rays", "TEST", 30, 42], ["surgery", "TREATMENT", 112, 119], ["Trauma Surgery", "TREATMENT", 137, 151], ["personal protective equipment", "TREATMENT", 171, 200], ["chest", "ANATOMY", 30, 35], ["surgery", "OBSERVATION", 112, 119]]], ["The results, the mortality and the nosocomial infection of Covid-19 were recorded, to know if it was pertinent to operate patients during this pandemic outbreak.", [["infection", "DISEASE", 46, 55], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["the nosocomial infection", "PROBLEM", 31, 55], ["Covid", "TEST", 59, 64], ["this pandemic outbreak", "PROBLEM", 138, 160], ["nosocomial", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 46, 55]]], ["Covid-19 nosocomial infection was defined as the Covid-19 infection that was acquired in the hospital.Minimizing Risk and Organization.Even though we adopted a split team policy and encouraged complete team segregation, out of 46 orthopaedics and trauma faculty and 28 orthopaedics and trauma residents, five faculty and three residents ultimately were discovered to have been infected with Covid-19.", [["nosocomial infection", "DISEASE", 9, 29], ["infection", "DISEASE", 58, 67], ["trauma", "DISEASE", 247, 253], ["trauma", "DISEASE", 286, 292], ["Covid-19", "SPECIES", 49, 57], ["Covid", "TEST", 0, 5], ["nosocomial infection", "PROBLEM", 9, 29], ["the Covid-19 infection", "PROBLEM", 45, 67], ["Covid", "TEST", 391, 396], ["nosocomial", "OBSERVATION_MODIFIER", 9, 19], ["infection", "OBSERVATION", 20, 29], ["infection", "OBSERVATION", 58, 67], ["infected", "OBSERVATION", 377, 385]]], ["Of these eight, seven have already recovered, while the other remains in isolation at home.Help to COVID areas and hospital beds.On March 14 th , 108 orthopaedic and trauma patients were admitted to the hospital.", [["trauma", "DISEASE", 166, 172], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["hospital beds", "TREATMENT", 115, 128]]], ["By the end of the first week, the number of patients admitted had been reduced to a third (42 patients).", [["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 94, 102]]], ["From that day forward, the mean number of hospital admissions for this cohort of patients has been 32 (range, 25 -42), all admitted to trauma emergency services.", [["trauma", "DISEASE", 135, 141], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["It was essential, the help of the faculty surgeons to make a faster discharge of the patients.Help to COVID areas and hospital beds.Eight faculty and eight residents help the COVID teams every day.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["hospital beds", "TREATMENT", 118, 131]]], ["A description of the duties that were performed in the ICUs is in Table 2 .Organization of clinical visitsPhone interviews were conducted with 6,413 outpatients.", [["outpatients", "ORGANISM", 149, 160], ["outpatients", "SPECIES", 149, 160]]], ["More than 95.6% of patients had their issueEmergency Clinical VisitsFive hundred twenty emergency clinical visits occurred.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["Mean patient visits per day were 28 (range 4-36).", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["A decrease of more than 25%, relative to the normal number of visits performed, was observed during this first month after stringent lock-down measures were implemented across the country.", [["stringent lock-down measures", "TREATMENT", 123, 151], ["decrease", "OBSERVATION_MODIFIER", 2, 10]]], ["There also was a decrease in the number of poly-trauma patients, traffic accidents and work-related accidents.", [["trauma", "DISEASE", 48, 54], ["traffic accidents", "DISEASE", 65, 82], ["accidents", "DISEASE", 100, 109], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["decrease", "OBSERVATION_MODIFIER", 17, 25]]], ["A comparison with the previous month, before lockdown measurements were done in Table 3 .Orthopaedics and Trauma Surgeries.We performed 102 trauma surgeries.", [["Trauma", "DISEASE", 106, 112], ["trauma", "DISEASE", 140, 146], ["lockdown measurements", "TEST", 45, 66], ["Trauma Surgeries", "TREATMENT", 106, 122], ["trauma surgeries", "TREATMENT", 140, 156]]], ["Because of the implementation of stringent lock-down measures for the general population, polytrauma surgeries decreased, such that only three such surgeries were performed.", [["polytrauma", "DISEASE", 90, 100], ["stringent lock-down measures", "TREATMENT", 33, 61], ["the general population", "PROBLEM", 66, 88], ["polytrauma surgeries", "TREATMENT", 90, 110], ["three such surgeries", "TREATMENT", 137, 157], ["polytrauma", "OBSERVATION", 90, 100]]], ["The remaining 97.3% of surgeries were deferred emergencies.", [["surgeries", "TREATMENT", 23, 32]]], ["Brief descriptions and percentages for the surgeries performed are provided in Table 4 .", [["the surgeries", "TREATMENT", 39, 52]]], ["Forty-six surgeries (41.1%) were for osteoporotic hip fractures, the most common indication for admission for surgery during this period.Orthopaedics and Trauma Surgeries.Among the 102 patients admitted for surgery, 10 Covid-19 positive patients were identified at admission.", [["hip", "ANATOMY", 50, 53], ["osteoporotic hip fractures", "DISEASE", 37, 63], ["Trauma", "DISEASE", 154, 160], ["hip", "ORGANISM_SUBDIVISION", 50, 53], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 237, 245], ["six surgeries", "TREATMENT", 6, 19], ["osteoporotic hip fractures", "PROBLEM", 37, 63], ["surgery", "TREATMENT", 110, 117], ["Trauma Surgeries", "TREATMENT", 154, 170], ["surgery", "TREATMENT", 207, 214], ["hip", "ANATOMY", 50, 53], ["fractures", "OBSERVATION", 54, 63]]], ["We also identified 11 nosocomial COVID-19 infections, 9 cases in elderly patients who underwent surgery for an osteoporotic hip fracture.", [["hip", "ANATOMY", 124, 127], ["infections", "DISEASE", 42, 52], ["osteoporotic hip fracture", "DISEASE", 111, 136], ["patients", "ORGANISM", 73, 81], ["hip", "ORGANISM_SUBDIVISION", 124, 127], ["patients", "SPECIES", 73, 81], ["nosocomial COVID", "TEST", 22, 38], ["surgery", "TREATMENT", 96, 103], ["an osteoporotic hip fracture", "PROBLEM", 108, 136], ["osteoporotic", "OBSERVATION", 111, 123], ["hip", "ANATOMY", 124, 127], ["fracture", "OBSERVATION", 128, 136]]], ["The nosocomial COVID-19 infection rate was 10.7%.", [["infection", "DISEASE", 24, 33], ["The nosocomial COVID", "TEST", 0, 20], ["infection rate", "TEST", 24, 38]]], ["Among the 81 COVID-19 free patients, 91% were discharged home, while six patients remain in the hospital with good outcomes and no intrahospital mortality.", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 73, 81], ["intrahospital mortality", "PROBLEM", 131, 154]]], ["Among the 21 COVID-19 patients, only three died after surgery, while 6 are still in-hospital and 12 were discharged to home or some other residence.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["surgery", "TREATMENT", 54, 61]]], ["The intrahospital mortality rate among operated-upon patients over this time was 1.7%.Orthopaedics and Trauma Surgeries.Among the eight healthcare personal who became infected with COVID-19, no infection was related to surgeries, since none of these physicians performed any surgery at our hospital prior to their infection.", [["Trauma", "DISEASE", 103, 109], ["infection", "DISEASE", 194, 203], ["infection", "DISEASE", 314, 323], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["The intrahospital mortality rate", "TEST", 0, 32], ["Trauma Surgeries", "TREATMENT", 103, 119], ["COVID", "TREATMENT", 181, 186], ["infection", "PROBLEM", 194, 203], ["surgeries", "TREATMENT", 219, 228], ["any surgery", "TREATMENT", 271, 282], ["their infection", "PROBLEM", 308, 323], ["infection", "OBSERVATION", 194, 203], ["infection", "OBSERVATION", 314, 323]]], ["For the surgeries, a maximum of three surgeons was allowed (2 faculty and one resident), although most of the surgeries were performed by only two surgeons (2 faculty or 1 faculty and 1 resident).DiscussionUsing the guidance of experts, we were able to help the hospital address the demands of the Covid-19 outbreak.", [["the surgeries", "TREATMENT", 4, 17], ["the surgeries", "TREATMENT", 106, 119], ["the Covid", "TEST", 294, 303], ["surgeries", "OBSERVATION", 8, 17], ["surgeries", "OBSERVATION", 110, 119]]], ["We reduced to a third our orthopaedics and trauma hospital beds, provided coverage for general emergency services and five ICUs, all the while continuing to provide care for our patients, in the form of 102 trauma surgeries, 6413 phone interviews and 520 emergency clinic visits.", [["trauma", "DISEASE", 43, 49], ["trauma", "DISEASE", 207, 213], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["trauma surgeries", "TREATMENT", 207, 223]]], ["On the other hand, eight of the healthcare personnel on our service (10.8%) became infected with COVID-19.", [["COVID-19", "CHEMICAL", 97, 105], ["COVID-19", "CHEMICAL", 97, 105], ["COVID", "TEST", 97, 102]]], ["Our biggest mistake was not performing a RT-PCR in all the patients that need hospital admission since the first day.DiscussionThat we had 10.8% of our attending and resident physicians become infected with COVID-19 is a problem.", [["COVID-19", "CHEMICAL", 207, 215], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["a RT-PCR", "TEST", 39, 47], ["COVID", "TREATMENT", 207, 212], ["infected", "OBSERVATION", 193, 201]]], ["In fact, this is one of the most important problems that has arisen facing the coronavirus outbreak.", [["coronavirus", "DISEASE", 79, 90], ["coronavirus", "ORGANISM", 79, 90], ["the coronavirus outbreak", "PROBLEM", 75, 99], ["coronavirus outbreak", "OBSERVATION", 79, 99]]], ["Of our own healthcare workers' infections, six were in the first week, and the other two in the second week.", [["infections", "DISEASE", 31, 41]]], ["We think that the reduced infection rate among healthcare workers was because we had implemented more stringent hospital policies.", [["infection", "DISEASE", 26, 35], ["the reduced infection rate", "PROBLEM", 14, 40], ["reduced", "OBSERVATION_MODIFIER", 18, 25], ["infection", "OBSERVATION", 26, 35]]], ["At the beginning of the first week, healthcare personnel only used surgical masks in the hospital, and we only tested emergency room patients who reported symptoms.", [["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["surgical masks", "TREATMENT", 67, 81], ["symptoms", "PROBLEM", 155, 163]]], ["Presently, all healthcare workers wear gloves and a surgical maskeither a N95 or FFP 2 maskthroughout their time in the hospital.", [["a surgical maskeither a N95", "TREATMENT", 50, 77], ["FFP", "TREATMENT", 81, 84]]], ["All patients who come to the hospital also must wear at least a surgical mask and gloves.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["a surgical mask", "TREATMENT", 62, 77], ["gloves", "TREATMENT", 82, 88]]], ["We perform chest x-rays and RT-PCR testing for COVID-19 on all patients who need hospital admission.", [["chest", "ANATOMY", 11, 16], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["chest x-rays", "TEST", 11, 23], ["RT-PCR testing", "TEST", 28, 42], ["COVID", "TEST", 47, 52], ["chest", "ANATOMY", 11, 16]]], ["Furthermore, among patients admitted through the emergency room or a clinic and those who undergo surgery and test positive for COVID-19, appropriate PPE has been implemented.DiscussionSupporting COVID-19 teams is important at this time.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["surgery", "TREATMENT", 98, 105], ["test", "TEST", 110, 114], ["COVID", "TEST", 128, 133]]], ["The first thing we can do is minimize patients' exposure to COVID-19 by postponing all elective surgical procedures and hastening the discharge of patients who are admitted.", [["COVID-19", "CHEMICAL", 60, 68], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 147, 155], ["COVID", "TREATMENT", 60, 65], ["all elective surgical procedures", "TREATMENT", 83, 115]]], ["We postponed all elective surgeries and were able to reduce our hospital bed use to a third of its baseline.", [["all elective surgeries", "TREATMENT", 13, 35]]], ["The purpose of this recommendation is also to limit the use of hospital beds, increasing the hospital beds available for COVID-19 patients [7] .", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["hospital beds", "TREATMENT", 63, 76]]], ["Discharging patients as early as possible also is important because it reduces the likelihood of nosocomial COVID-19 infection via spread back and forth between patients and healthcare workers.", [["infection", "DISEASE", 117, 126], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 161, 169], ["nosocomial COVID", "PROBLEM", 97, 113], ["19 infection", "PROBLEM", 114, 126], ["infection", "OBSERVATION", 117, 126]]], ["Even though many of us are relatively unprepared to handle the use of mechanical ventilators, and many of us have not worked in an ER or ICU in years, we can help.", [["ER", "GENE_OR_GENE_PRODUCT", 131, 133], ["mechanical ventilators", "TREATMENT", 70, 92]]], ["We must recognize that, just like we understand that most physicians cannot apply an external fixator device, they also know that we cannot intubate patients and operate mechanical ventilators.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["an external fixator device", "TREATMENT", 82, 108], ["mechanical ventilators", "TREATMENT", 170, 192], ["fixator", "OBSERVATION", 94, 101]]], ["Depending on the will, knowledge and skills of each member, our teams were divided in such a way that all necessary aspects of care could be addressed, including handling patients' medications, making calls to patients' relatives, providing emergency care prior to the initial triage of COVID-19 and non-COVID-19 patients, and helping to transport patients.", [["patients", "ORGANISM", 171, 179], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 313, 321], ["patients", "ORGANISM", 348, 356], ["patients", "SPECIES", 171, 179], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 313, 321], ["patients", "SPECIES", 348, 356], ["handling patients' medications", "TREATMENT", 162, 192], ["COVID", "TEST", 287, 292]]], ["In our institution, none have regretted having helped.DiscussionAlso, apart from helping, we must not forget our service, our patients and the formation of our residents.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134]]], ["Over 100 trauma surgeries were performed.", [["trauma", "DISEASE", 9, 15], ["trauma surgeries", "TREATMENT", 9, 25]]], ["To our knowledge, no healthcare personnel has become infected with COVID-19 during any of these surgical procedures.", [["COVID", "TREATMENT", 67, 72], ["these surgical procedures", "TREATMENT", 90, 115], ["infected", "OBSERVATION", 53, 61], ["surgical", "OBSERVATION", 96, 104]]], ["Even most trauma surgery could be performed with regional anesthesia, as we must remember that intubation is considered one of the highest-risk procedures when dealing with COVID-19 patients [14] .", [["trauma", "DISEASE", 10, 16], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["trauma surgery", "TREATMENT", 10, 24], ["regional anesthesia", "TREATMENT", 49, 68], ["intubation", "TREATMENT", 95, 105], ["COVID", "TEST", 173, 178]]], ["In locations with widespread infections and limited resources, the risk of surgical procedures, both for the patient and community, may outweigh the benefit [15] .", [["infections", "DISEASE", 29, 39], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["widespread infections", "PROBLEM", 18, 39], ["surgical procedures", "TREATMENT", 75, 94], ["widespread", "OBSERVATION_MODIFIER", 18, 28], ["infections", "OBSERVATION", 29, 39]]], ["In the current literature, Lei et al, in their retrospective review, analyzed 34 surgical patients who underwent elective surgeries during the incubation of COVID-19 in Wuhan, and found that all patients developed COVID-19, 44% required admission to an ICU, and seven died after ICU admission [15] .", [["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 195, 203], ["elective surgeries", "TREATMENT", 113, 131], ["COVID", "TEST", 157, 162], ["COVID", "TEST", 214, 219]]], ["Even though the intrahospital mortality rate was low (1.7%), nosocomial COVID-19 infections developed in 10.7%.", [["infections", "DISEASE", 81, 91], ["COVID-19", "SPECIES", 72, 80], ["the intrahospital mortality rate", "TEST", 12, 44], ["nosocomial COVID", "TEST", 61, 77], ["infections", "PROBLEM", 81, 91]]], ["This percentage correlates with that of our healthcare workers, so that we believe that these new COVID-19 infections occurred during inpatient visits.", [["infections", "DISEASE", 107, 117], ["these new COVID-19 infections", "PROBLEM", 88, 117], ["new", "OBSERVATION_MODIFIER", 94, 97]]], ["One potential explanation is that hospital inpatient floors are more fluid sites, where doctors, nurses, security, and housekeeping personnel change every 8 or 12 hours.", [["fluid sites", "PROBLEM", 69, 80]]], ["For this reason, minimizing the number of healthcare workers and increasing protective measures (e.g., PPE, cleaning supplies, etc.) is vital on hospital floors.", [["increasing protective measures", "TREATMENT", 65, 95]]], ["During the first week, two patients admitted to the hospital for an osteoporotic hip fracture were discovered to be COVID-19 positive, so we decided to delay their surgery; both ultimately died.", [["hip", "ANATOMY", 81, 84], ["fracture", "DISEASE", 85, 93], ["patients", "ORGANISM", 27, 35], ["hip", "ORGANISM_SUBDIVISION", 81, 84], ["patients", "SPECIES", 27, 35], ["an osteoporotic hip fracture", "PROBLEM", 65, 93], ["COVID", "TEST", 116, 121], ["their surgery", "TREATMENT", 158, 171], ["osteoporotic", "OBSERVATION", 68, 80], ["hip", "ANATOMY", 81, 84], ["fracture", "OBSERVATION", 85, 93]]], ["Based on this, if resources and equipment are available, we recommend trying to operate on such patients promptly.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104]]], ["Among our 46 elderly patients, 28 were discharged home COVID-19 free, while 9 patients developed a COVID-19 infection.", [["infection", "DISEASE", 108, 117], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 78, 86], ["a COVID-19 infection", "PROBLEM", 97, 117], ["infection", "OBSERVATION", 108, 117]]], ["Surgical contraindication would be a patient with active pneumonia, dyspnea or fever.", [["pneumonia", "DISEASE", 57, 66], ["dyspnea", "DISEASE", 68, 75], ["fever", "DISEASE", 79, 84], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["Surgical contraindication", "TREATMENT", 0, 25], ["active pneumonia", "PROBLEM", 50, 66], ["dyspnea", "PROBLEM", 68, 75], ["fever", "PROBLEM", 79, 84], ["active", "OBSERVATION_MODIFIER", 50, 56], ["pneumonia", "OBSERVATION", 57, 66], ["fever", "OBSERVATION", 79, 84]]], ["But for the mere fact of being COVID, the surgery of any patient should not be postponed.DiscussionEvery doctor can help to keep as many patients as possible at home [1] .", [["patient", "ORGANISM", 57, 64], ["patients", "ORGANISM", 137, 145], ["patient", "SPECIES", 57, 64], ["patients", "SPECIES", 137, 145], ["the surgery", "TREATMENT", 38, 49]]], ["As in the USA, trauma and orthopaedic consultations comprise almost 70% of all clinical consultations [6] .", [["trauma", "DISEASE", 15, 21]]], ["Because losing a friend or a coworker can be fatal for a service, despite their willingness to help, elderly physicians and those with newborn children were asked to contribute from home, especially providing clinical consultations by phone.", [["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151]]], ["As such, infection of our center's healthcare personnel generally affected our younger physicians, ranging in age from 28-50.DiscussionFinally, another important objective is the training of residents.", [["infection", "DISEASE", 9, 18], ["infection", "OBSERVATION", 9, 18]]], ["It is obvious that their time in surgery has decreased, but their development should not [16] .", [["surgery", "TREATMENT", 33, 40], ["decreased", "OBSERVATION_MODIFIER", 45, 54]]], ["The use of videoconferencing is strongly recommended to facilitate continued learning and counteract the stress of social isolation.", [["videoconferencing", "TREATMENT", 11, 28], ["social isolation", "TREATMENT", 115, 131]]], ["With respect to assisting in surgical procedures, all residents took turns so they continued to develop their skills, stressing the importance of there currently being as few people in the operating room as possible.ConclusionsAs priorities and resources increasingly shift towards the COVID-19 pandemic, will it be possible to maintain the high standard and quality of care necessary for trauma and orthopaedics patients while the pandemic persists?", [["trauma", "DISEASE", 389, 395], ["people", "ORGANISM", 175, 181], ["patients", "ORGANISM", 413, 421], ["people", "SPECIES", 175, 181], ["patients", "SPECIES", 413, 421], ["surgical procedures", "TREATMENT", 29, 48], ["the COVID", "TEST", 282, 291], ["trauma", "PROBLEM", 389, 395]]], ["We must be prepared to organize our healthcare workers in such a way that the needs of both inpatients and outpatients are met.", [["inpatients", "ORGANISM", 92, 102], ["outpatients", "ORGANISM", 107, 118]]], ["Daily telematics-obtained information on the status of COVID-19 positive patients is vital.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 55, 63], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["COVID", "TEST", 55, 60]]], ["It is still possible to operate on those patients who need it, being careful both in the operating room and, even more importantly, on hospital floors.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["Unfortunately, some healthcare workers will become infected.", [["infected", "PROBLEM", 51, 59], ["infected", "OBSERVATION", 51, 59]]], ["It is essential that we protect those most susceptible to severer consequences of COVID-19, like those who are elderly and those with young children.", [["children", "ORGANISM", 140, 148], ["children", "SPECIES", 140, 148]]], ["Because of the power tools, aerosols are produced during procedures, so that complete ocular screen coverage is essential.", [["ocular", "ANATOMY", 86, 92], ["aerosols", "TREATMENT", 28, 36], ["complete ocular screen coverage", "TREATMENT", 77, 108]]], ["Full face coverage screen.", [["Full face coverage screen", "TEST", 0, 25]]], ["This does not protect from aerosols, but is necessary when there is a risk of splashing (blood, vomiting or other biological fluids).Sterile gloves (2 pairs)6.", [["blood", "ANATOMY", 89, 94], ["vomiting", "DISEASE", 96, 104], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["aerosols", "TREATMENT", 27, 35], ["splashing (blood", "PROBLEM", 78, 94], ["vomiting", "PROBLEM", 96, 104], ["other biological fluids", "TREATMENT", 108, 131], ["Sterile gloves (2 pairs)", "TREATMENT", 133, 157], ["aerosols", "OBSERVATION", 27, 35]]], ["Cap.", [["Cap", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cap", "TEST", 0, 3]]], ["It is a good idea for all staff with long hair to have it fully tied up in a low bun and properly restrained.Sterile gloves (2 pairs)7.", [["hair", "ANATOMY", 42, 46], ["hair", "ORGAN", 42, 46], ["Sterile gloves (2 pairs)", "TREATMENT", 109, 133]]], ["Exclusive footwear for the area of activity, without perforations.", [["perforations", "PROBLEM", 53, 65], ["activity", "OBSERVATION", 35, 43], ["without", "UNCERTAINTY", 45, 52], ["perforations", "OBSERVATION", 53, 65]]], ["We recommend long boots for arthroscopy.Sterile gloves (2 pairs)Once the PPE is in place, surgical scrubbing with an alcohol gel will be performed on the surgical gloves, and sterile equipment necessary for the surgical intervention (gown and sterile gloves) will be placed on the PPE. %: Percentage, PPE: Personal protective equipment Table 2 .", [["alcohol", "CHEMICAL", 117, 124], ["alcohol", "CHEMICAL", 117, 124], ["alcohol", "SIMPLE_CHEMICAL", 117, 124], ["long boots", "TREATMENT", 13, 23], ["arthroscopy", "TREATMENT", 28, 39], ["Sterile gloves (2 pairs", "TREATMENT", 40, 63], ["the PPE", "TREATMENT", 69, 76], ["surgical scrubbing", "TREATMENT", 90, 108], ["an alcohol gel", "TREATMENT", 114, 128], ["the surgical gloves", "TREATMENT", 150, 169], ["sterile equipment", "TREATMENT", 175, 192], ["the surgical intervention", "TREATMENT", 207, 232], ["gown and sterile gloves)", "TREATMENT", 234, 258], ["gloves", "OBSERVATION", 48, 54], ["PPE", "OBSERVATION", 73, 76]]], ["Description of the duties that were performed in the intensive critic units (ICUs).Description of the duties that were performed in the intensive critic units (ICUs)Verification of medical treatment (computerized system) of admitted patients: -Review ALLERGIES of the patients.", [["patients", "ORGANISM", 233, 241], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 233, 241], ["patients", "SPECIES", 268, 276], ["medical treatment", "TREATMENT", 181, 198]]], ["If they have allergies, activate the computer alert -Review standard basic treatment: -Check that all patients have an EKG in the computer system.Description of the duties that were performed in the intensive critic units (ICUs)-Check that medical orders are printed and signed on top of the patient's folder.", [["allergies", "DISEASE", 13, 22], ["patients", "ORGANISM", 102, 110], ["patient", "ORGANISM", 292, 299], ["patients", "SPECIES", 102, 110], ["patient", "SPECIES", 292, 299], ["allergies", "PROBLEM", 13, 22], ["an EKG", "TEST", 116, 122]]]], "PMC7127332": [["IntroductionAirborne microorganisms are ubiquitous in nature and exposure to either pathogenic or opportunistic species is known to cause a variety of adverse health effects [1], [2], [3].", [["[2]", "SIMPLE_CHEMICAL", 179, 182], ["[3]", "SIMPLE_CHEMICAL", 184, 187], ["IntroductionAirborne microorganisms", "PROBLEM", 0, 35], ["pathogenic or opportunistic species", "PROBLEM", 84, 119], ["adverse health effects", "PROBLEM", 151, 173], ["opportunistic species", "OBSERVATION", 98, 119]]], ["In the interest of public health, rapid and accurate methods for differentiating and identifying aerosolized bacteria, fungi, and viruses are needed.", [["aerosolized bacteria", "PROBLEM", 97, 117], ["fungi", "PROBLEM", 119, 124], ["viruses", "PROBLEM", 130, 137], ["aerosolized bacteria", "OBSERVATION", 97, 117]]], ["Early recognition of airborne pathogens would be extremely important in preventing outbreaks of infectious diseases.", [["infectious diseases", "DISEASE", 96, 115], ["airborne pathogens", "PROBLEM", 21, 39], ["infectious diseases", "PROBLEM", 96, 115], ["airborne pathogens", "OBSERVATION", 21, 39], ["infectious", "OBSERVATION", 96, 106]]], ["Microbial identification systems designed for this purpose could effectively be used in industrial/agricultural settings, health facilities, and locations where large groups of people assemble for work, leisure, or travel.", [["people", "ORGANISM", 177, 183], ["people", "SPECIES", 177, 183], ["Microbial identification systems", "TEST", 0, 32]]], ["Mounting concerns regarding the deliberate use of biological substances as weapons by state-sponsored organizations and terrorist groups [4], [5] also places a high priority on fast, reliable techniques for detecting airborne pathogenic microorganisms.IntroductionAtmospheric sampling of microorganisms is generally achieved by impaction onto a solid growth media or an adhesive surface, filtration through a filter membrane, or impingement into a liquid media [6], [7], [8].", [["surface", "ANATOMY", 379, 386], ["membrane", "ANATOMY", 416, 424], ["impingement", "DISEASE", 429, 440], ["membrane", "CELLULAR_COMPONENT", 416, 424], ["[7]", "SIMPLE_CHEMICAL", 466, 469], ["airborne pathogenic microorganisms", "PROBLEM", 217, 251], ["IntroductionAtmospheric sampling of microorganisms", "PROBLEM", 252, 302], ["impaction", "PROBLEM", 328, 337], ["a solid growth media", "TREATMENT", 343, 363], ["an adhesive surface", "TREATMENT", 367, 386], ["filtration", "TREATMENT", 388, 398], ["a filter membrane", "TREATMENT", 407, 424], ["impingement into a liquid media", "TREATMENT", 429, 460], ["microorganisms", "OBSERVATION", 288, 302], ["impaction", "OBSERVATION", 328, 337], ["adhesive", "OBSERVATION_MODIFIER", 370, 378], ["surface", "OBSERVATION_MODIFIER", 379, 386]]], ["The ensuing analysis of the collected bioaerosol has traditionally relied on culture-based techniques or direct microscopic examination.", [["the collected bioaerosol", "TREATMENT", 24, 48], ["culture", "TEST", 77, 84], ["direct microscopic examination", "TEST", 105, 135]]], ["Furthermore, culture methods are limited to detecting only those organisms that can be cultivated on the specified media employed for the analysis.", [["culture methods", "TEST", 13, 28], ["those organisms", "PROBLEM", 59, 74], ["the analysis", "TEST", 134, 146]]], ["Therefore, nonculturable and nonviable airborne pathogens escape detection and give false\u2013negative results for the assay.IntroductionBiochemical analysis using modern analytical instrumentation is an attractive alternative to conventional microbiological techniques.", [["nonculturable", "PROBLEM", 11, 24], ["nonviable airborne pathogens escape detection", "PROBLEM", 29, 74], ["the assay", "TEST", 111, 120], ["Biochemical analysis", "TEST", 133, 153], ["modern analytical instrumentation", "TREATMENT", 160, 193]]], ["In particular, methodologies utilizing mass spectrometry display great promise.", [["mass spectrometry", "TEST", 39, 56], ["great", "OBSERVATION_MODIFIER", 65, 70], ["promise", "OBSERVATION_MODIFIER", 71, 78]]], ["Mass spectrometry is well established as a rapid microbial characterization/identification method [10], [11], [12].", [["[11]", "SIMPLE_CHEMICAL", 104, 108], ["[12]", "SIMPLE_CHEMICAL", 110, 114], ["Mass spectrometry", "TEST", 0, 17], ["a rapid microbial characterization", "TEST", 41, 75]]], ["This technique can be used to search for a large number of diverse biological and chemical agents in a matter of minutes including nonculturable and nonviable organisms.IntroductionProcedures using mass spectrometry attempt to differentiate and identify biological specimens based on the detection of specific chemical markers.", [["specimens", "ANATOMY", 265, 274], ["chemical markers", "PROTEIN", 310, 326], ["This technique", "TREATMENT", 0, 14], ["diverse biological and chemical agents", "TREATMENT", 59, 97], ["nonculturable and nonviable organisms", "PROBLEM", 131, 168], ["IntroductionProcedures", "TREATMENT", 169, 191], ["mass spectrometry", "TEST", 198, 215], ["biological specimens", "TEST", 254, 274], ["the detection", "TEST", 284, 297], ["large", "OBSERVATION_MODIFIER", 43, 48]]], ["Using this chemotaxonomic approach, organisms are classified according to intrinsic differences in their individual chemical constituents.", [["this chemotaxonomic approach", "TREATMENT", 6, 34], ["organisms", "PROBLEM", 36, 45]]], ["A chemical and/or physical preprocessing step is usually used to release endogenous biochemical compounds producing a unique set of chemical signals of taxonomic significance.", [["A chemical and/or physical preprocessing step", "TREATMENT", 0, 45], ["endogenous biochemical compounds", "PROBLEM", 73, 105]]], ["Subsequent mass analysis of these liberated chemical markers results in a distinguishing mass spectrum that can be used to \u2018fingerprint\u2019 and identify microorganisms.IntroductionCellular lipids have been used extensively as signatory biomarkers for the chemical identification of microorganisms [13], [14], [15].", [["Cellular", "ANATOMY", 177, 185], ["[14]", "SIMPLE_CHEMICAL", 300, 304], ["[15]", "SIMPLE_CHEMICAL", 306, 310], ["Subsequent mass analysis", "TEST", 0, 24], ["a distinguishing mass spectrum", "PROBLEM", 72, 102], ["microorganisms", "PROBLEM", 150, 164], ["Cellular lipids", "TREATMENT", 177, 192], ["signatory biomarkers", "TEST", 223, 243], ["microorganisms", "PROBLEM", 279, 293], ["mass", "OBSERVATION", 11, 15], ["mass", "OBSERVATION", 89, 93]]], ["Lipid biomarkers, and in particular, the relative concentration and distribution of the fatty acid moieties, have long been recognized for their chemotaxonomic importance [16], [17].", [["fatty acid", "CHEMICAL", 88, 98], ["fatty acid", "CHEMICAL", 88, 98], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["fatty acid", "SIMPLE_CHEMICAL", 88, 98], ["Lipid biomarkers", "TEST", 0, 16], ["the fatty acid moieties", "PROBLEM", 84, 107]]], ["Classification, based on varying distributions of fatty acids, has become a routine method in microbiology laboratories.", [["fatty acids", "CHEMICAL", 50, 61], ["fatty acids", "CHEMICAL", 50, 61], ["fatty acids", "SIMPLE_CHEMICAL", 50, 61], ["fatty acids", "PROBLEM", 50, 61], ["fatty acids", "OBSERVATION", 50, 61]]], ["A typical method involves saponification of whole microbial cells releasing glycerol bound fatty acids followed by methylation and subsequent extraction of the derivatized fatty acid methyl esters (FAMEs) into a nonpolar organic solvent.", [["cells", "ANATOMY", 60, 65], ["glycerol", "CHEMICAL", 76, 84], ["fatty acids", "CHEMICAL", 91, 102], ["fatty acid methyl esters", "CHEMICAL", 172, 196], ["FAMEs", "CHEMICAL", 198, 203], ["glycerol", "CHEMICAL", 76, 84], ["fatty acids", "CHEMICAL", 91, 102], ["fatty acid methyl esters", "CHEMICAL", 172, 196], ["FAMEs", "CHEMICAL", 198, 203], ["microbial cells", "CELL", 50, 65], ["glycerol", "SIMPLE_CHEMICAL", 76, 84], ["fatty acids", "SIMPLE_CHEMICAL", 91, 102], ["fatty acid methyl esters", "SIMPLE_CHEMICAL", 172, 196], ["FAMEs", "SIMPLE_CHEMICAL", 198, 203], ["whole microbial cells", "CELL_TYPE", 44, 65], ["A typical method", "PROBLEM", 0, 16], ["whole microbial cells", "TREATMENT", 44, 65], ["glycerol bound fatty acids", "TREATMENT", 76, 102], ["methylation and subsequent extraction", "TREATMENT", 115, 152], ["the derivatized fatty acid methyl esters", "TREATMENT", 156, 196], ["a nonpolar organic solvent", "TREATMENT", 210, 236]]], ["Separation and analysis of the FAME extract is then completed by gas chromatography (GC).", [["FAME extract", "CHEMICAL", 31, 43], ["FAME", "CHEMICAL", 31, 35], ["FAME", "SIMPLE_CHEMICAL", 31, 35], ["analysis", "TEST", 15, 23], ["gas chromatography", "TEST", 65, 83]]], ["Exemplifying this technique is the well known commercialized Microbial Identification System (MIDI) [18].", [["this technique", "TREATMENT", 13, 27]]], ["Here, GC analysis and data interpretation are completely automated and a ranked list of probable matches based on the comparison of GC-FAME extract profiles to a database of known organisms is made available to the user.IntroductionThe entire GC-based FAME procedure is extensive, requiring \u223c1.5 h per sample, in which 20\u201330 min are necessary for the chromatographic analysis and another 50\u201360 min are needed for the preceding sample preparation.", [["sample", "ANATOMY", 427, 433], ["GC-FAME extract", "CHEMICAL", 132, 147], ["GC analysis", "TEST", 6, 17], ["data interpretation", "TEST", 22, 41], ["known organisms", "PROBLEM", 174, 189], ["The entire GC-based FAME procedure", "TREATMENT", 232, 266], ["the chromatographic analysis", "TEST", 347, 375], ["the preceding sample preparation", "TREATMENT", 413, 445], ["extensive", "OBSERVATION_MODIFIER", 270, 279]]], ["Efforts to reduce the sample preparation time were successfully accomplished by Dworzanski [19], [20] and Holzer [21].", [["the sample preparation time", "TREATMENT", 18, 45]]], ["Both research groups utilized an on-line derivatization procedure in which whole bacterial cells, in the presence of strongly basic methylating reagents (e.g. tetramethylammonium hydroxide or trimethylanilinium hydroxide), were pyrolyzed in the injector block of the GC.", [["cells", "ANATOMY", 91, 96], ["tetramethylammonium hydroxide", "CHEMICAL", 159, 188], ["trimethylanilinium hydroxide", "CHEMICAL", 192, 220], ["tetramethylammonium hydroxide", "CHEMICAL", 159, 188], ["trimethylanilinium hydroxide", "CHEMICAL", 192, 220], ["bacterial cells", "CELL", 81, 96], ["tetramethylammonium hydroxide", "SIMPLE_CHEMICAL", 159, 188], ["trimethylanilinium hydroxide", "SIMPLE_CHEMICAL", 192, 220], ["bacterial cells", "CELL_TYPE", 81, 96], ["an on-line derivatization procedure", "TREATMENT", 30, 65], ["whole bacterial cells", "PROBLEM", 75, 96], ["strongly basic methylating reagents", "TREATMENT", 117, 152], ["tetramethylammonium hydroxide", "TREATMENT", 159, 188], ["trimethylanilinium hydroxide", "TREATMENT", 192, 220], ["bacterial cells", "OBSERVATION", 81, 96], ["methylating reagents", "OBSERVATION", 132, 152]]], ["Thermal hydrolysis and subsequent methylation of the cellular lipids was observed to occur nearly instantaneously during each heating cycle.", [["cellular", "ANATOMY", 53, 61], ["cellular", "CELL", 53, 61], ["Thermal hydrolysis", "TREATMENT", 0, 18], ["the cellular lipids", "TREATMENT", 49, 68], ["hydrolysis", "OBSERVATION", 8, 18]]], ["The resulting chromatograms of the volatile methyl derivatives showed a high degree of similarity to FAME profiles obtained from extracts prepared by conventional wet-chemistry methods.", [["extracts", "ANATOMY", 129, 137], ["methyl", "CHEMICAL", 44, 50], ["FAME", "CHEMICAL", 101, 105], ["methyl", "CHEMICAL", 44, 50], ["FAME", "CHEMICAL", 101, 105], ["volatile methyl derivatives", "SIMPLE_CHEMICAL", 35, 62], ["FAME", "SIMPLE_CHEMICAL", 101, 105], ["extracts", "ORGANISM_SUBSTANCE", 129, 137], ["The resulting chromatograms", "TEST", 0, 27], ["the volatile methyl derivatives", "TREATMENT", 31, 62], ["high degree", "OBSERVATION_MODIFIER", 72, 83]]], ["Aside from coating a pyrolysis filament with a mixture of sample and derivatizing reagent, no further sample manipulation was necessary, hence reducing the chance of losing or contaminating the sample.", [["sample", "ANATOMY", 58, 64], ["sample", "ANATOMY", 102, 108], ["sample", "ANATOMY", 194, 200], ["coating a pyrolysis filament", "TREATMENT", 11, 39], ["derivatizing reagent", "TREATMENT", 69, 89], ["further sample manipulation", "TREATMENT", 94, 121], ["pyrolysis filament", "OBSERVATION", 21, 39]]], ["The thermal hydrolysis/methylation (THM) technique required only 5\u201310 \u03bcg of sample, whereas the wet chemistry procedure required 10\u201315 mg of sample.", [["sample", "ANATOMY", 76, 82], ["THM", "CHEMICAL", 36, 39], ["The thermal hydrolysis/methylation (THM) technique", "TREATMENT", 0, 50], ["the wet chemistry procedure", "TREATMENT", 92, 119]]], ["Therefore, the THM process is better suited for situations involving low levels of analyte.", [["THM", "CHEMICAL", 15, 18], ["the THM process", "PROBLEM", 11, 26], ["low levels of analyte", "PROBLEM", 69, 90]]], ["A thorough review of on-line derivatization procedures using quaternary ammonium salts has been published [22].IntroductionMore recently, the in-situ THM procedure has been utilized for the analysis of whole cell bacteria in which the volatilized hydrolysates were introduced directly to the mass spectrometer eliminating the chromatographic step [23], [24], [25].", [["whole cell", "ANATOMY", 202, 212], ["quaternary ammonium salts", "CHEMICAL", 61, 86], ["quaternary ammonium salts", "CHEMICAL", 61, 86], ["quaternary ammonium salts", "SIMPLE_CHEMICAL", 61, 86], ["whole cell bacteria", "CELL", 202, 221], ["on-line derivatization procedures", "TREATMENT", 21, 54], ["quaternary ammonium salts", "TREATMENT", 61, 86], ["the in-situ THM procedure", "TREATMENT", 138, 163], ["the analysis", "TEST", 186, 198], ["whole cell bacteria", "PROBLEM", 202, 221], ["the volatilized hydrolysates", "TREATMENT", 231, 259]]], ["In these studies, sample preparation and mass analysis were accomplished in less then five minutes producing spectral profiles featuring taxonomically significant biochemical signals.", [["sample", "ANATOMY", 18, 24], ["these studies", "TEST", 3, 16], ["sample preparation", "TEST", 18, 36], ["mass analysis", "TEST", 41, 54], ["spectral profiles", "TEST", 109, 126], ["mass", "OBSERVATION", 41, 45], ["taxonomically", "OBSERVATION_MODIFIER", 137, 150], ["significant", "OBSERVATION_MODIFIER", 151, 162], ["biochemical signals", "OBSERVATION", 163, 182]]], ["For the present study, use of this rapid technique was extended to the analysis of intact fungi, pollen, viral infected cell culture media, and proteins.", [["pollen", "ANATOMY", 97, 103], ["cell", "ANATOMY", 120, 124], ["pollen", "DEVELOPING_ANATOMICAL_STRUCTURE", 97, 103], ["cell", "CELL", 120, 124], ["the present study", "TEST", 4, 21], ["this rapid technique", "TREATMENT", 30, 50], ["the analysis", "TEST", 67, 79], ["intact fungi", "PROBLEM", 83, 95], ["pollen", "PROBLEM", 97, 103], ["viral infected cell culture media", "TEST", 105, 138], ["fungi", "OBSERVATION", 90, 95], ["viral infected cell", "OBSERVATION", 105, 124]]], ["These biological samples were chosen to emulate constituents normally found dispersed in the atmosphere.", [["samples", "ANATOMY", 17, 24], ["These biological samples", "TEST", 0, 24]]], ["The aim of this current report was to identify characteristic biomarkers that could facilitate the differentiation of these samples from each other and from whole cell bacteria.", [["samples", "ANATOMY", 124, 131], ["whole cell", "ANATOMY", 157, 167], ["whole cell bacteria", "CELL", 157, 176], ["whole cell bacteria", "PROBLEM", 157, 176]]], ["For comparison, five known human pathogenic bacteria were included in the analysis.", [["human", "ORGANISM", 27, 32], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["five known human pathogenic bacteria", "PROBLEM", 16, 52], ["the analysis", "TEST", 70, 82]]], ["Positive identification of pathogenic bacteria collected during atmospheric sampling must include an initial step that is capable of differentiating the prokaryotic organism from a multitude of other possible airborne constituents.", [["pathogenic bacteria", "PROBLEM", 27, 46], ["atmospheric sampling", "TEST", 64, 84], ["the prokaryotic organism", "PROBLEM", 149, 173], ["pathogenic", "OBSERVATION_MODIFIER", 27, 37], ["bacteria", "OBSERVATION_MODIFIER", 38, 46], ["prokaryotic organism", "OBSERVATION", 153, 173]]], ["The simplicity and speed of THM-MS makes it an attractive approach to solving this problem.Instrumental ::: Experimental sectionAll measurements were performed using an Extrel ELQ400 triple quadrupole mass spectrometer modified with a Curie-point pyrolysis inlet.", [["THM", "CHEMICAL", 28, 31], ["Experimental sectionAll measurements", "TEST", 108, 144], ["an Extrel ELQ400 triple quadrupole mass spectrometer", "TREATMENT", 166, 218], ["a Curie-point pyrolysis inlet", "TREATMENT", 233, 262]]], ["The basic instrumental design and layout has previously been described [26].", [["basic", "OBSERVATION_MODIFIER", 4, 9], ["instrumental", "OBSERVATION", 10, 22]]], ["Mass spectra were collected in the positive electron ionization (EI) mode at 70 eV electron energy over the scan range m/z 180\u2013450.", [["Mass spectra", "PROBLEM", 0, 12]]], ["This spectral range was selected in order to emphasize FAME and steroid molecular ions.", [["FAME", "CHEMICAL", 55, 59], ["steroid", "CHEMICAL", 64, 71], ["FAME", "CHEMICAL", 55, 59], ["steroid", "CHEMICAL", 64, 71], ["FAME", "SIMPLE_CHEMICAL", 55, 59], ["steroid", "SIMPLE_CHEMICAL", 64, 71], ["steroid molecular ions", "TREATMENT", 64, 86]]], ["Mass spectra were collected and stored by averaging twenty scans from the pyrogram.", [["Mass spectra", "PROBLEM", 0, 12], ["averaging twenty scans from the pyrogram", "TEST", 42, 82]]], ["Curie-point filaments used for sample introduction were heated to 358\u00b0C (rise time 100 ms) and held for 10 s.", [["Curie-point filaments", "ANATOMY", 0, 21], ["sample", "ANATOMY", 31, 37], ["sample introduction", "TREATMENT", 31, 50]]], ["The transfer line interface (5-cm-long glass tube between the pyrolysis chamber and ion source) and the ion source were both maintained at 140\u00b0C.Instrumental ::: Experimental sectionGC-MS data were acquired on the Extrel ELQ 400 system described above using similar operating parameters.", [["The transfer line interface (5-cm-long glass tube", "TREATMENT", 0, 49], ["the pyrolysis chamber", "TREATMENT", 58, 79], ["Experimental sectionGC", "TEST", 162, 184], ["MS data", "TEST", 185, 192], ["pyrolysis chamber", "OBSERVATION", 62, 79]]], ["The interface between the GC and mass spectrometer was maintained at 225\u00b0C. Separations were performed using a J&W Scientific (Folsom, CA) DB-5 column (30 m\u00d70.320 mm\u00d70.25 \u03bcm).", [["the GC and mass spectrometer", "TREATMENT", 22, 50], ["GC", "OBSERVATION_MODIFIER", 26, 28], ["mass", "OBSERVATION", 33, 37]]], ["The GC oven was held at 150\u00b0C for 3 min and then ramped 5\u00b0C min\u22121 to 250\u00b0C with a final hold of 2 min.", [["The GC oven", "TREATMENT", 0, 11]]], ["FAME mixtures were injected as 2 \u03bcl aliquots at a temperature of 225\u00b0C with a split ratio of 40:1.", [["FAME", "CHEMICAL", 0, 4], ["FAME", "CHEMICAL", 0, 4], ["FAME", "SIMPLE_CHEMICAL", 0, 4], ["a temperature", "TEST", 48, 61], ["a split ratio", "TEST", 76, 89]]], ["Lipid extractions and subsequent saponification and methylation were preformed according to the procedure outlined in the MIDI manual [18].Reagent and biological samplesTetramethylammonium hydroxide (TMAH) (Aldrich), prepared as a 0.1 M solution in HPLC grade methanol, was used as the derivatizing reagent in all in-situ THM reactions.", [["Tetramethylammonium hydroxide", "CHEMICAL", 169, 198], ["TMAH", "CHEMICAL", 200, 204], ["Aldrich", "CHEMICAL", 207, 214], ["THM", "CHEMICAL", 322, 325], ["Tetramethylammonium hydroxide", "CHEMICAL", 169, 198], ["TMAH", "CHEMICAL", 200, 204], ["methanol", "CHEMICAL", 260, 268], ["THM", "CHEMICAL", 322, 325], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["Tetramethylammonium hydroxide", "SIMPLE_CHEMICAL", 169, 198], ["TMAH", "SIMPLE_CHEMICAL", 200, 204], ["Aldrich", "SIMPLE_CHEMICAL", 207, 214], ["methanol", "SIMPLE_CHEMICAL", 260, 268], ["Lipid extractions", "TREATMENT", 0, 17], ["subsequent saponification", "TREATMENT", 22, 47], ["methylation", "TREATMENT", 52, 63], ["the procedure", "TREATMENT", 92, 105], ["Reagent and biological samplesTetramethylammonium hydroxide (TMAH) (Aldrich)", "TREATMENT", 139, 215], ["a 0.1 M solution in HPLC grade methanol", "TREATMENT", 229, 268], ["the derivatizing reagent", "TREATMENT", 282, 306]]], ["Biological samples used in this study are listed in Table 1.", [["samples", "ANATOMY", 11, 18], ["Biological samples", "TEST", 0, 18], ["this study", "TEST", 27, 37]]], ["Five replicate mass spectra were generated for each different sample by randomly alternating the order in which replicates of different samples were run.", [["samples", "ANATOMY", 136, 143], ["Five replicate mass spectra", "TREATMENT", 0, 27], ["mass", "OBSERVATION", 15, 19]]], ["Bacteria samples were obtained from a continuous cell-line maintained at the Armed Forces Institute of Pathology (AFIP).", [["samples", "ANATOMY", 9, 16], ["cell-line", "ANATOMY", 49, 58], ["cell-line", "CELL", 49, 58], ["Bacteria samples", "TEST", 0, 16], ["a continuous cell-line", "TREATMENT", 36, 58]]], ["Cells were cultured using standard procedures and harvested by washing with distilled water.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["standard procedures", "TREATMENT", 26, 45]]], ["The cells were lyophilized and transferred to our laboratory where they were stored at \u221220\u00b0C until use.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["To ensure safe handling, each bacterial sample was gamma killed in a cobalt radiation source prior to shipment.", [["sample", "ANATOMY", 40, 46], ["cobalt", "CHEMICAL", 69, 75], ["cobalt", "CHEMICAL", 69, 75], ["each bacterial sample", "PROBLEM", 25, 46], ["a cobalt radiation source", "TREATMENT", 67, 92]]], ["Fungi samples purchased from the American Type Culture Collection (ATCC) were grown on potato dextrose agar for 8 days at room temperature.", [["samples", "ANATOMY", 6, 13], ["potato dextrose", "CHEMICAL", 87, 102], ["potato", "SPECIES", 87, 93], ["ATCC", "SPECIES", 67, 71], ["potato", "SPECIES", 87, 93], ["Fungi samples", "TEST", 0, 13], ["potato dextrose agar", "TREATMENT", 87, 107]]], ["Mycelia were carefully removed from the agar surface, washed with distilled water, freeze dried and stored at \u221220\u00b0C. Lyophilized samples of cell culture media containing viruses were also received from the AFIP.", [["surface", "ANATOMY", 45, 52], ["samples", "ANATOMY", 129, 136], ["cell", "ANATOMY", 140, 144], ["Mycelia", "SIMPLE_CHEMICAL", 0, 7], ["cell", "CELL", 140, 144], ["Mycelia", "TREATMENT", 0, 7], ["cell culture media", "TREATMENT", 140, 158], ["viruses", "PROBLEM", 170, 177], ["agar surface", "OBSERVATION_MODIFIER", 40, 52], ["cell culture media", "OBSERVATION", 140, 158]]], ["Pollen samples were hand collected from various locations in the Rocky Mountain region.", [["Pollen samples", "ANATOMY", 0, 14], ["hand", "ANATOMY", 20, 24], ["Pollen samples", "ORGANISM_SUBSTANCE", 0, 14], ["Pollen samples", "TEST", 0, 14], ["Rocky Mountain", "OBSERVATION", 65, 79]]], ["Mortar and pestle were used to crush the dried pollen into a fine powder.", [["pollen", "ANATOMY", 47, 53], ["Mortar and pestle", "TREATMENT", 0, 17], ["a fine powder", "TREATMENT", 59, 72]]], ["A total of 10 mg of dried samples of bacteria, fungi, viral media, and pollen were resuspended in 1 ml of deionized water prior to application to the Curie-point filaments.", [["samples", "ANATOMY", 26, 33], ["pollen", "ANATOMY", 71, 77], ["bacteria", "PROBLEM", 37, 45], ["fungi", "PROBLEM", 47, 52], ["viral media", "TREATMENT", 54, 65], ["viral media", "OBSERVATION", 54, 65]]], ["The fungi suspensions were sonicated for 15 s in order to break apart the mycelia and produce more homogenous solutions.", [["mycelia", "ANATOMY", 74, 81], ["The fungi suspensions", "TREATMENT", 0, 21], ["fungi suspensions", "OBSERVATION", 4, 21]]], ["Standard protein samples (Sigma) were prepared as 1 mg ml\u22121 suspensions.", [["samples", "ANATOMY", 17, 24], ["Standard protein samples (Sigma)", "TREATMENT", 0, 32]]], ["Aliquots of 10 \u03bcl of each sample suspension were applied to Curie-point filaments, air-dried, and overlaid with 10 \u03bcl of the methanolic derivatizing reagent.", [["Aliquots", "ANATOMY", 0, 8], ["sample", "ANATOMY", 26, 32], ["filaments", "ANATOMY", 72, 81], ["each sample suspension", "TREATMENT", 21, 43], ["the methanolic derivatizing reagent", "TREATMENT", 121, 156]]], ["The filaments were then introduced via direct inlet probe into the mass spectrometer.Multivariate analysisMultivariate analysis was performed with the Resolve Software Package developed at the Colorado School of Mines [28].", [["filaments", "ANATOMY", 4, 13], ["filaments", "CELLULAR_COMPONENT", 4, 13], ["The filaments", "TREATMENT", 0, 13], ["direct inlet probe", "TREATMENT", 39, 57], ["Multivariate analysisMultivariate analysis", "TEST", 85, 127], ["mass", "OBSERVATION", 67, 71]]], ["Mass spectra were collected as a set of raw intensities and normalized to constant length to correct for variations in total ion current.", [["Mass spectra", "PROBLEM", 0, 12], ["total ion current", "TREATMENT", 119, 136]]], ["The following equation was used:xi,j1000/\u2211j=1nxi,j2,where xi,j* is the normalized intensity of mass spectrum i and mass j, 1000 is a constant scaling factor and n is the number of masses in the spectrum.", [["masses", "CANCER", 180, 186], ["The following equation", "TEST", 0, 22], ["a constant scaling factor", "PROBLEM", 131, 156], ["masses in the spectrum", "PROBLEM", 180, 202], ["j2", "ANATOMY", 49, 51], ["mass", "OBSERVATION", 95, 99], ["masses", "OBSERVATION", 180, 186]]], ["Mass peaks corresponding to m/z 207, 267, 281, 327, 341, and 355 were omitted (silicone contamination) from the calculations.", [["Mass peaks", "PROBLEM", 0, 10], ["m/z", "TEST", 28, 31], ["silicone contamination", "TEST", 79, 101], ["the calculations", "TEST", 108, 124]]], ["The multidimensional data set was mean centered and reduced by principal component analysis (PCA) to a smaller collection of factors still containing a significant proportion (\u223c95%) of the total variance.", [["a smaller collection of factors", "PROBLEM", 101, 132], ["the total variance", "TEST", 185, 203], ["smaller", "OBSERVATION_MODIFIER", 103, 110], ["collection", "OBSERVATION", 111, 121], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["proportion", "OBSERVATION_MODIFIER", 164, 174], ["total variance", "OBSERVATION", 189, 203]]], ["Subsequent examination of this reduced set of factors or principal components (PCs) was conducted using linear discriminant analysis (LDA).", [["Subsequent examination", "TEST", 0, 22], ["linear discriminant analysis", "TEST", 104, 132]]], ["In this way, mass spectra from samples listed in Table 1 (five replicates of each run in random order) were used to train a model for classifying unknown samples.", [["samples", "ANATOMY", 31, 38], ["samples", "ANATOMY", 154, 161], ["samples", "CANCER", 154, 161], ["mass spectra from samples", "PROBLEM", 13, 38], ["mass", "OBSERVATION", 13, 17]]], ["Test sets were produced from the same samples examined in triplicate and submitted, as unknowns, to the LDA model for classification.", [["samples", "ANATOMY", 38, 45], ["Test sets", "TEST", 0, 9]]], ["Samples for the training set, first test set, and second test set, were analyzed on July 21, August 3, and August 19, 1999, respectively.", [["Samples", "ANATOMY", 0, 7], ["the training set", "TEST", 12, 28], ["first test set", "TEST", 30, 44], ["second test set", "TEST", 50, 65]]], ["Cross-validation was used as an assurance against over fitting the trained models with measurement noise [29].THM-MS of fungi ::: Results and discussionsThe THM mass spectra shown in Fig. 1represent five different genera of fungi frequently encountered in the atmosphere [2].", [["THM", "CHEMICAL", 110, 113], ["THM", "CHEMICAL", 157, 160], ["THM", "CHEMICAL", 157, 160], ["THM", "SIMPLE_CHEMICAL", 157, 160], ["Cross-validation", "TEST", 0, 16], ["measurement noise", "TEST", 87, 104], ["The THM mass spectra", "PROBLEM", 153, 173], ["fungi", "PROBLEM", 224, 229], ["mass", "OBSERVATION", 161, 165], ["Fig", "OBSERVATION_MODIFIER", 183, 186], ["different", "OBSERVATION_MODIFIER", 204, 213], ["genera", "OBSERVATION_MODIFIER", 214, 220], ["fungi", "OBSERVATION", 224, 229]]], ["For each fungal species studied, a distinctive series of peaks (m/z 410, 396, 378, 363,337, and 253) were detected and identified as products of electron ionization of ergosterol.", [["ergosterol", "CHEMICAL", 168, 178], ["ergosterol", "CHEMICAL", 168, 178], ["electron", "SIMPLE_CHEMICAL", 145, 153], ["ergosterol", "SIMPLE_CHEMICAL", 168, 178], ["each fungal species", "TEST", 4, 23], ["m/z", "TEST", 64, 67], ["ergosterol", "TREATMENT", 168, 178], ["fungal species", "OBSERVATION", 9, 23], ["electron ionization", "OBSERVATION", 145, 164]]], ["The mass peak observed at m/z 396 is the molecular ion of the free steroid while the mass peak observed at m/z 410 corresponds to the methylated derivative.", [["steroid", "CHEMICAL", 67, 74], ["steroid", "CHEMICAL", 67, 74], ["steroid", "SIMPLE_CHEMICAL", 67, 74], ["The mass peak", "TEST", 0, 13], ["the free steroid", "TREATMENT", 58, 74], ["the mass peak", "PROBLEM", 81, 94], ["the methylated derivative", "TREATMENT", 130, 155], ["mass", "OBSERVATION", 4, 8], ["peak", "OBSERVATION_MODIFIER", 9, 13], ["free steroid", "OBSERVATION", 62, 74], ["mass", "OBSERVATION", 85, 89], ["methylated derivative", "OBSERVATION", 134, 155]]], ["The incomplete derivatization of ergosterol is attributed to the fact that steroids are weakly acidic and as such do not favorably methylate to form ethers during the THM process [22].", [["ergosterol", "CHEMICAL", 33, 43], ["steroids", "CHEMICAL", 75, 83], ["THM", "CHEMICAL", 167, 170], ["ergosterol", "CHEMICAL", 33, 43], ["steroids", "CHEMICAL", 75, 83], ["ethers", "CHEMICAL", 149, 155], ["THM", "CHEMICAL", 167, 170], ["ergosterol", "SIMPLE_CHEMICAL", 33, 43], ["steroids", "SIMPLE_CHEMICAL", 75, 83], ["ethers", "SIMPLE_CHEMICAL", 149, 155], ["THM", "SIMPLE_CHEMICAL", 167, 170], ["The incomplete derivatization of ergosterol", "TREATMENT", 0, 43], ["steroids", "TREATMENT", 75, 83], ["weakly acidic", "PROBLEM", 88, 101]]], ["Chemically, this process involves the liberation of bound ergosterol and fatty acids by saponification and transesterification (competing mechanisms) following the application of an aliquot of a methanolic solution of tetramethylammonium hydroxide to the intact fungal cells.", [["cells", "ANATOMY", 269, 274], ["ergosterol", "CHEMICAL", 58, 68], ["fatty acids", "CHEMICAL", 73, 84], ["tetramethylammonium hydroxide", "CHEMICAL", 218, 247], ["ergosterol", "CHEMICAL", 58, 68], ["fatty acids", "CHEMICAL", 73, 84], ["tetramethylammonium hydroxide", "CHEMICAL", 218, 247], ["ergosterol", "SIMPLE_CHEMICAL", 58, 68], ["fatty acids", "SIMPLE_CHEMICAL", 73, 84], ["tetramethylammonium hydroxide", "SIMPLE_CHEMICAL", 218, 247], ["fungal cells", "CELL", 262, 274], ["intact fungal cells", "CELL_TYPE", 255, 274], ["bound ergosterol and fatty acids", "TEST", 52, 84], ["transesterification", "TREATMENT", 107, 126], ["a methanolic solution of tetramethylammonium hydroxide", "TREATMENT", 193, 247], ["intact", "OBSERVATION", 255, 261], ["fungal cells", "OBSERVATION", 262, 274]]], ["The released fatty acids (as well as any naturally free fatty acids), being more acidic, are readily deprotonated in this highly basic medium and form salts with the quartenary ammonium cations.", [["fatty acids", "CHEMICAL", 13, 24], ["fatty acids", "CHEMICAL", 56, 67], ["quartenary ammonium", "CHEMICAL", 166, 185], ["fatty acids", "CHEMICAL", 13, 24], ["fatty acids", "CHEMICAL", 56, 67], ["ammonium", "CHEMICAL", 177, 185], ["fatty acids", "SIMPLE_CHEMICAL", 13, 24], ["free fatty acids", "SIMPLE_CHEMICAL", 51, 67], ["salts", "SIMPLE_CHEMICAL", 151, 156], ["quartenary ammonium cations", "SIMPLE_CHEMICAL", 166, 193], ["The released fatty acids", "TEST", 0, 24], ["any naturally free fatty acids", "PROBLEM", 37, 67], ["the quartenary ammonium cations", "TREATMENT", 162, 193], ["fatty acids", "OBSERVATION", 13, 24], ["more acidic", "OBSERVATION_MODIFIER", 76, 87]]], ["These salts thermally degrade (nucleophilic attack of the carboxylate anion upon the quartenary N-methylammonium cation) to FAMEs and tertiary amines when heated to a sufficiently high temperature.THM-MS of fungi ::: Results and discussionsIn general, steroid biomarkers allow quick differentiation of eukaryotic (higher order organisms including mammalian, fungal, and vegetative) from prokaryotic (bacteria) cells, since the latter do not carry the biosynthetic machinery required to make steroids.", [["cells", "ANATOMY", 410, 415], ["salts", "CHEMICAL", 6, 11], ["N-methylammonium cation", "CHEMICAL", 96, 119], ["amines", "CHEMICAL", 143, 149], ["THM", "CHEMICAL", 197, 200], ["steroid", "CHEMICAL", 252, 259], ["steroids", "CHEMICAL", 491, 499], ["carboxylate", "CHEMICAL", 58, 69], ["N-methylammonium", "CHEMICAL", 96, 112], ["FAMEs", "CHEMICAL", 124, 129], ["tertiary amines", "CHEMICAL", 134, 149], ["steroid", "CHEMICAL", 252, 259], ["steroids", "CHEMICAL", 491, 499], ["salts", "SIMPLE_CHEMICAL", 6, 11], ["FAMEs", "SIMPLE_CHEMICAL", 124, 129], ["tertiary amines", "SIMPLE_CHEMICAL", 134, 149], ["prokaryotic (bacteria) cells", "CELL", 387, 415], ["steroids", "SIMPLE_CHEMICAL", 491, 499], ["prokaryotic (bacteria) cells", "CELL_TYPE", 387, 415], ["the carboxylate anion", "TREATMENT", 54, 75], ["the quartenary N-methylammonium cation", "TREATMENT", 81, 119], ["tertiary amines", "TREATMENT", 134, 149], ["a sufficiently high temperature", "PROBLEM", 165, 196], ["steroid biomarkers", "TEST", 252, 270], ["eukaryotic (higher order organisms", "PROBLEM", 302, 336], ["mammalian, fungal, and vegetative)", "PROBLEM", 347, 381], ["prokaryotic (bacteria) cells", "PROBLEM", 387, 415], ["steroids", "TREATMENT", 491, 499]]], ["Moreover, ergosterol is produced almost exclusively by fungi making it an excellent chemotaxonomic marker for differentiating fungi from other eukaryotic organisms.THM-MS of fungi ::: Results and discussionsBesides the group of ergosterol molecular and fragment ions, a series of electron ionization ions from FAMEs were also detected for the whole cell fungi.", [["cell", "ANATOMY", 349, 353], ["ergosterol", "CHEMICAL", 10, 20], ["THM", "CHEMICAL", 164, 167], ["ergosterol", "CHEMICAL", 228, 238], ["ergosterol", "CHEMICAL", 10, 20], ["ergosterol", "CHEMICAL", 228, 238], ["ergosterol", "SIMPLE_CHEMICAL", 10, 20], ["ergosterol", "SIMPLE_CHEMICAL", 228, 238], ["electron", "SIMPLE_CHEMICAL", 280, 288], ["FAMEs", "SIMPLE_CHEMICAL", 310, 315], ["cell fungi", "CELL", 349, 359], ["ergosterol", "TREATMENT", 10, 20], ["other eukaryotic organisms", "PROBLEM", 137, 163], ["ergosterol molecular and fragment ions", "PROBLEM", 228, 266], ["electron ionization ions from FAMEs", "TEST", 280, 315], ["the whole cell fungi", "PROBLEM", 339, 359], ["fragment ions", "OBSERVATION", 253, 266], ["whole cell fungi", "OBSERVATION", 343, 359]]], ["The predominant fatty acids synthesized by fungi are straight-chained and 16 or 18 carbons in length [30].", [["fatty acids", "CHEMICAL", 16, 27], ["fatty acids", "CHEMICAL", 16, 27], ["carbons", "CHEMICAL", 83, 90], ["fatty acids", "SIMPLE_CHEMICAL", 16, 27], ["The predominant fatty acids", "TEST", 0, 27], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["fatty acids", "OBSERVATION", 16, 27]]], ["For each fungus analyzed, molecular ions for the methyl esters of hexadecanoic acid (C16:0), octadecanoic acid (C18:0), octadecenoic acid (C18:1), and octadecadienoic acid (C18:2) were detected (Fig. 1).", [["methyl esters", "CHEMICAL", 49, 62], ["hexadecanoic acid", "CHEMICAL", 66, 83], ["C16:0", "CHEMICAL", 85, 90], ["octadecanoic acid", "CHEMICAL", 93, 110], ["C18:0), octadecenoic acid", "CHEMICAL", 112, 137], ["C18:1), and octadecadienoic acid", "CHEMICAL", 139, 171], ["methyl esters", "CHEMICAL", 49, 62], ["hexadecanoic acid", "CHEMICAL", 66, 83], ["C16:0", "CHEMICAL", 85, 90], ["octadecanoic acid", "CHEMICAL", 93, 110], ["C18:0", "CHEMICAL", 112, 117], ["octadecenoic acid", "CHEMICAL", 120, 137], ["octadecadienoic acid", "CHEMICAL", 151, 171], ["C18:2", "CHEMICAL", 173, 178], ["methyl esters", "SIMPLE_CHEMICAL", 49, 62], ["hexadecanoic acid", "SIMPLE_CHEMICAL", 66, 83], ["C16:0", "SIMPLE_CHEMICAL", 85, 90], ["octadecanoic acid", "SIMPLE_CHEMICAL", 93, 110], ["C18:0", "SIMPLE_CHEMICAL", 112, 117], ["octadecenoic acid", "SIMPLE_CHEMICAL", 120, 137], ["C18:1)", "SIMPLE_CHEMICAL", 139, 145], ["octadecadienoic acid", "SIMPLE_CHEMICAL", 151, 171], ["C18:2", "SIMPLE_CHEMICAL", 173, 178], ["each fungus", "TEST", 4, 15], ["the methyl esters", "TEST", 45, 62], ["hexadecanoic acid", "TEST", 66, 83], ["octadecanoic acid", "TEST", 93, 110], ["octadecenoic acid", "TEST", 120, 137], ["octadecadienoic acid", "TEST", 151, 171]]], ["Unlike the situation with ergosterol, near complete thermal methylation was observed for the cellular fatty acids.", [["cellular", "ANATOMY", 93, 101], ["ergosterol", "CHEMICAL", 26, 36], ["fatty acids", "CHEMICAL", 102, 113], ["ergosterol", "CHEMICAL", 26, 36], ["fatty acids", "CHEMICAL", 102, 113], ["ergosterol", "SIMPLE_CHEMICAL", 26, 36], ["cellular fatty acids", "SIMPLE_CHEMICAL", 93, 113], ["ergosterol", "TREATMENT", 26, 36], ["near complete thermal methylation", "TREATMENT", 38, 71], ["the cellular fatty acids", "PROBLEM", 89, 113], ["fatty acids", "OBSERVATION", 102, 113]]], ["A compiled list of FAMEs and their observed electron ionization molecular and fragment ions are listed in Table 2.", [["FAMEs", "SIMPLE_CHEMICAL", 19, 24], ["electron", "SIMPLE_CHEMICAL", 44, 52], ["fragment ions", "PROBLEM", 78, 91], ["fragment ions", "OBSERVATION", 78, 91]]], ["The common fragment ions detected included the series of carbomethoxy ions (185, 199, 213, 227, etc.) formed during electron ionization of saturated FAMEs.", [["carbomethoxy", "CHEMICAL", 57, 69], ["carbomethoxy", "CHEMICAL", 57, 69], ["carbomethoxy ions", "SIMPLE_CHEMICAL", 57, 74], ["electron", "SIMPLE_CHEMICAL", 116, 124], ["FAMEs", "SIMPLE_CHEMICAL", 149, 154], ["The common fragment ions", "PROBLEM", 0, 24], ["common", "OBSERVATION_MODIFIER", 4, 10], ["fragment", "OBSERVATION", 11, 19]]], ["Also originating from saturated FAMEs, but lower in abundance, is the series of fragment ions detected 31 Da.", [["FAMEs", "CHEMICAL", 32, 37], ["FAMEs", "SIMPLE_CHEMICAL", 32, 37], ["fragment ions", "PROBLEM", 80, 93], ["saturated", "OBSERVATION_MODIFIER", 22, 31], ["FAMEs", "OBSERVATION_MODIFIER", 32, 37], ["lower", "OBSERVATION_MODIFIER", 43, 48], ["abundance", "OBSERVATION_MODIFIER", 52, 61]]], ["([M-31]+) below the molecular weight of the precursor fatty acid.", [["fatty acid", "CHEMICAL", 54, 64], ["fatty acid", "CHEMICAL", 54, 64], ["[M-31]+", "SIMPLE_CHEMICAL", 1, 8], ["precursor fatty acid", "SIMPLE_CHEMICAL", 44, 64], ["fatty acid", "OBSERVATION", 54, 64]]], ["Mechanistically, these ions are created by homolytic cleavage of the methoxy group resulting in the formation of a stable acylium ion.", [["methoxy", "CHEMICAL", 69, 76], ["methoxy", "CHEMICAL", 69, 76], ["acylium", "CHEMICAL", 122, 129], ["acylium ion", "SIMPLE_CHEMICAL", 122, 133], ["a stable acylium ion", "PROBLEM", 113, 133], ["stable", "OBSERVATION_MODIFIER", 115, 121], ["acylium", "OBSERVATION", 122, 129]]], ["For unsaturated FAMEs, the two major electron ionization fragment ions were observed at 32 Da.", [["unsaturated FAMEs", "CHEMICAL", 4, 21], ["FAMEs", "SIMPLE_CHEMICAL", 16, 21], ["electron", "SIMPLE_CHEMICAL", 37, 45], ["unsaturated FAMEs", "PROBLEM", 4, 21], ["the two major electron ionization fragment ions", "TREATMENT", 23, 70], ["ionization fragment", "OBSERVATION", 46, 65]]], ["([M-32]+) and 74 Da.", [["[M-32]+", "SIMPLE_CHEMICAL", 1, 8]]], ["([M-74]+) below the molecular mass of the analyte.", [["mass", "OBSERVATION", 30, 34]]], ["Generally, the M-32 ion is the base peak when electron ionization at 70 eV is used to analyze FAMEs containing double bonds.THM-MS of fungi ::: Results and discussionsDetection of C18:2, which is produced by most eukaryotic cells, is a valuable signatory marker since prokaryotic organisms usually do not produce polyunsaturated fatty acids.", [["cells", "ANATOMY", 224, 229], ["THM", "CHEMICAL", 124, 127], ["polyunsaturated fatty acids", "CHEMICAL", 313, 340], ["C18:2", "CHEMICAL", 180, 185], ["polyunsaturated fatty acids", "CHEMICAL", 313, 340], ["electron", "SIMPLE_CHEMICAL", 46, 54], ["FAMEs", "SIMPLE_CHEMICAL", 94, 99], ["C18:2", "SIMPLE_CHEMICAL", 180, 185], ["cells", "CELL", 224, 229], ["polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 313, 340], ["FAMEs", "PROTEIN", 94, 99], ["eukaryotic cells", "CELL_TYPE", 213, 229], ["electron ionization", "TEST", 46, 65], ["C18:2", "TEST", 180, 185], ["prokaryotic organisms", "PROBLEM", 268, 289], ["polyunsaturated fatty acids", "PROBLEM", 313, 340], ["eukaryotic cells", "OBSERVATION", 213, 229], ["fatty acids", "OBSERVATION", 329, 340]]], ["Therefore, the detection of FAMEs with two or more double bonds could be used to corroborate the presence of eukaryotic organisms.", [["FAMEs", "GENE_OR_GENE_PRODUCT", 28, 33], ["FAMEs", "TEST", 28, 33], ["more double bonds", "TREATMENT", 46, 63], ["eukaryotic organisms", "PROBLEM", 109, 129], ["eukaryotic organisms", "OBSERVATION", 109, 129]]], ["In addition, if mass peaks from ergosterol are also detected, then it may be inferred that the sample contains fungal cells.", [["sample", "ANATOMY", 95, 101], ["cells", "ANATOMY", 118, 123], ["ergosterol", "CHEMICAL", 32, 42], ["ergosterol", "CHEMICAL", 32, 42], ["ergosterol", "SIMPLE_CHEMICAL", 32, 42], ["fungal cells", "CELL", 111, 123], ["fungal cells", "CELL_TYPE", 111, 123], ["mass peaks", "PROBLEM", 16, 26], ["ergosterol", "PROBLEM", 32, 42], ["fungal cells", "PROBLEM", 111, 123], ["fungal cells", "OBSERVATION", 111, 123]]], ["Unfortunately, fungi do not produce a large variety of fatty acids, as such; there is not much variation between different FAME profiles [31].", [["fatty acids", "CHEMICAL", 55, 66], ["FAME", "CHEMICAL", 123, 127], ["fatty acids", "CHEMICAL", 55, 66], ["FAME", "CHEMICAL", 123, 127], ["fatty acids", "SIMPLE_CHEMICAL", 55, 66], ["FAME", "SIMPLE_CHEMICAL", 123, 127], ["fungi", "PROBLEM", 15, 20], ["a large variety of fatty acids", "PROBLEM", 36, 66], ["large", "OBSERVATION_MODIFIER", 38, 43], ["fatty acids", "OBSERVATION", 55, 66]]], ["This limits the ability of using THM-MS to identify whole fungal cells at the genus or species level.", [["cells", "ANATOMY", 65, 70], ["THM", "CHEMICAL", 33, 36], ["THM", "SIMPLE_CHEMICAL", 33, 36], ["fungal cells", "CELL", 58, 70], ["whole fungal cells", "CELL_TYPE", 52, 70], ["whole fungal cells", "PROBLEM", 52, 70], ["fungal cells", "OBSERVATION", 58, 70], ["genus", "ANATOMY", 78, 83]]], ["However, the THM mass spectra exhibited by fungi do differ significantly from profiles generated by bacteria, pollen, viral infected media, and proteins.THM-MS of viruses ::: Results and discussionsViruses are parasitic in nature.", [["pollen", "ANATOMY", 110, 116], ["THM", "CHEMICAL", 13, 16], ["viral infected", "DISEASE", 118, 132], ["THM", "CHEMICAL", 153, 156], ["THM", "CHEMICAL", 13, 16], ["THM", "SIMPLE_CHEMICAL", 13, 16], ["pollen", "ORGANISM_SUBDIVISION", 110, 116], ["the THM mass spectra", "PROBLEM", 9, 29], ["fungi", "PROBLEM", 43, 48], ["bacteria", "PROBLEM", 100, 108], ["pollen", "PROBLEM", 110, 116], ["viral infected media", "PROBLEM", 118, 138], ["Viruses", "PROBLEM", 198, 205], ["mass", "OBSERVATION", 17, 21], ["fungi", "OBSERVATION", 43, 48], ["bacteria", "OBSERVATION", 100, 108], ["viral infected media", "OBSERVATION", 118, 138], ["viruses", "OBSERVATION", 163, 170], ["parasitic", "OBSERVATION_MODIFIER", 210, 219]]], ["Because of this host/guest relationship, interest was focused, not on a purified viral preparation, but rather, on media recovered (supernatant) from cell cultures used to propagate the viruses.", [["supernatant", "ANATOMY", 132, 143], ["cell cultures", "ANATOMY", 150, 163], ["cell cultures", "CELL", 150, 163], ["cell cultures", "CELL_LINE", 150, 163], ["a purified viral preparation", "TREATMENT", 70, 98], ["cell cultures", "TEST", 150, 163], ["viruses", "OBSERVATION", 186, 193]]], ["Two such media were examined by THM-MS and the mass spectra are shown in Fig. 2(a\u2013b).", [["THM", "CHEMICAL", 32, 35], ["the mass spectra", "PROBLEM", 43, 59], ["mass", "OBSERVATION", 47, 51]]], ["These two media were inoculated separately, one with feline enteric coronavirus (FECV), and the other with Venezuela Equine Encephalitis (VEE).", [["feline enteric coronavirus", "DISEASE", 53, 79], ["Equine Encephalitis", "DISEASE", 117, 136], ["VEE", "DISEASE", 138, 141], ["feline enteric coronavirus", "ORGANISM", 53, 79], ["feline enteric coronavirus", "SPECIES", 53, 79], ["feline enteric coronavirus", "SPECIES", 53, 79], ["FECV", "SPECIES", 81, 85], ["Venezuela Equine Encephalitis (VEE", "SPECIES", 107, 141], ["feline enteric coronavirus (FECV)", "PROBLEM", 53, 86], ["Venezuela Equine Encephalitis", "PROBLEM", 107, 136], ["enteric coronavirus", "ANATOMY", 60, 79], ["Encephalitis", "OBSERVATION", 124, 136]]], ["For comparison, a non-infected medium (same medium used to propagate VEE) was also analyzed and is shown in Fig. 2(c).", [["VEE", "SPECIES", 69, 72], ["a non-infected medium (same medium", "TREATMENT", 16, 50]]], ["From an earlier study, it was found that viruses do not contribute significantly to the overall mass spectrum from cell culture media [27].", [["cell", "ANATOMY", 115, 119], ["cell", "CELL", 115, 119], ["an earlier study", "TEST", 5, 21], ["viruses", "PROBLEM", 41, 48], ["cell culture media", "TEST", 115, 133], ["viruses", "OBSERVATION", 41, 48], ["mass", "OBSERVATION", 96, 100]]], ["The relative contribution of the viruses to the total mass of the cell culture medium is only about a tenth of a percent and accordingly does not generate an intense set of ion signals (relative to the cell culture media).", [["cell", "ANATOMY", 66, 70], ["cell", "ANATOMY", 202, 206], ["cell", "CELL", 66, 70], ["cell", "CELL", 202, 206], ["the viruses", "PROBLEM", 29, 40], ["the cell culture", "TEST", 62, 78], ["the cell culture media", "TEST", 198, 220], ["viruses", "OBSERVATION", 33, 40], ["total", "OBSERVATION_MODIFIER", 48, 53], ["mass", "OBSERVATION", 54, 58], ["cell", "OBSERVATION", 66, 70], ["culture", "OBSERVATION_MODIFIER", 71, 78], ["medium", "OBSERVATION_MODIFIER", 79, 85]]], ["Hence, the two mass spectra (Fig. 7(b\u2013c)) of media recovered from Vero cell cultures (one with the virus the other without) are essentially indistinguishable.", [["Vero cell cultures", "ANATOMY", 66, 84], ["Vero cell cultures", "CELL", 66, 84], ["Vero cell cultures", "CELL_LINE", 66, 84], ["the two mass spectra (Fig.", "TEST", 7, 33], ["media", "PROBLEM", 45, 50], ["Vero cell cultures", "TEST", 66, 84], ["the virus", "PROBLEM", 95, 104], ["mass", "OBSERVATION", 15, 19], ["Vero cell cultures", "OBSERVATION", 66, 84]]], ["It was further discovered that the major source of fatty acids and steroids detected from the media supernatant originated from blood serum.", [["supernatant", "ANATOMY", 100, 111], ["blood serum", "ANATOMY", 128, 139], ["fatty acids", "CHEMICAL", 51, 62], ["steroids", "CHEMICAL", 67, 75], ["fatty acids", "CHEMICAL", 51, 62], ["steroids", "CHEMICAL", 67, 75], ["fatty acids", "SIMPLE_CHEMICAL", 51, 62], ["steroids", "SIMPLE_CHEMICAL", 67, 75], ["blood serum", "ORGANISM_SUBSTANCE", 128, 139], ["fatty acids", "PROBLEM", 51, 62], ["steroids", "TREATMENT", 67, 75], ["the media supernatant", "PROBLEM", 90, 111], ["blood serum", "TEST", 128, 139], ["fatty acids", "OBSERVATION", 51, 62]]], ["Serum is commonly added to cell cultures as a rich supplement of proteins and lipids.THM-MS of viruses ::: Results and discussionsThe FECV sample shown in Fig. 2(a) was taken from a feline kidney cell culture supplemented with 10% (v/v) horse serum while the VEE sample (Fig. 2(b)) was recovered from a Vero cell culture supplement with 5% (v/v) fetal bovine serum.", [["Serum", "ANATOMY", 0, 5], ["cell cultures", "ANATOMY", 27, 40], ["FECV sample", "ANATOMY", 134, 145], ["kidney cell", "ANATOMY", 189, 200], ["serum", "ANATOMY", 243, 248], ["sample", "ANATOMY", 263, 269], ["cell", "ANATOMY", 308, 312], ["fetal bovine serum", "ANATOMY", 346, 364], ["THM", "CHEMICAL", 85, 88], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cell cultures", "CELL", 27, 40], ["lipids", "SIMPLE_CHEMICAL", 78, 84], ["feline", "ORGANISM", 182, 188], ["kidney cell", "CELL", 189, 200], ["horse", "ORGANISM", 237, 242], ["serum", "ORGANISM_SUBSTANCE", 243, 248], ["VEE", "ORGANISM", 259, 262], ["Vero cell", "CELL", 303, 312], ["bovine", "ORGANISM", 352, 358], ["serum", "ORGANISM_SUBSTANCE", 359, 364], ["cell cultures", "CELL_LINE", 27, 40], ["feline kidney cell culture", "CELL_LINE", 182, 208], ["horse", "SPECIES", 237, 242], ["bovine", "SPECIES", 352, 358], ["VEE", "SPECIES", 259, 262], ["bovine", "SPECIES", 352, 358], ["Serum", "TEST", 0, 5], ["cell cultures", "TEST", 27, 40], ["a rich supplement of proteins", "TREATMENT", 44, 73], ["lipids", "TREATMENT", 78, 84], ["The FECV sample", "TEST", 130, 145], ["a feline kidney cell culture", "TEST", 180, 208], ["horse serum", "TEST", 237, 248], ["the VEE sample", "TEST", 255, 269], ["a Vero cell culture supplement", "TEST", 301, 331], ["fetal bovine serum", "TEST", 346, 364], ["viruses", "OBSERVATION", 95, 102], ["kidney", "ANATOMY", 189, 195]]], ["While both spectra show peaks consistent with the methyl esters of C16:0 (M+, m/z 270), C18:0 (M+, m/z 298), and C18:1 (M+, m/z 296 and [M-32]+, m/z 264), only the FECV spectrum contains a peak indicative of methylated C18:2 (M+, m/z 294).", [["methyl esters", "CHEMICAL", 50, 63], ["C16:0", "CHEMICAL", 67, 72], ["methyl esters", "CHEMICAL", 50, 63], ["C16:0", "CHEMICAL", 67, 72], ["C18:0", "CHEMICAL", 88, 93], ["C18:1", "CHEMICAL", 113, 118], ["C18:2", "CHEMICAL", 219, 224], ["methyl esters", "SIMPLE_CHEMICAL", 50, 63], ["C16:0", "SIMPLE_CHEMICAL", 67, 72], ["C18:0", "SIMPLE_CHEMICAL", 88, 93], ["m/z 298)", "SIMPLE_CHEMICAL", 99, 107], ["C18:1", "SIMPLE_CHEMICAL", 113, 118], ["[M-32]+", "SIMPLE_CHEMICAL", 136, 143], ["C18:2", "SIMPLE_CHEMICAL", 219, 224], ["the methyl esters", "TEST", 46, 63], ["C18:0", "TEST", 88, 93], ["C18:1", "TEST", 113, 118], ["M", "TEST", 120, 121], ["M-", "TEST", 137, 139], ["m/z", "TEST", 145, 148], ["the FECV spectrum", "TEST", 160, 177], ["methylated C18:2", "PROBLEM", 208, 224], ["peaks", "OBSERVATION", 24, 29], ["consistent with", "UNCERTAINTY", 30, 45]]], ["Comparable results were obtained for the THM mass spectra of just the horse and fetal bovine sera (data not shown) demonstrating their overall strong contributions to the culture media.THM-MS of viruses ::: Results and discussionsThe series of peaks in the upper scan range (m/z 386, 368, and 353) are known electron ionization products of cholesterol; the most abundant steroid found in mammalian blood [32].", [["horse", "ANATOMY", 70, 75], ["fetal bovine sera", "ANATOMY", 80, 97], ["blood", "ANATOMY", 398, 403], ["THM", "CHEMICAL", 41, 44], ["THM", "CHEMICAL", 185, 188], ["cholesterol", "CHEMICAL", 340, 351], ["steroid", "CHEMICAL", 371, 378], ["THM", "CHEMICAL", 41, 44], ["cholesterol", "CHEMICAL", 340, 351], ["steroid", "CHEMICAL", 371, 378], ["THM", "SIMPLE_CHEMICAL", 41, 44], ["horse", "ORGANISM", 70, 75], ["bovine", "ORGANISM", 86, 92], ["sera", "ORGANISM_SUBSTANCE", 93, 97], ["cholesterol", "SIMPLE_CHEMICAL", 340, 351], ["steroid", "SIMPLE_CHEMICAL", 371, 378], ["blood", "ORGANISM_SUBSTANCE", 398, 403], ["horse", "SPECIES", 70, 75], ["bovine", "SPECIES", 86, 92], ["bovine", "SPECIES", 86, 92], ["the THM mass spectra", "TEST", 37, 57], ["fetal bovine sera", "TEST", 80, 97], ["the culture media", "TEST", 167, 184], ["cholesterol", "TEST", 340, 351], ["viruses", "OBSERVATION", 195, 202], ["upper", "ANATOMY_MODIFIER", 257, 262]]], ["Again, no ions were detected indicating the formation of the methyl ether derivative of cholesterol.", [["methyl ether", "CHEMICAL", 61, 73], ["cholesterol", "CHEMICAL", 88, 99], ["methyl ether", "CHEMICAL", 61, 73], ["cholesterol", "CHEMICAL", 88, 99], ["methyl ether derivative", "SIMPLE_CHEMICAL", 61, 84], ["cholesterol", "SIMPLE_CHEMICAL", 88, 99], ["ions", "PROBLEM", 10, 14], ["the methyl ether derivative of cholesterol", "TREATMENT", 57, 99]]], ["The detection of cholesterol indicates the presence of mammalian type cellular systems.", [["cellular", "ANATOMY", 70, 78], ["cholesterol", "CHEMICAL", 17, 28], ["cholesterol", "CHEMICAL", 17, 28], ["cholesterol", "SIMPLE_CHEMICAL", 17, 28], ["cellular", "CELL", 70, 78], ["The detection of cholesterol", "TEST", 0, 28], ["mammalian type cellular systems", "PROBLEM", 55, 86], ["cholesterol", "OBSERVATION", 17, 28], ["mammalian type cellular systems", "OBSERVATION", 55, 86]]], ["This biomarker has also been detected from a purified mouse hepatitis virus [23] further substantiating its general use as a mammalian/viral signatory biomarker.", [["hepatitis", "DISEASE", 60, 69], ["mouse hepatitis virus", "ORGANISM", 54, 75], ["mouse", "SPECIES", 54, 59], ["hepatitis virus", "SPECIES", 60, 75], ["mouse hepatitis virus", "SPECIES", 54, 75], ["This biomarker", "TEST", 0, 14], ["a purified mouse hepatitis virus", "PROBLEM", 43, 75], ["a mammalian/viral signatory biomarker", "TEST", 123, 160]]], ["For enveloped viruses, cholesterol is incorporated within the lipid bilayer that covers the viral protein coat.", [["lipid bilayer", "ANATOMY", 62, 75], ["cholesterol", "CHEMICAL", 23, 34], ["cholesterol", "CHEMICAL", 23, 34], ["cholesterol", "SIMPLE_CHEMICAL", 23, 34], ["lipid bilayer", "CELLULAR_COMPONENT", 62, 75], ["viral protein coat", "PROTEIN", 92, 110], ["cholesterol", "TEST", 23, 34], ["the lipid bilayer", "TREATMENT", 58, 75], ["the viral protein coat", "TREATMENT", 88, 110], ["viruses", "OBSERVATION", 14, 21], ["cholesterol", "OBSERVATION_MODIFIER", 23, 34], ["viral protein coat", "OBSERVATION", 92, 110]]], ["Furthermore, the virus acquires both steroids and lipids from the host and therefore the composition of these biomarkers will resemble the media that was used in propagation.", [["steroids", "CHEMICAL", 37, 45], ["steroids", "CHEMICAL", 37, 45], ["steroids", "SIMPLE_CHEMICAL", 37, 45], ["lipids", "SIMPLE_CHEMICAL", 50, 56], ["the virus", "PROBLEM", 13, 22], ["both steroids", "TREATMENT", 32, 45], ["lipids", "TREATMENT", 50, 56], ["these biomarkers", "TEST", 104, 120], ["the media", "TREATMENT", 135, 144], ["virus", "OBSERVATION", 17, 22]]], ["It can further be postulated that if a selective trapping method is employed to capture airborne viruses prior to THM-MS analysis then mass spectra simliar to those shown in Fig. 4 will be generated and directly attributed to the viruses.THM-MS of pollen ::: Results and discussionsPollen grains are normal constituents found in relatively high concentrations in the atmospheric load of particulant matter.", [["pollen", "ANATOMY", 248, 254], ["Pollen grains", "ANATOMY", 282, 295], ["THM", "CHEMICAL", 114, 117], ["THM", "CHEMICAL", 238, 241], ["pollen", "ORGAN", 248, 254], ["Pollen grains", "MULTI-TISSUE_STRUCTURE", 282, 295], ["a selective trapping method", "TREATMENT", 37, 64], ["airborne viruses", "PROBLEM", 88, 104], ["MS analysis", "TEST", 118, 129], ["mass spectra", "PROBLEM", 135, 147], ["the viruses", "PROBLEM", 226, 237], ["viruses", "OBSERVATION", 230, 237], ["normal", "OBSERVATION", 300, 306], ["relatively", "OBSERVATION_MODIFIER", 329, 339], ["high concentrations", "OBSERVATION_MODIFIER", 340, 359], ["atmospheric load", "OBSERVATION", 367, 383]]], ["Spectra from four different pollens, indigenous to the Rocky Mountain area, are shown in Fig. 3.", [["Spectra from four different pollens", "PROBLEM", 0, 35], ["four different", "OBSERVATION_MODIFIER", 13, 27], ["pollens", "OBSERVATION", 28, 35], ["indigenous", "OBSERVATION_MODIFIER", 37, 47], ["Rocky", "OBSERVATION_MODIFIER", 55, 60], ["Fig", "OBSERVATION_MODIFIER", 89, 92]]], ["Similiar to other eukaryotic organisms, the fatty acids synthesized by pollen are also predominately 16 and 18 carbons in length with varying degrees of unsaturation.", [["pollen", "ANATOMY", 71, 77], ["fatty acids", "CHEMICAL", 44, 55], ["fatty acids", "CHEMICAL", 44, 55], ["carbons", "CHEMICAL", 111, 118], ["fatty acids", "SIMPLE_CHEMICAL", 44, 55], ["pollen", "ORGAN", 71, 77], ["other eukaryotic organisms", "PROBLEM", 12, 38], ["the fatty acids", "TEST", 40, 55], ["eukaryotic organisms", "OBSERVATION", 18, 38], ["fatty acids", "OBSERVATION", 44, 55], ["varying degrees", "OBSERVATION_MODIFIER", 134, 149], ["unsaturation", "OBSERVATION_MODIFIER", 153, 165]]], ["The methyl ester of hexadecanoic acid (M+, m/z 270) is the base peak in each of the pollen mass spectra.", [["methyl ester", "CHEMICAL", 4, 16], ["hexadecanoic acid", "CHEMICAL", 20, 37], ["methyl ester", "CHEMICAL", 4, 16], ["hexadecanoic acid", "CHEMICAL", 20, 37], ["methyl ester", "SIMPLE_CHEMICAL", 4, 16], ["hexadecanoic acid", "SIMPLE_CHEMICAL", 20, 37], ["M+", "SIMPLE_CHEMICAL", 39, 41], ["The methyl ester of hexadecanoic acid (M+, m/z", "TREATMENT", 0, 46], ["base", "ANATOMY_MODIFIER", 59, 63], ["peak", "OBSERVATION_MODIFIER", 64, 68], ["mass", "OBSERVATION", 91, 95]]], ["Furthermore, each different pollen investigated exhibited a unique distribution of saturated (C18:0Me, M+m/z 298) monenoic (C18:1ME, M+m/z 296), dienoic (C18:2, M+m/z 294), and trienoic (C18:3Me, M+m/z 292) methylated fatty acids of 18 carbons atoms in length.", [["pollen", "ANATOMY", 28, 34], ["C18:1ME, M+m/z 296", "CHEMICAL", 124, 142], ["dienoic", "CHEMICAL", 145, 152], ["C18:2, M+m/z 294", "CHEMICAL", 154, 170], ["trienoic", "CHEMICAL", 177, 185], ["C18:3Me", "CHEMICAL", 187, 194], ["fatty acids", "CHEMICAL", 218, 229], ["C18:0Me", "CHEMICAL", 94, 101], ["monenoic", "CHEMICAL", 114, 122], ["dienoic", "CHEMICAL", 145, 152], ["trienoic", "CHEMICAL", 177, 185], ["C18:3Me", "CHEMICAL", 187, 194], ["fatty acids", "CHEMICAL", 218, 229], ["carbons", "CHEMICAL", 236, 243], ["+m/z 298) monenoic", "SIMPLE_CHEMICAL", 104, 122], ["C18:1ME", "SIMPLE_CHEMICAL", 124, 131], ["M+m/z 296)", "SIMPLE_CHEMICAL", 133, 143], ["dienoic (C18:2, M+m/z 294)", "SIMPLE_CHEMICAL", 145, 171], ["trienoic (C18:3Me, M+m/z 292) methylated fatty acids", "SIMPLE_CHEMICAL", 177, 229], ["carbons atoms", "SIMPLE_CHEMICAL", 236, 249], ["monenoic", "TEST", 114, 122], ["C18", "TEST", 124, 127], ["M", "TEST", 133, 134], ["dienoic", "TEST", 145, 152], ["C18:2", "TEST", 154, 159], ["M", "TEST", 161, 162], ["trienoic", "TEST", 177, 185], ["methylated fatty acids of 18 carbons atoms in length", "TREATMENT", 207, 259], ["saturated", "OBSERVATION_MODIFIER", 83, 92]]], ["Similar FAME profiles of pollen from maize [33], tea [34], and rapeseed [35] have been reported.", [["pollen", "ANATOMY", 25, 31], ["FAME", "CHEMICAL", 8, 12], ["pollen from maize [33], tea", "CHEMICAL", 25, 52], ["FAME", "CHEMICAL", 8, 12], ["FAME", "SIMPLE_CHEMICAL", 8, 12], ["pollen", "ORGANISM_SUBDIVISION", 25, 31], ["tea", "ORGANISM_SUBDIVISION", 49, 52], ["maize", "SPECIES", 37, 42], ["maize", "SPECIES", 37, 42]]], ["The distinct FAME profiles not only permit a quick way to differentiate the different types of pollen shown in Fig. 3, but also can be used to separate this taxonomic group of airborne constituents from bacteria and other potential air contaminates.THM-MS of pollen ::: Results and discussionsAnother noteworthy feature in each of the the pollen mass spectra shown in Fig. 3 was the emergence of mass peaks of low relative abundance at m/z 414, 382, and 354, repectively.", [["pollen", "ANATOMY", 95, 101], ["pollen", "ANATOMY", 259, 265], ["THM", "CHEMICAL", 249, 252], ["pollen", "DEVELOPING_ANATOMICAL_STRUCTURE", 95, 101], ["pollen", "ORGAN", 259, 265], ["airborne constituents", "PROBLEM", 176, 197], ["bacteria", "PROBLEM", 203, 211], ["other potential air contaminates", "PROBLEM", 216, 248], ["mass peaks", "PROBLEM", 396, 406], ["low relative abundance", "PROBLEM", 410, 432], ["air contaminates", "OBSERVATION", 232, 248], ["mass", "OBSERVATION", 346, 350], ["mass", "OBSERVATION", 396, 400], ["low relative", "OBSERVATION_MODIFIER", 410, 422], ["abundance", "OBSERVATION_MODIFIER", 423, 432]]], ["A lipid extraction was prepared off-line for sunflower pollen and analyzed using GC/MS. The elution peak corresponding to m/z 414 produced a mass spectrum that best matched sistosterol (comparison with unmethylated steroid in NIST database), a familiar pollen steroid [36].", [["pollen", "ANATOMY", 55, 61], ["sistosterol", "CHEMICAL", 173, 184], ["steroid", "CHEMICAL", 215, 222], ["steroid", "CHEMICAL", 260, 267], ["sistosterol", "CHEMICAL", 173, 184], ["steroid", "CHEMICAL", 215, 222], ["steroid", "CHEMICAL", 260, 267], ["lipid", "SIMPLE_CHEMICAL", 2, 7], ["sunflower", "ORGANISM", 45, 54], ["pollen", "ORGANISM_SUBSTANCE", 55, 61], ["sistosterol", "SIMPLE_CHEMICAL", 173, 184], ["sunflower", "SPECIES", 45, 54], ["A lipid extraction", "TREATMENT", 0, 18], ["sunflower pollen", "TREATMENT", 45, 61], ["The elution peak", "TEST", 88, 104], ["m/z", "TEST", 122, 125], ["a mass spectrum", "PROBLEM", 139, 154], ["unmethylated steroid", "TREATMENT", 202, 222], ["a familiar pollen steroid", "TREATMENT", 242, 267], ["mass", "OBSERVATION", 141, 145]]], ["Meanwhile, m/z 382 and m/z 354, were found in trace amounts and gave corresponding retention times and comparable mass spectra to C24:0Me and C22:0Me, repectively.", [["C24:0Me", "CHEMICAL", 130, 137], ["C22:0Me", "CHEMICAL", 142, 149], ["C24:0Me", "SIMPLE_CHEMICAL", 130, 137], ["C22:0Me", "SIMPLE_CHEMICAL", 142, 149], ["m/z", "TEST", 23, 26], ["trace amounts", "OBSERVATION_MODIFIER", 46, 59], ["mass", "OBSERVATION", 114, 118]]], ["The prominent peak at m/z 316 in the mass spectrum of sunflower (Fig. 3(d)) was not found in the lipid extraction and will require addional examination for positive identification.THM-MS of proteins ::: Results and discussionsThe focus of this study was to identify key FAME and steroid biomarkers of chemotaxonomic significance.", [["THM", "CHEMICAL", 180, 183], ["FAME", "CHEMICAL", 270, 274], ["steroid", "CHEMICAL", 279, 286], ["FAME", "CHEMICAL", 270, 274], ["steroid", "CHEMICAL", 279, 286], ["sunflower", "ORGANISM_SUBDIVISION", 54, 63], ["lipid", "SIMPLE_CHEMICAL", 97, 102], ["FAME", "SIMPLE_CHEMICAL", 270, 274], ["steroid", "SIMPLE_CHEMICAL", 279, 286], ["The prominent peak at m/z", "PROBLEM", 0, 25], ["the lipid extraction", "TREATMENT", 93, 113], ["addional examination", "TEST", 131, 151], ["this study", "TEST", 239, 249], ["steroid biomarkers", "TEST", 279, 297], ["prominent", "OBSERVATION_MODIFIER", 4, 13], ["peak", "OBSERVATION_MODIFIER", 14, 18], ["mass", "OBSERVATION", 37, 41], ["sunflower", "OBSERVATION_MODIFIER", 54, 63]]], ["Proteins were included as a comparative measure of the isobaric effects made by a biological compound containing no lipids.", [["lipids", "SIMPLE_CHEMICAL", 116, 122], ["Proteins", "TEST", 0, 8], ["the isobaric effects", "TREATMENT", 51, 71], ["lipids", "TREATMENT", 116, 122]]], ["The mass spectra from three protein standards, mass analyzed following thermal treatment with TMAH, are shown in Fig. 4.", [["The mass spectra", "PROBLEM", 0, 16], ["three protein standards", "TREATMENT", 22, 45], ["mass", "PROBLEM", 47, 51], ["thermal treatment", "TREATMENT", 71, 88], ["TMAH", "TREATMENT", 94, 98], ["mass", "OBSERVATION", 4, 8], ["mass", "OBSERVATION", 47, 51]]], ["Peaks were observed at virtually every mass signifying the complicated nature involved with the thermal clevage of high molecular weight proteins.", [["high molecular weight proteins", "PROTEIN", 115, 145], ["Peaks", "PROBLEM", 0, 5], ["virtually every mass", "PROBLEM", 23, 43], ["the thermal clevage", "TREATMENT", 92, 111], ["high molecular weight proteins", "PROBLEM", 115, 145], ["mass", "OBSERVATION", 39, 43], ["complicated", "OBSERVATION", 59, 70]]], ["Thermal degradation coupled with electron ionization produces a mulititude of possible fragmentation mechanisms resulting in a complex mixture of predominantly low molecular weight gaseouse ions.", [["electron", "SIMPLE_CHEMICAL", 33, 41], ["Thermal degradation", "PROBLEM", 0, 19], ["electron ionization", "TEST", 33, 52], ["fragmentation mechanisms", "PROBLEM", 87, 111], ["predominantly low molecular weight gaseouse ions", "PROBLEM", 146, 194], ["possible", "UNCERTAINTY", 78, 86], ["fragmentation", "OBSERVATION", 87, 100], ["complex", "OBSERVATION_MODIFIER", 127, 134], ["mixture", "OBSERVATION_MODIFIER", 135, 142], ["predominantly", "OBSERVATION_MODIFIER", 146, 159], ["low molecular", "OBSERVATION_MODIFIER", 160, 173]]], ["The most abundant ions observed in the subsequent mass spectra are the smaller (generally below 150 Da), more volatile distillents.", [["most", "OBSERVATION_MODIFIER", 4, 8], ["abundant", "OBSERVATION_MODIFIER", 9, 17], ["ions", "OBSERVATION", 18, 22], ["mass", "OBSERVATION", 50, 54], ["smaller", "OBSERVATION_MODIFIER", 71, 78], ["volatile distillents", "OBSERVATION", 110, 130]]], ["The ions observed in the mass spectra illustrated in Fig. 4 are most likely dipeptide remnants and diketopiperazines that were formed by a known intra-polypeptide cyclization mechanism [37].THM-MS of proteins ::: Results and discussionsRelatively high intensity mass peaks with nominal masses equivalent to FAME and steroid biomaker compounds were not observed in the mass spectra from the protein standards.", [["diketopiperazines", "CHEMICAL", 99, 116], ["THM", "CHEMICAL", 190, 193], ["FAME", "CHEMICAL", 307, 311], ["steroid", "CHEMICAL", 316, 323], ["dipeptide", "CHEMICAL", 76, 85], ["diketopiperazines", "CHEMICAL", 99, 116], ["FAME", "CHEMICAL", 307, 311], ["steroid", "CHEMICAL", 316, 323], ["diketopiperazines", "SIMPLE_CHEMICAL", 99, 116], ["intra-polypeptide", "SIMPLE_CHEMICAL", 145, 162], ["FAME", "SIMPLE_CHEMICAL", 307, 311], ["steroid biomaker compounds", "SIMPLE_CHEMICAL", 316, 342], ["The ions", "PROBLEM", 0, 8], ["dipeptide remnants", "PROBLEM", 76, 94], ["diketopiperazines", "TREATMENT", 99, 116], ["a known intra-polypeptide cyclization mechanism", "TREATMENT", 137, 184], ["Relatively high intensity mass peaks", "PROBLEM", 236, 272], ["nominal masses", "PROBLEM", 278, 292], ["steroid biomaker compounds", "TREATMENT", 316, 342], ["ions", "OBSERVATION", 4, 8], ["mass", "OBSERVATION", 25, 29], ["Fig", "OBSERVATION_MODIFIER", 53, 56], ["most likely", "UNCERTAINTY", 64, 75], ["dipeptide remnants", "OBSERVATION", 76, 94], ["high", "OBSERVATION_MODIFIER", 247, 251], ["intensity", "OBSERVATION_MODIFIER", 252, 261], ["mass", "OBSERVATION", 262, 266], ["peaks", "OBSERVATION_MODIFIER", 267, 272], ["nominal", "OBSERVATION_MODIFIER", 278, 285], ["masses", "OBSERVATION", 286, 292], ["mass", "OBSERVATION", 368, 372]]], ["The experimental setup was designed to enrich the cellular lipid fraction and minimize contributions from proteins, carbohydrates, and DNA.", [["cellular", "ANATOMY", 50, 58], ["carbohydrates", "CHEMICAL", 116, 129], ["cellular", "CELL", 50, 58], ["carbohydrates", "SIMPLE_CHEMICAL", 116, 129], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["The experimental setup", "TREATMENT", 0, 22], ["the cellular lipid fraction", "TREATMENT", 46, 73], ["carbohydrates", "TREATMENT", 116, 129], ["DNA", "PROBLEM", 135, 138]]], ["Lipid products, from thermal degradation of biological samples, are more volatile than other constituent biochemicals, especially for the mass range above 180 Da.", [["samples", "ANATOMY", 55, 62], ["Lipid products", "SIMPLE_CHEMICAL", 0, 14], ["Lipid products", "TREATMENT", 0, 14], ["biological samples", "TEST", 44, 62], ["the mass range", "PROBLEM", 134, 148], ["mass", "OBSERVATION", 138, 142]]], ["Consequentially, by maintaining the transfer line from the heating chamber at lower temperatures (140\u00b0C), we could effectively prevent (by condensation onto the cold walls) less volatile thermal products from reaching the ion source.", [["the transfer line", "TREATMENT", 32, 49], ["the heating chamber", "TREATMENT", 55, 74], ["volatile thermal products", "TREATMENT", 178, 203]]], ["In fact, for proportionally similar amounts of samples, the total ion current (TIC) from whole cells (containing lipids) was an order of magnitude or more greater than the TIC produced from pure proteins.", [["samples", "ANATOMY", 47, 54], ["whole cells", "ANATOMY", 89, 100], ["ion", "SIMPLE_CHEMICAL", 66, 69], ["cells", "CELL", 95, 100], ["whole cells", "CELL_TYPE", 89, 100], ["pure proteins", "PROTEIN", 190, 203], ["the total ion current (TIC) from whole cells (containing lipids", "TREATMENT", 56, 119]]], ["Needless to say, there does exist isobaric contributions from cellular proteins, but the overall contribution is minimal.", [["cellular", "ANATOMY", 62, 70], ["cellular", "CELL", 62, 70], ["cellular proteins", "PROTEIN", 62, 79], ["cellular proteins", "PROBLEM", 62, 79], ["isobaric", "OBSERVATION", 34, 42], ["cellular proteins", "OBSERVATION", 62, 79], ["overall", "OBSERVATION_MODIFIER", 89, 96], ["contribution", "OBSERVATION_MODIFIER", 97, 109], ["minimal", "OBSERVATION_MODIFIER", 113, 120]]], ["In view of their negated significance to this study, no further attempt was made to identify the protein mass peaks demonstrated in Fig. 4.THM-MS of bacteria ::: Results and discussionsThe THM mass spectra generated for the five species of bacteria selected for this study are depicted in Fig. 5.", [["THM", "CHEMICAL", 139, 142], ["THM", "CHEMICAL", 189, 192], ["THM", "CHEMICAL", 189, 192], ["THM", "SIMPLE_CHEMICAL", 189, 192], ["this study", "TEST", 41, 51], ["the protein mass peaks", "PROBLEM", 93, 115], ["bacteria", "PROBLEM", 149, 157], ["The THM mass spectra", "PROBLEM", 185, 205], ["bacteria", "PROBLEM", 240, 248], ["this study", "TEST", 262, 272], ["mass", "OBSERVATION", 105, 109], ["Fig", "OBSERVATION_MODIFIER", 132, 135], ["mass", "OBSERVATION", 193, 197]]], ["These bacteria were of interest because of their potential use as biological weapons [4].", [["These bacteria", "PROBLEM", 0, 14]]], ["A brief discussion of the bacterial FAMEs detected is given here.", [["bacterial FAMEs", "PROTEIN", 26, 41], ["the bacterial FAMEs", "TEST", 22, 41]]], ["The results were consistent with a more detail description reported by Basile [38].THM-MS of bacteria ::: Results and discussions", [["THM", "CHEMICAL", 83, 86], ["bacteria", "PROBLEM", 93, 101], ["consistent with", "UNCERTAINTY", 17, 32]]]], "5850f34d1d26f9271e5713f8d2b72d3fd6e6873c": [["Materials and methodsModelling the interaction between nAChR and Y674-R685 from S protein The structural models for the complexes formed by the extracellular domains of the human \u03b17, human \u03b14\u03b22 and muscle-like \u03b1\u03b2\u03b3\u03b4 nAChR from Tetronarce californica and the Y674-R685 region from SARS-CoV-2 (hereafter named as S-peptide) were constructed using the cryoEM structure of the \u03b1\u03b2\u03b3\u03b4 receptor from Tetronarce californica (formerly Torpedo californica) with \u03b1-bungarotoxin 1 (PDB code: 6UWZ) as a template.", [["extracellular", "ANATOMY", 144, 157], ["\u03b1-bungarotoxin", "CHEMICAL", 450, 464], ["\u03b1-bungarotoxin", "CHEMICAL", 450, 464], ["nAChR", "GENE_OR_GENE_PRODUCT", 55, 60], ["Y674-R685", "GENE_OR_GENE_PRODUCT", 65, 74], ["S protein", "GENE_OR_GENE_PRODUCT", 80, 89], ["human", "ORGANISM", 173, 178], ["\u03b17", "GENE_OR_GENE_PRODUCT", 179, 181], ["human", "ORGANISM", 183, 188], ["\u03b14\u03b22", "GENE_OR_GENE_PRODUCT", 189, 193], ["muscle", "ORGAN", 198, 204], ["-like \u03b1\u03b2\u03b3\u03b4 nAChR", "GENE_OR_GENE_PRODUCT", 204, 220], ["Tetronarce californica", "ORGANISM", 226, 248], ["SARS-CoV-2", "ORGANISM", 279, 289], ["S-peptide", "SIMPLE_CHEMICAL", 310, 319], ["\u03b1\u03b2\u03b3\u03b4 receptor", "GENE_OR_GENE_PRODUCT", 372, 385], ["Tetronarce californica", "ORGANISM", 391, 413], ["Torpedo californica", "ORGANISM", 424, 443], ["\u03b1-bungarotoxin 1", "GENE_OR_GENE_PRODUCT", 450, 466], ["nAChR", "PROTEIN", 55, 60], ["Y674", "PROTEIN", 65, 69], ["R685", "PROTEIN", 70, 74], ["S protein", "PROTEIN", 80, 89], ["extracellular domains", "PROTEIN", 144, 165], ["human \u03b17", "PROTEIN", 173, 181], ["human \u03b14\u03b22 and muscle-like \u03b1\u03b2\u03b3\u03b4 nAChR", "PROTEIN", 183, 220], ["Y674-R685 region", "DNA", 257, 273], ["\u03b1\u03b2\u03b3\u03b4 receptor", "PROTEIN", 372, 385], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 183, 188], ["Tetronarce californica", "SPECIES", 226, 248], ["Tetronarce californica", "SPECIES", 391, 413], ["Torpedo californica", "SPECIES", 424, 443], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 183, 188], ["Tetronarce californica", "SPECIES", 226, 248], ["SARS-CoV", "SPECIES", 279, 287], ["Tetronarce californica", "SPECIES", 391, 413], ["Torpedo californica", "SPECIES", 424, 443], ["nAChR", "TEST", 55, 60], ["muscle", "TEST", 198, 204], ["SARS", "TEST", 279, 283], ["CoV", "TEST", 284, 287], ["Tetronarce californica", "TREATMENT", 391, 413], ["\u03b1-bungarotoxin", "TREATMENT", 450, 464], ["muscle", "ANATOMY", 198, 204]]], ["Note that the homology model for the ECDs of human \u03b17 nAChR was constructed because there is no Xray or cryoEM structure for this nAChR sub-type in the Protein Data Bank.", [["human", "ORGANISM", 45, 50], ["\u03b17 nAChR", "GENE_OR_GENE_PRODUCT", 51, 59], ["Xray", "GENE_OR_GENE_PRODUCT", 96, 100], ["ECDs", "PROTEIN", 37, 41], ["human \u03b17 nAChR", "PROTEIN", 45, 59], ["Xray", "PROTEIN", 96, 100], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["human \u03b17 nAChR", "TREATMENT", 45, 59], ["Xray or cryoEM structure", "PROBLEM", 96, 120]]], ["Note also that the experimentally-determined structures available for the human \u03b14\u03b22 nAChR 2, 3 have nicotine bound in the binding pockets and as such show loop C in the a closed ''capped''Materials and methodsconformation.", [["nicotine", "CHEMICAL", 101, 109], ["nicotine", "CHEMICAL", 101, 109], ["human", "ORGANISM", 74, 79], ["\u03b14\u03b22 nAChR 2", "GENE_OR_GENE_PRODUCT", 80, 92], ["3", "GENE_OR_GENE_PRODUCT", 94, 95], ["nicotine", "SIMPLE_CHEMICAL", 101, 109], ["loop C", "PROTEIN", 156, 162], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["loop C", "PROBLEM", 156, 162], ["a closed ''capped''Materials", "TREATMENT", 170, 198], ["methodsconformation", "TREATMENT", 203, 222]]], ["Loop C acts as a binding-pocket lid and it adapts its shape to the size of the ligands.", [["Loop C", "CHEMICAL", 0, 6], ["Loop C", "GENE_OR_GENE_PRODUCT", 0, 6], ["Loop C", "PROTEIN", 0, 6], ["Loop C acts", "TREATMENT", 0, 11], ["a binding-pocket lid", "PROBLEM", 15, 35], ["shape", "OBSERVATION_MODIFIER", 54, 59], ["size", "OBSERVATION_MODIFIER", 67, 71], ["ligands", "ANATOMY", 79, 86]]], ["4, 5 Given that there is no experimental structure for this sub-type with loop C in the open \"uncapped\" conformation, a homology model was built for the ECDs of human \u03b14\u03b22 nAChR based in the cryoEM structure of the \u03b1\u03b2\u03b3\u03b4 receptor with an antagonist (\u03b1-bungarotoxin) bound.", [["\u03b1-bungarotoxin", "CHEMICAL", 249, 263], ["loop C", "SIMPLE_CHEMICAL", 74, 80], ["human", "ORGANISM", 161, 166], ["\u03b14\u03b22 nAChR", "GENE_OR_GENE_PRODUCT", 167, 177], ["\u03b1\u03b2\u03b3\u03b4 receptor", "GENE_OR_GENE_PRODUCT", 215, 228], ["\u03b1-bungarotoxin", "SIMPLE_CHEMICAL", 249, 263], ["loop C", "PROTEIN", 74, 80], ["ECDs", "PROTEIN", 153, 157], ["human \u03b14\u03b22 nAChR", "PROTEIN", 161, 177], ["cryoEM structure", "PROTEIN", 191, 207], ["\u03b1\u03b2\u03b3\u03b4 receptor", "PROTEIN", 215, 228], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["experimental structure", "PROBLEM", 28, 50], ["loop C", "PROBLEM", 74, 80], ["human \u03b1", "TREATMENT", 161, 168], ["the \u03b1\u03b2\u03b3\u03b4 receptor", "TREATMENT", 211, 228], ["an antagonist (\u03b1-bungarotoxin)", "TREATMENT", 234, 264], ["no", "UNCERTAINTY", 25, 27], ["experimental structure", "OBSERVATION", 28, 50]]], ["1 The structure used here as template reflects the closed state of the muscle-type \u03b1\u03b2\u03b3\u03b4 nAChR stabilized by the binding of the two \u03b1-bungarotoxin molecules at the \u03b1-\u03b3 and \u03b1-\u03b4 interfaces.", [["muscle", "ANATOMY", 71, 77], ["\u03b1-bungarotoxin", "CHEMICAL", 131, 145], ["muscle", "ORGAN", 71, 77], ["\u03b1\u03b2\u03b3\u03b4 nAChR", "GENE_OR_GENE_PRODUCT", 83, 93], ["\u03b1-bungarotoxin", "GENE_OR_GENE_PRODUCT", 131, 145], ["\u03b1-\u03b3", "GENE_OR_GENE_PRODUCT", 163, 166], ["\u03b1-\u03b4", "GENE_OR_GENE_PRODUCT", 171, 174], ["muscle-type \u03b1\u03b2\u03b3\u03b4 nAChR", "PROTEIN", 71, 93], ["\u03b1-bungarotoxin molecules", "PROTEIN", 131, 155], ["\u03b1-\u03b3", "PROTEIN", 163, 166], ["closed", "OBSERVATION", 51, 57], ["muscle", "ANATOMY", 71, 77]]], ["1 \u03b1-bungarotoxin is a 74residue neurotoxin that binds to the muscle receptors in an (almost) irreversibly way 6 , and it acts as nAChRs antagonist directly competing with acetylcholine.", [["muscle", "ANATOMY", 61, 67], ["1 \u03b1-bungarotoxin", "CHEMICAL", 0, 16], ["acetylcholine", "CHEMICAL", 171, 184], ["1 \u03b1-bungarotoxin", "CHEMICAL", 0, 16], ["acetylcholine", "CHEMICAL", 171, 184], ["1 \u03b1-bungarotoxin", "SIMPLE_CHEMICAL", 0, 16], ["74residue neurotoxin", "SIMPLE_CHEMICAL", 22, 42], ["muscle", "ORGAN", 61, 67], ["acetylcholine", "SIMPLE_CHEMICAL", 171, 184], ["muscle receptors", "PROTEIN", 61, 77], ["bungarotoxin", "TREATMENT", 4, 16], ["a 74residue neurotoxin", "TREATMENT", 20, 42], ["acetylcholine", "TREATMENT", 171, 184], ["muscle", "ANATOMY", 61, 67]]], ["4, 5 The binding of \u03b1-bungarotoxin to the neuromuscular junction receptors induces paralysis, respiratory failure, and eventually death.", [["neuromuscular junction", "ANATOMY", 42, 64], ["respiratory", "ANATOMY", 94, 105], ["\u03b1-bungarotoxin", "CHEMICAL", 20, 34], ["paralysis", "DISEASE", 83, 92], ["respiratory failure", "DISEASE", 94, 113], ["death", "DISEASE", 130, 135], ["\u03b1-bungarotoxin", "CHEMICAL", 20, 34], ["\u03b1-bungarotoxin", "SIMPLE_CHEMICAL", 20, 34], ["\u03b1-bungarotoxin", "PROTEIN", 20, 34], ["neuromuscular junction receptors", "PROTEIN", 42, 74], ["\u03b1-bungarotoxin", "TREATMENT", 20, 34], ["the neuromuscular junction receptors", "TREATMENT", 38, 74], ["paralysis", "PROBLEM", 83, 92], ["respiratory failure", "PROBLEM", 94, 113], ["eventually death", "PROBLEM", 119, 135], ["neuromuscular junction", "ANATOMY", 42, 64], ["paralysis", "OBSERVATION", 83, 92], ["respiratory failure", "OBSERVATION", 94, 113]]], ["7 The sequence alignment between the S-peptide and \u03b1-bungarotoxin was taken from the work of Changeux et al. 8 The sequences for the different nAChRs subunits were obtained from the UniProt database: 9 human \uf0617 (UniProt code P36544), human \uf0614 (UniProt code P43681), human \uf0622 (UniProt code P17787) and aligned with the template using Clustal Omega.", [["\u03b1-bungarotoxin", "CHEMICAL", 51, 65], ["\u03b1-bungarotoxin", "CHEMICAL", 51, 65], ["S-peptide", "SIMPLE_CHEMICAL", 37, 46], ["\u03b1-bungarotoxin", "SIMPLE_CHEMICAL", 51, 65], ["human", "ORGANISM", 202, 207], ["human", "ORGANISM", 234, 239], ["human", "ORGANISM", 266, 271], ["S-peptide", "PROTEIN", 37, 46], ["nAChRs subunits", "PROTEIN", 143, 158], ["human \uf0617", "PROTEIN", 202, 210], ["human \uf0614", "PROTEIN", 234, 242], ["human \uf0622", "PROTEIN", 266, 274], ["Clustal Omega", "DNA", 333, 346], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 266, 271], ["The sequence alignment", "TEST", 2, 24], ["the S-peptide", "TEST", 33, 46], ["The sequences", "TEST", 111, 124], ["the different nAChRs subunits", "TEST", 129, 158], ["Clustal Omega", "TREATMENT", 333, 346]]], ["12, 13 The best model for each complex (the one with the lowest value for Modeller's objective function 13 ) was further analyzed using Procheck.", [["Procheck", "TREATMENT", 136, 144]]], ["14 Overall, the \u03b14\u03b22 and \u03b17 models are similar to the structures used by us in previous work, 15, 16 with the exception of the loop C region that shows an open \"uncapped\" conformation and loop F that was slightly displaced to accommodate the S-peptide.MD simulationsThe best model for each complex was used as the starting point for molecular dynamics (MD) simulations.", [["S-peptide", "CHEMICAL", 242, 251], ["\u03b14\u03b22", "GENE_OR_GENE_PRODUCT", 16, 20], ["\u03b17", "GENE_OR_GENE_PRODUCT", 25, 27], ["\u03b14\u03b22 and \u03b17 models", "DNA", 16, 34], ["loop C region", "PROTEIN", 127, 140], ["loop F", "PROTEIN", 188, 194], ["S-peptide", "PROTEIN", 242, 251], ["the loop C region", "PROBLEM", 123, 140], ["an open \"uncapped\" conformation", "PROBLEM", 152, 183], ["slightly displaced", "PROBLEM", 204, 222], ["loop", "OBSERVATION", 127, 131], ["slightly", "OBSERVATION_MODIFIER", 204, 212], ["displaced", "OBSERVATION", 213, 222]]], ["Three systems were prepared, the human \u03b17, human \u03b14\u03b22 and \u03b1\u03b2\u03b3\u03b4 nAChR from Tetronarce californica, each with two SARS-CoV-2 S-peptides bound, one in each nonconsecutive binding pocket.", [["human", "ORGANISM", 33, 38], ["\u03b17", "GENE_OR_GENE_PRODUCT", 39, 41], ["human", "ORGANISM", 43, 48], ["\u03b14\u03b22", "GENE_OR_GENE_PRODUCT", 49, 53], ["\u03b1\u03b2\u03b3\u03b4 nAChR", "GENE_OR_GENE_PRODUCT", 58, 68], ["Tetronarce californica", "ORGANISM", 74, 96], ["human \u03b17", "PROTEIN", 33, 41], ["human \u03b14\u03b22", "PROTEIN", 43, 53], ["\u03b1\u03b2\u03b3\u03b4 nAChR", "PROTEIN", 58, 68], ["nonconsecutive binding pocket", "PROTEIN", 153, 182], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 43, 48], ["Tetronarce californica", "SPECIES", 74, 96], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 43, 48], ["Tetronarce californica", "SPECIES", 74, 96], ["Tetronarce californica", "TREATMENT", 74, 96], ["binding pocket", "OBSERVATION", 168, 182]]], ["The protonation state of each titrable residue in the receptor and peptides at pH 7.0 was determined using PROPKA.", [["PROPKA", "PROTEIN", 107, 113], ["each titrable residue", "PROBLEM", 25, 46], ["pH", "TEST", 79, 81], ["PROPKA", "TREATMENT", 107, 113], ["protonation state", "OBSERVATION", 4, 21]]], ["17, 18 All systems were solvated using TIP3P water molecules, 19 and an ionic concentration of 0.1 M sodium chloride was used.", [["sodium chloride", "CHEMICAL", 101, 116], ["TIP3P", "CHEMICAL", 39, 44], ["sodium chloride", "CHEMICAL", 101, 116], ["sodium chloride", "SIMPLE_CHEMICAL", 101, 116], ["TIP3P water molecules", "TREATMENT", 39, 60], ["an ionic concentration", "TREATMENT", 69, 91], ["sodium chloride", "TREATMENT", 101, 116]]], ["The Amber ff99SB-ILDN 20 force-field was used to describe the receptors and the peptides.", [["ff99SB", "PROTEIN", 10, 16], ["The Amber ff99SB", "TEST", 0, 16], ["Amber", "OBSERVATION", 4, 9]]], ["All simulations were carried out in the isothermal-isobaric (NPT) ensemble at 310 K and 1 atm.", [["All simulations", "TEST", 0, 15], ["isobaric", "ANATOMY", 51, 59]]], ["The velocity-rescaling thermostat 21 and the Parrinello-Rahman barostat 22, 23 were applied to keep the temperature and pressure constant.", [["The velocity", "TEST", 0, 12], ["rescaling thermostat", "TEST", 13, 33], ["the Parrinello-Rahman barostat", "TREATMENT", 41, 71], ["the temperature", "TEST", 100, 115], ["velocity", "OBSERVATION_MODIFIER", 4, 12], ["pressure", "OBSERVATION_MODIFIER", 120, 128], ["constant", "OBSERVATION_MODIFIER", 129, 137]]], ["Non-bonded long-range electrostatic interactions were calculated using PME.", [["Non-bonded long-range electrostatic interactions", "PROBLEM", 0, 48]]], ["24 A 12 \u00c5 cut-off was used for the van der Waals interactions with long-range dispersion corrections for the energy and pressure.", [["the van der Waals interactions", "TREATMENT", 31, 61], ["long-range dispersion corrections", "TREATMENT", 67, 100]]], ["The solvated complexes systems were energy minimised, equilibrated (for 1.5 ns) and simulated using the protocol described in our previous work.", [["the protocol", "TREATMENT", 100, 112]]], ["16AnalysisAnalyses were performed using Gromacs 26 and in-house tools.", [["Analyses", "TEST", 10, 18], ["Gromacs", "TEST", 40, 47]]], ["Images were produced with PyMOL.", [["Images", "TEST", 0, 6]]], ["28, 29 Principal component analysis (PCA) was used to examine the sampling of the peptide and to identify its relevant motions.", [["Principal component analysis", "TEST", 7, 35], ["the sampling of the peptide", "TEST", 62, 89]]], ["All replicates for the three complexes were combined before the analysis so that all share the same subspace, and their motions could be directly compared.", [["the analysis", "TEST", 60, 72]]], ["5400 frames (corresponding to one conformation per nanosecond per replicate per peptide) were used for the PCA.", [["5400 frames", "DNA", 0, 11], ["the PCA", "TREATMENT", 103, 110], ["PCA", "ANATOMY", 107, 110]]], ["The two principal components included \u223c53% of the peptide dynamics and, hence, we restricted our analysis to PC1 and PC2 only.AnalysisPCA was also used to assess the sampling and equilibration/relaxation of the receptors similarly to e.g. 30, 31 For this, all replicates for each complex were combined, and two conformations per nanosecond per replicate (totalling 1801 frames) were used for this analysis.", [["PC1", "GENE_OR_GENE_PRODUCT", 109, 112], ["PC2", "GENE_OR_GENE_PRODUCT", 117, 120], ["PC1", "DNA", 109, 112], ["PC2", "PROTEIN", 117, 120], ["the peptide dynamics", "TEST", 46, 66], ["PC1", "TEST", 109, 112], ["PC2", "TEST", 117, 120], ["the sampling", "TEST", 162, 174], ["equilibration/relaxation of the receptors", "TREATMENT", 179, 220], ["this analysis", "TEST", 392, 405], ["two", "OBSERVATION_MODIFIER", 4, 7], ["principal", "OBSERVATION_MODIFIER", 8, 17], ["components", "OBSERVATION_MODIFIER", 18, 28]]], ["PCA, together with the RMSD of the receptors over time, suggests that all systems were equilibrated after 50 ns ( Figure S8 ).", [["PCA", "TREATMENT", 0, 3]]], ["The RMSD values for the ECDs of the human \u03b14\u03b22 and \u03b17 nAChR are consistent with our previously published simulations.", [["human", "ORGANISM", 36, 41], ["\u03b14\u03b22", "GENE_OR_GENE_PRODUCT", 42, 46], ["\u03b17 nAChR", "GENE_OR_GENE_PRODUCT", 51, 59], ["human \u03b14\u03b22", "PROTEIN", 36, 46], ["\u03b17 nAChR", "PROTEIN", 51, 59], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["The RMSD values", "TEST", 0, 15], ["consistent with", "UNCERTAINTY", 64, 79]]], ["15MM-PBSA calculationsA Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) approach was used to calculate the binding free energy (\u0394Gbind) for each complex.", [["PBSA calculationsA Molecular Mechanics Poisson", "TREATMENT", 5, 51], ["Boltzmann Surface Area (MM-PBSA) approach", "TREATMENT", 52, 93], ["Mechanics Poisson", "OBSERVATION", 34, 51]]], ["In this approach, the contribution of nonpolar, polar and entropic terms to the overall free energy of binding is estimated from a MD simulation of the solvated complex.", [["solvated complex", "PROTEIN", 152, 168], ["nonpolar", "ANATOMY_MODIFIER", 38, 46], ["polar", "OBSERVATION_MODIFIER", 48, 53]]], ["Binding free energies were computed using g_mmpbsa.", [["g_mmpbsa", "PROTEIN", 42, 50], ["Binding free energies", "PROBLEM", 0, 21]]], ["34 This tool uses Gromacs 26 and APBS 35In silico alanine-scanning mutagenesisIn silico alanine-scanning mutagenesis involves the sequential mutation of the residues in the proteins to alanine to identify the key determinants for the thermodynamic stability of a given complex.", [["alanine", "CHEMICAL", 50, 57], ["alanine", "CHEMICAL", 88, 95], ["alanine", "CHEMICAL", 185, 192], ["alanine", "CHEMICAL", 50, 57], ["alanine", "CHEMICAL", 88, 95], ["alanine", "CHEMICAL", 185, 192], ["alanine", "AMINO_ACID", 50, 57], ["alanine", "AMINO_ACID", 88, 95], ["alanine", "AMINO_ACID", 185, 192], ["Gromacs", "TEST", 18, 25], ["APBS", "TEST", 33, 37], ["silico alanine", "TEST", 43, 57], ["scanning mutagenesis", "TEST", 58, 78], ["silico alanine-scanning mutagenesis", "TEST", 81, 116]]], ["In this approach, the binding free energies for the mutant and wild-type complexes are calculated, and the difference between the two values (\u0394\u0394Gbind) is a way to evaluate the contribution of each reside for the interface.", [["mutant and wild-type complexes", "PROTEIN", 52, 82]]], ["In this work, the \u0394\u0394Gbind was computed using the command-line Python application BudeAlaScan.", [["BudeAlaScan", "CHEMICAL", 81, 92], ["BudeAlaScan", "SIMPLE_CHEMICAL", 81, 92], ["\u0394\u0394Gbind", "DNA", 18, 25], ["the command-line Python application BudeAlaScan", "TREATMENT", 45, 92]]], ["36 This application uses ISAMBARD 37 for structure manipulation and a customized version of the Bristol University Docking Engine (BUDE) 38 for energy calculations.", [["ISAMBARD 37", "DNA", 25, 36], ["ISAMBARD", "TREATMENT", 25, 33], ["structure manipulation", "TREATMENT", 41, 63], ["energy calculations", "TEST", 144, 163]]], ["Snapshots were taken every three nanoseconds in a total of 303 frames per complex.Molecular characterization of the S-peptide in MD simulations of the full-length model of the glycosylated S protein from SARS-CoV-2To examine the conformational dynamics and the accessibility of S-peptide (Y674-R685 region) in the glycosylated SARS-CoV-2 S protein, we used the extensive all-atom MD simulations conducted previously by some of us (Casalino et al).", [["SARS-CoV-2To", "ORGANISM", 204, 216], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 327, 339], ["S-peptide", "PROTEIN", 116, 125], ["glycosylated S protein", "PROTEIN", 176, 198], ["glycosylated SARS-CoV-2 S protein", "PROTEIN", 314, 347], ["SARS-CoV", "SPECIES", 204, 212], ["the glycosylated S protein", "TEST", 172, 198], ["CoV", "TEST", 209, 212], ["the conformational dynamics", "TEST", 225, 252], ["S-peptide", "TEST", 278, 287], ["the glycosylated SARS", "TEST", 310, 331], ["CoV", "TEST", 332, 335]]], ["27 In that work, two sets of simulations were performed on two full-length models of the glycosylated S protein accounting for ~4.2 \u03bcs in the open (1 RBD 'up', 2 'down') and ~1.7 \u03bcs in the closed (3 RBDs 'down') states, which were based on 6VSB 39 and 6VXX 40 cryoEM structures, respectively.", [["glycosylated S protein", "PROTEIN", 89, 111], ["simulations", "TEST", 29, 40], ["the glycosylated S protein", "TEST", 85, 111], ["6VSB", "TEST", 240, 244]]], ["In these simulations, the models were cleaved at the S1/S2 site (i.e., between R685 and S686) to model the physiological state of S-peptide.", [["S-peptide", "CHEMICAL", 130, 139], ["S-peptide", "SIMPLE_CHEMICAL", 130, 139], ["S1/S2 site", "DNA", 53, 63], ["S-peptide", "PROTEIN", 130, 139], ["S1", "ANATOMY_MODIFIER", 53, 55], ["S2", "ANATOMY", 56, 58]]], ["Considering that the S protein is a homotrimer, these simulations have accumulated a comprehensive total of ~12.6 \u03bcs and ~5.1 \u03bcs of sampling for S-peptide in the open and closed systems, respectively.", [["S-peptide", "CHEMICAL", 145, 154], ["S-peptide", "GENE_OR_GENE_PRODUCT", 145, 154], ["S protein", "PROTEIN", 21, 30], ["sampling", "TEST", 132, 140], ["S-peptide", "TREATMENT", 145, 154], ["closed", "OBSERVATION", 171, 177]]], ["With the aim of elucidating the availability of S-peptide in the glycosylated full-length model of the S protein for binding to nAChRs, we have investigated the conformational behaviour of the S-peptide, and characterized its accessibility in the presence of the glycan shield.Accessible Surface AreaDuring the simulations of the glycosylated S ptotein, the S-peptide establishes intermittent interactions with nearby N-glycans, especially N-603, N-657, N-717, N-801 and N-1074.", [["S-peptide", "CHEMICAL", 48, 57], ["N-603", "CHEMICAL", 440, 445], ["N-657, N-717, N-801", "CHEMICAL", 447, 466], ["N-1074", "CHEMICAL", 471, 477], ["S-peptide", "CHEMICAL", 48, 57], ["N", "CHEMICAL", 418, 419], ["N-801", "CHEMICAL", 461, 466], ["N-1074", "CHEMICAL", 471, 477], ["S-peptide", "SIMPLE_CHEMICAL", 48, 57], ["glycosylated S ptotein", "GENE_OR_GENE_PRODUCT", 330, 352], ["N-603", "SIMPLE_CHEMICAL", 440, 445], ["N-657", "SIMPLE_CHEMICAL", 447, 452], ["N-717", "SIMPLE_CHEMICAL", 454, 459], ["N-801", "SIMPLE_CHEMICAL", 461, 466], ["N-1074", "SIMPLE_CHEMICAL", 471, 477], ["S-peptide", "PROTEIN", 48, 57], ["S protein", "PROTEIN", 103, 112], ["nAChRs", "PROTEIN", 128, 134], ["glycosylated S ptotein", "PROTEIN", 330, 352], ["S-peptide", "TREATMENT", 48, 57], ["the glycan shield", "TREATMENT", 259, 276], ["the glycosylated S ptotein", "TEST", 326, 352], ["N", "TEST", 447, 448], ["N", "TEST", 454, 455], ["N", "TEST", 461, 462], ["N", "TEST", 471, 472], ["glycan shield", "OBSERVATION", 263, 276], ["Surface", "OBSERVATION_MODIFIER", 288, 295]]], ["To characterize the extent of the glycan shield, we calculated the accessible surface area (ASA) of the S-peptide (with and without glycans) using 15 different probes increasing in radius size from 1.4 \u00c5 to 15 \u00c5, as described in Casalino et al. 27 Using a continuous range of values allows us to approximate different size molecules, ranging from small molecules at 2-5 \u00c5 to larger peptide-and antibody-sized molecules at 10-15 \u00c5.", [["surface area", "ANATOMY", 78, 90], ["antibody-sized molecules", "PROTEIN", 394, 418], ["the glycan shield", "TREATMENT", 30, 47], ["ASA", "TREATMENT", 92, 95], ["the S-peptide", "TREATMENT", 100, 113], ["glycans", "TREATMENT", 132, 139], ["larger peptide", "TEST", 375, 389], ["antibody", "TEST", 394, 402], ["extent", "OBSERVATION_MODIFIER", 20, 26], ["glycan shield", "OBSERVATION", 34, 47], ["surface", "OBSERVATION_MODIFIER", 78, 85], ["radius", "OBSERVATION_MODIFIER", 181, 187], ["size", "OBSERVATION_MODIFIER", 188, 192], ["size", "OBSERVATION_MODIFIER", 318, 322]]], ["27 The ASA of the S-peptide was calculated across the replicate simulations at 2 ns intervals ( Figure S4 ).", [["S-peptide", "GENE_OR_GENE_PRODUCT", 18, 27], ["S-peptide", "PROTEIN", 18, 27], ["The ASA", "TREATMENT", 3, 10], ["the S-peptide", "TREATMENT", 14, 27]]], ["Note that the difference between the overall accessibility of the 'naked' protein (without glycans) and the glycan shielded area corresponds to the effective accessibility of the S-peptide in the presence of glycans (cyan coloured area in Figure S4 ).", [["naked' protein", "PROTEIN", 67, 81], ["the glycan shielded area", "PROBLEM", 104, 128], ["glycans (cyan coloured area", "PROBLEM", 208, 235], ["effective", "OBSERVATION_MODIFIER", 148, 157], ["cyan coloured", "OBSERVATION", 217, 230]]], ["The peptide shows a different amount of glycan shield, with an average maximum coverage (across replicas and chains) of 47% in the open system and 30% in the closed system, at 15 \u00c5 probe radii ( Figure S4 ).", [["The peptide", "TEST", 0, 11], ["glycan shield", "TREATMENT", 40, 53], ["an average maximum coverage (across replicas and chains", "TREATMENT", 60, 115], ["different", "OBSERVATION_MODIFIER", 20, 29], ["amount", "OBSERVATION_MODIFIER", 30, 36], ["glycan shield", "OBSERVATION", 40, 53], ["average", "OBSERVATION_MODIFIER", 63, 70], ["maximum", "OBSERVATION_MODIFIER", 71, 78], ["coverage", "OBSERVATION_MODIFIER", 79, 87], ["closed", "OBSERVATION", 158, 164]]], ["Although the calculated ASA and glycan shield values show a marked variability due to the high flexibility of the peptide and the glycans, this analysis reveals that the S-peptide is weakly shielded, especially when the S protein is in the closed state, and potentially available for engaging with nAChRs.", [["ASA", "CHEMICAL", 24, 27], ["ASA", "GENE_OR_GENE_PRODUCT", 24, 27], ["S protein", "PROTEIN", 220, 229], ["nAChRs", "PROTEIN", 298, 304], ["the calculated ASA and glycan shield values", "TEST", 9, 52], ["a marked variability", "PROBLEM", 58, 78], ["the high flexibility of the peptide and the glycans", "PROBLEM", 86, 137], ["this analysis", "TEST", 139, 152]]], ["Interestingly, the presence of one RBD in the \"up\" conformation within chain A of the open system slightly alters the packing of the three monomers with respect to the closed system.", [["RBD", "PROTEIN", 35, 38], ["chain A", "PROTEIN", 71, 78], ["one RBD", "PROBLEM", 31, 38], ["one", "OBSERVATION_MODIFIER", 31, 34], ["RBD", "OBSERVATION", 35, 38], ["chain", "OBSERVATION_MODIFIER", 71, 76], ["slightly", "OBSERVATION_MODIFIER", 98, 106], ["alters", "OBSERVATION_MODIFIER", 107, 113], ["packing", "OBSERVATION_MODIFIER", 118, 125], ["closed", "OBSERVATION", 168, 174]]], ["This most likely results in the observed differences of accessibility and glycan shield between the two systems and even across chains ( Figure S4 ).", [["glycan shield", "TREATMENT", 74, 87], ["most likely", "UNCERTAINTY", 5, 16], ["glycan shield", "OBSERVATION", 74, 87]]], ["We also note that the same region of the S protein has been experimentally shown to bind to human neuropilin receptors, 41 which is clear evidence of its accessibility and ability to bind.Radius of gyrationThe radius of gyration (Rg) of the S-peptide was calculated from MD simulations of the glycosylated full-length S protein ( Figure S5) .", [["human", "ORGANISM", 92, 97], ["neuropilin receptors", "GENE_OR_GENE_PRODUCT", 98, 118], ["S-peptide", "SIMPLE_CHEMICAL", 241, 250], ["S protein", "PROTEIN", 41, 50], ["human neuropilin receptors", "PROTEIN", 92, 118], ["glycosylated full-length S protein", "PROTEIN", 293, 327], ["Figure S5", "PROTEIN", 330, 339], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["human neuropilin receptors", "TEST", 92, 118], ["the S-peptide", "TEST", 237, 250], ["gyration", "OBSERVATION", 198, 206], ["radius", "OBSERVATION_MODIFIER", 210, 216], ["gyration", "OBSERVATION_MODIFIER", 220, 228]]], ["Interestingly, the closed system exhibits a single Rg population, with nAChR (for details see the \"In silico alanine-scanning mutagenesis\" section above).", [["alanine", "CHEMICAL", 109, 116], ["alanine", "CHEMICAL", 109, 116], ["nAChR", "PROTEIN", 71, 76], ["closed", "OBSERVATION", 19, 25]]], ["The average was determined over the three replicates.", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["Note that the \u0394\u0394Gbind corresponds to the difference between mutant and wild-type complexes, and as such positive \u0394\u0394Gbind values mean that the mutation to alanine destabilizes the complex.Radius of gyration26 Figure S20 .", [["alanine", "CHEMICAL", 154, 161], ["alanine", "CHEMICAL", 154, 161], ["\u0394\u0394Gbind", "GENE_OR_GENE_PRODUCT", 113, 120], ["alanine", "AMINO_ACID", 154, 161], ["\u0394\u0394Gbind", "DNA", 14, 21], ["wild-type complexes", "PROTEIN", 71, 90], ["\u0394\u0394Gbind", "PROTEIN", 113, 120], ["mutant and wild-type complexes", "PROBLEM", 60, 90], ["such positive \u0394\u0394Gbind values", "PROBLEM", 99, 127], ["the mutation", "PROBLEM", 138, 150]]], ["Average predicted \u0394\u0394Gbind from the alanine-scanning mutagenesis 36 for the human \u03b17 nAChR.", [["alanine", "CHEMICAL", 35, 42], ["alanine", "CHEMICAL", 35, 42], ["alanine", "AMINO_ACID", 35, 42], ["human", "ORGANISM", 75, 80], ["\u03b17 nAChR", "GENE_OR_GENE_PRODUCT", 81, 89], ["human \u03b17 nAChR", "PROTEIN", 75, 89], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["the alanine-scanning mutagenesis", "TEST", 31, 63]]], ["Average predicted \u0394\u0394Gbind from the alanine-scanning mutagenesis 36 for the muscle-like \uf061\uf062\u03b3\u03b4 nAChR from Tetronarce californica.", [["muscle", "ANATOMY", 75, 81], ["alanine", "CHEMICAL", 35, 42], ["alanine", "CHEMICAL", 35, 42], ["alanine", "AMINO_ACID", 35, 42], ["muscle", "ORGAN", 75, 81], ["\uf061\uf062\u03b3\u03b4 nAChR", "GENE_OR_GENE_PRODUCT", 87, 97], ["Tetronarce californica", "ORGANISM", 103, 125], ["muscle-like \uf061\uf062\u03b3\u03b4 nAChR", "PROTEIN", 75, 97], ["Tetronarce californica", "SPECIES", 103, 125], ["Tetronarce californica", "SPECIES", 103, 125], ["the alanine-scanning mutagenesis", "TEST", 31, 63], ["muscle", "ANATOMY", 75, 81]]], ["Hot spots in the binding interface of the receptors that favour binding.", [["Hot spots", "PROBLEM", 0, 9]]], ["Note that the \u0394\u0394Gbind corresponds to the difference between mutant and wild-type complexes.", [["\u0394\u0394Gbind", "DNA", 14, 21], ["wild-type complexes", "PROTEIN", 71, 90], ["the difference between mutant and wild-type complexes", "PROBLEM", 37, 90]]], ["In this image, the red colour indicates a stabilizing contribution to the complex whereas blue indicates a destabilizing contribution.", [["the red colour", "TEST", 15, 29], ["the complex whereas blue", "PROBLEM", 70, 94], ["stabilizing", "OBSERVATION", 42, 53], ["destabilizing", "OBSERVATION_MODIFIER", 107, 120]]], ["Hot spots in the S-peptide.", [["S-peptide", "CHEMICAL", 17, 26], ["S-peptide", "SIMPLE_CHEMICAL", 17, 26], ["Hot spots in the S-peptide", "PROBLEM", 0, 26]]], ["Note that the \u0394\u0394Gbind corresponds to the difference between mutant and wild-type complexes.", [["\u0394\u0394Gbind", "DNA", 14, 21], ["wild-type complexes", "PROTEIN", 71, 90], ["the difference between mutant and wild-type complexes", "PROBLEM", 37, 90]]], ["In this image, the red colour indicates a stabilizing contribution to the complex whereas blue indicates a destabilizing contribution.", [["the red colour", "TEST", 15, 29], ["the complex whereas blue", "PROBLEM", 70, 94], ["stabilizing", "OBSERVATION", 42, 53], ["destabilizing", "OBSERVATION_MODIFIER", 107, 120]]]], "PMC7526892": [["1 IntroductionThere is currently a great deal of interest in the use of mobile apps to facilitate Covid-19 contact tracing, see e.g. [1\u20133].", [["mobile apps", "TREATMENT", 72, 83], ["Covid", "TEST", 98, 103]]], ["The basic idea of a contact tracing app is that if two people carrying mobile handsets installed with the app spend significant time in close proximity to one another (e.g. spending 15 minutes within 2 metres) then the apps on their handsets will both record this contact event.1 IntroductionContact tracing apps based on the Google/Apple Exposure Notification (GAEN) API [4] are currently being rolled out across Europe, with apps already deployed in Italy, Switzerland and Germany.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61], ["Contact tracing apps", "TEST", 292, 312]]], ["These apps use Bluetooth received signal strength to estimate proximity and will likely be used as an adjunct to existing manual contact tracing and test systems.", [["manual contact tracing", "TEST", 122, 144], ["test systems", "TEST", 149, 161]]], ["Existing manual systems can usually readily identify the people with whom an infected person share accommodation and with work colleagues with whom the infected person is in regular contact.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["person", "SPECIES", 86, 92], ["person", "SPECIES", 161, 167], ["Existing manual systems", "TREATMENT", 0, 23], ["infected", "OBSERVATION", 77, 85]]], ["More difficult is to identify people travelling on public transport with whom an infected person has been in contact, since the identities of these people are usually not known to the infected person and are generally not otherwise recorded.", [["people", "ORGANISM", 30, 36], ["people", "ORGANISM", 148, 154], ["people", "SPECIES", 30, 36], ["person", "SPECIES", 90, 96], ["people", "SPECIES", 148, 154], ["person", "SPECIES", 193, 199], ["infected", "OBSERVATION", 81, 89]]], ["Public transport is therefore potentially an important use case where effective contact tracing apps may be of significant assistance in infection control.1 IntroductionWe report on the results of a Covid-19 contact tracing app measurement study carried out on a commuter tram.", [["infection", "DISEASE", 137, 146], ["infection control", "TREATMENT", 137, 154], ["a Covid", "TEST", 197, 204], ["contact tracing", "TEST", 208, 223], ["app measurement study", "TEST", 224, 245], ["a commuter tram", "TREATMENT", 261, 276], ["infection", "OBSERVATION", 137, 146]]], ["Measurements were collected between 108 pairs of handset locations and are publicly available [5].1 IntroductionIn summary, our measurements indicate that in the tram there is little correlation between received signal strength and distance between handsets.", [["Measurements", "TEST", 0, 12], ["our measurements", "TEST", 124, 140]]], ["Similar ranges of signal strength are observed both between handsets which are less than 2m apart and handsets which are greater than 2m apart (including when handsets are up to 5m apart).", [["ranges", "OBSERVATION_MODIFIER", 8, 14], ["signal strength", "OBSERVATION", 18, 33], ["greater", "OBSERVATION_MODIFIER", 121, 128]]], ["This is likely due to reflections from the metal walls, floor and ceiling within the tram, metal being known to be a strong reflector of radio signals [6, 7], and is coherent with the behaviour observed on a commuter bus [8].1 IntroductionWe applied the detection rules used by the Italian, Swiss and German contact tracing apps to our measurement data and also characterised the impact on performance of changes in the parameters used in these detection rules.", [["our measurement data", "TEST", 332, 352], ["these detection rules", "TEST", 439, 460], ["likely due to", "UNCERTAINTY", 8, 21], ["reflections", "OBSERVATION", 22, 33], ["metal walls", "OBSERVATION", 43, 54]]], ["We find that the Swiss and German detection rules trigger no exposure notifications, despite around half of the pairs of handsets in our data being less than 2m apart.", [["German detection", "TEST", 27, 43]]], ["The Italian detection rule has a true positive rate (i.e. correct detections of handsets less than 2m apart) of around 50%.", [["The Italian detection", "TEST", 0, 21], ["a true positive rate", "PROBLEM", 31, 51]]], ["However, it also has a false positive rate of around 50% i.e. it incorrectly triggers exposure notifications for around 50% of the handsets which are greater than 2m apart.", [["a false positive rate", "PROBLEM", 21, 42], ["false", "OBSERVATION_MODIFIER", 23, 28], ["positive", "OBSERVATION_MODIFIER", 29, 37], ["rate", "OBSERVATION_MODIFIER", 38, 42]]], ["This performance is similar to that of triggering notifications by randomly selecting from the participants in our experiments, regardless of proximity.1 IntroductionWe observe that changing the people holding a pair of handsets, with the location of the handsets otherwise remaining unchanged, can cause variations of \u00b110dB in the attenuation level reported by the GAEN API.", [["people", "ORGANISM", 195, 201], ["\u00b110dB", "PROTEIN", 319, 324], ["participants", "SPECIES", 95, 107], ["people", "SPECIES", 195, 201], ["a pair of handsets", "TREATMENT", 210, 228], ["unchanged", "OBSERVATION_MODIFIER", 284, 293]]], ["This is pertinent because this level of \u201cnoise\u201d is large enough to potrentially have a substantial impact on proximity detection.2.1 Ethical approval ::: 2 MethodologyThe experimental protocol was reviewed and approved by the Ethics Committee of the School of Computer Science and Statistics, Trinity College Dublin.", [["large", "OBSERVATION_MODIFIER", 51, 56], ["substantial", "OBSERVATION_MODIFIER", 87, 98], ["impact", "OBSERVATION", 99, 105]]], ["Oral consent was obtained from participants.2.2 Experimental protocol ::: 2 MethodologyOur experimental measurements were collected on a standard light-rail tram carriage used to carry commuters in Dublin, Ireland, see Fig 1(a).", [["Oral", "ANATOMY", 0, 4], ["participants", "SPECIES", 31, 43], ["Experimental protocol", "TREATMENT", 48, 69], ["Our experimental measurements", "TEST", 87, 116], ["a standard light-rail tram carriage", "TREATMENT", 135, 170]]], ["We recruited seven participants and gave each of them Google Pixel 2 handsets.", [["participants", "SPECIES", 19, 31]]], ["This positioning aims to mimic passengers respecting the relaxed social distancing rules likely during easing of lockdown and with the distances between participants including a range of values < 2m and a range of values > 2m, see Fig 2.", [["participants", "SPECIES", 153, 165]]], ["Each experiment is 15 minutes duration giving around 3 scans by the GAEN API when scans are made every 4 mins (per measurements reported in [9]).", [["scans", "TEST", 82, 87]]], ["A Wifi hotspot was set up on the tram and the participants were asked to hold the handset in their hand and use it for normal commuter activities such as browsing the internet.2.2 Experimental protocol ::: 2 MethodologyAfter the first experiment was carried out participants were then asked to switch seats (they chose seats themselves) and a second 15 minute experiment run.", [["hand", "ANATOMY", 99, 103], ["hand", "ORGANISM_SUBDIVISION", 99, 103], ["Wifi hotspot", "DNA", 2, 14], ["participants", "SPECIES", 46, 58], ["participants", "SPECIES", 262, 274], ["Experimental protocol", "TREATMENT", 180, 201]]], ["After the second experiment participants were again asked to change seats for the third 15 minute experiment and, in addition, two participants were asked to place their handsets in their left trouser pocket (in an orientation of their choice).2.2 Experimental protocol ::: 2 MethodologyEach handset had the GAEN API and a modified version of the Google exemplar Exposure Notification app [10] installed, and was registered to a gmail user included on the Google GAEN whitelist so as to allow use of the GAEN API by the Exposure Notification app.", [["participants", "SPECIES", 28, 40], ["participants", "SPECIES", 131, 143], ["Experimental protocol", "TREATMENT", 248, 269], ["left", "ANATOMY_MODIFIER", 188, 192]]], ["This app implements the transmitter side of the GAEN API and allowed us to control the TEK used and also to start/stop the broadcasting of Bluetooth LE beacons.2.2 Experimental protocol ::: 2 MethodologyAt the start of each 15 minute experiment participants were asked to configure the GAENAdvertiser app with a new TEK and then to instruct the app to start broadcasting GAEN beacons.", [["LE", "GENE_OR_GENE_PRODUCT", 149, 151], ["TEK", "DNA", 87, 90], ["participants", "SPECIES", 245, 257], ["the GAEN API", "TREATMENT", 44, 56], ["Bluetooth LE beacons", "PROBLEM", 139, 159], ["Experimental protocol", "TREATMENT", 164, 185]]], ["In this way a unique TEK is associated with each handset in each experiment, and these can be used to query GAEN API to obtain separate exposure information reports for each handset in each experiment.2.2 Experimental protocol ::: 2 MethodologyFollowing all three experiments the handsets were collected, the TEKs used by each handset extracted and the GAEN API on each then queried for exposure information relating to the TEKs of the other handsets.", [["TEK", "CANCER", 21, 24], ["TEK", "DNA", 21, 24], ["TEKs", "DNA", 309, 313], ["Experimental protocol", "TREATMENT", 205, 226]]], ["This measurement data is publicly available [5].2.2 Experimental protocol ::: 2 MethodologyTo provide baseline data on the radio propagation environment we also used the standard Android Bluetooth LE scanner API to collect measurements of RSSI as the distance was varied between two Google Pixel 2 handsets placed at a height of approximately 0.5m (about the same height as the tram seating) in the centre aisle of the tram carriage.2.3 Hardware & software used ::: 2 MethodologyWe used Google Pixel 2 handsets running GAEN API version 202512001 As reported in the Settings-COVID 19 Notifications handset display, which includes a major update by Google issued on 13th June 2020.2.3 Hardware & software used ::: 2 MethodologyWe used a version of the Google exemplar Exposure Notification app modified to allow us to query the GAEN API over USB using a python script (the source code for the modified app is available on github [10]).2.3 Hardware & software used ::: 2 MethodologyIn addition we also wrote our own GAENAdvertiser app that implements the Bluetooth LE transmitter side of the GAEN API [4].", [["tram", "ANATOMY", 419, 423], ["202512001", "CHEMICAL", 536, 545], ["tram", "ORGANISM_SUBDIVISION", 419, 423], ["USB", "PROTEIN", 840, 843], ["This measurement data", "TEST", 0, 21], ["Experimental protocol", "TREATMENT", 52, 73], ["the standard Android Bluetooth LE scanner API", "TREATMENT", 166, 211], ["RSSI", "TREATMENT", 239, 243], ["tram", "ANATOMY", 419, 423], ["Hardware", "OBSERVATION", 437, 445], ["Hardware", "OBSERVATION", 683, 691], ["Hardware", "OBSERVATION", 937, 945]]], ["GAENAdvertiser allows us to control the TEK, and in particular reset it to a new value at the start of each experiment.", [["TEK", "DNA", 40, 43]]], ["In effect, resetting the TEK makes the handset appear as a new device from the point of view of the GAEN API, and so this allows us to easily collect clean data (the GAEN API otherwise only resets the TEK on a handset once per day).", [["TEK", "DNA", 25, 28], ["TEK", "PROTEIN", 201, 204], ["a new device", "TREATMENT", 57, 69]]], ["We carried out extensive tests running GAENAdvertiser and the GAEN API on the same device to confirm that under a wide range of conditions the responses of the GAEN API on a second receiver handset were the same for beacons from GAENAdvertiser and the GAEN API, see [9] for further details.", [["GAEN API", "DNA", 160, 168], ["extensive tests", "TEST", 15, 30], ["the GAEN API", "TREATMENT", 58, 70], ["the same device", "TREATMENT", 74, 89]]], ["Subsequent to our measurement study Google has now published the code for the transmitter side implementation and details of the receiver side attenuation calculation [11, 12].", [["our measurement study", "TEST", 14, 35], ["the transmitter side implementation", "TREATMENT", 74, 109], ["the receiver side attenuation calculation", "TEST", 125, 166]]], ["These also confirm that the GAENAdvertiser implementation is essentially identical to the Google transmitter-side implementation.2.3 Hardware & software used ::: 2 MethodologyGAENAdvertiser is open source and can be obtained by contacting the authors (we have not made it publicly available, however, since it can be used to facilitate a known replay attack against the GAEN API [13]).2.4 GAEN use of Bluetooth for proximity detection ::: 2 MethodologyThe basic idea of a contact tracing app is that if two people carrying mobile handsets installed with the app spend significant time in close proximity to one another (e.g. spending 15 minutes within 2 metres) then the apps on their handsets will both record this contact event.", [["people", "ORGANISM", 507, 513], ["people", "SPECIES", 507, 513], ["proximity detection", "TEST", 415, 434], ["Hardware", "OBSERVATION", 133, 141]]], ["If, subsequently, one of these people is diagnosed with Covid-19 then the contact events logged on that person\u2019s handset in the recent past, e.g. over the last two weeks, are used to identify people who have been in close contact with the infected person.", [["people", "ORGANISM", 31, 37], ["people", "ORGANISM", 192, 198], ["people", "SPECIES", 31, 37], ["person", "SPECIES", 104, 110], ["people", "SPECIES", 192, 198], ["person", "SPECIES", 248, 254]]], ["These people might then be made aware of the contact and advised to self-isolate or take other appropriate precautions.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["appropriate precautions", "TREATMENT", 95, 118]]], ["For this approach to be effective it is, of course, necessary that the app can accurately detect contact events.2.4 GAEN use of Bluetooth for proximity detection ::: 2 MethodologyThe GAEN API uses Bluetooth LE wireless technology as the means for detecting contact events.", [["proximity detection", "TEST", 142, 161]]], ["Bluetooth LE devices can be configured to transmit beacons at regular intervals.", [["Bluetooth LE devices", "TREATMENT", 0, 20]]], ["To distinguish between beacons sent by different handsets each handset running GAEN generates a random Temporary Exposure Key (TEK) once a day.", [["a random Temporary Exposure Key (TEK)", "TREATMENT", 94, 131]]], ["This TEK is then used to generate a sequence of Rolling Proximity Identifiers (RPIs), approximately one for each 10 minute interval during the day (so around 144 RPIs are generated).", [["TEK", "DNA", 5, 8]]], ["The GAEN system running on a handset transmits beacons roughly every 250ms.", [["a handset transmits beacons", "TREATMENT", 27, 54]]], ["Each beacon contains the current RPI value.", [["RPI", "PROTEIN", 33, 36]]], ["Approximately every 10 minutes the beacons are updated to transmit the next RPI value.", [["RPI", "PROTEIN", 76, 79]]], ["By constantly changing the content of beacons in this way the privacy of the system is improved.", [["improved", "OBSERVATION_MODIFIER", 87, 95]]], ["In addition to the RPI each beacon also carries encrypted metadata containing the wireless transmit power level used.", [["RPI", "DNA", 19, 22]]], ["Although beacons are emitted roughly every 250ms, on the receiving side, devices only scan for beacons roughly every 4 minutes [9].2.4 GAEN use of Bluetooth for proximity detection ::: 2 MethodologyThe basic idea is that the signal strength with which a beacon is received provides a rough measure of the distance between transmitter and receiver.", [["proximity detection", "TEST", 161, 180]]], ["This is based on the fact that in general the radio signal gets weaker as it travels further since the transmit power is spread over a greater area.", [["spread", "OBSERVATION_MODIFIER", 121, 127], ["greater", "OBSERVATION_MODIFIER", 135, 142]]], ["However, many complex effects can be superimposed upon this basic behaviour.", [["many", "OBSERVATION_MODIFIER", 9, 13], ["complex", "OBSERVATION", 14, 21]]], ["A person\u2019s body also absorbs radio signals in the 2.4 GHz band used by Bluetooth LE and so the received signal strength can be substantially reduced if their body lies on the path between the transmitter and receiver.", [["body", "ANATOMY", 11, 15], ["body", "ANATOMY", 158, 162], ["body", "ORGANISM_SUBDIVISION", 11, 15], ["body", "ORGANISM_SUBDIVISION", 158, 162], ["person", "SPECIES", 2, 8], ["the 2.4 GHz band", "TREATMENT", 46, 62]]], ["The relative orientation of two handsets can strongly affect the received signal strength owing to way antennae are packaged within the handset body.", [["body", "ANATOMY", 144, 148], ["antennae", "ORGANISM_SUBDIVISION", 103, 111], ["body", "ORGANISM_SUBDIVISION", 144, 148]]], ["The Exposure Configuration data structure allows specification of the TEK to be queried, the start time and duration of the interval of interest (specified in 10 minute intervals since 1st Jan 1970) and a low and high attenuation threshold (specified in dB).", [["TEK", "DNA", 70, 73], ["a low and high attenuation threshold", "PROBLEM", 203, 239], ["high attenuation", "OBSERVATION_MODIFIER", 213, 229]]], ["The GAEN system responds with one or more Exposure Information data structures that report an exposure duration (field durationMinutes) and an array with three atttenuation duration values, giving the duration (in minutes) that the attenuation level is below the low threshold, the duration the attenuation level is between the low and high thresholds and the duration above the high threshold.", [["the attenuation level", "TEST", 228, 249], ["attenuation", "OBSERVATION_MODIFIER", 232, 243], ["low threshold", "OBSERVATION_MODIFIER", 263, 276], ["low", "OBSERVATION_MODIFIER", 328, 331], ["high threshold", "OBSERVATION_MODIFIER", 379, 393]]], ["It is also possible to query for an Exposure Summary response, but we did not make use of this since the relevant information that this contains can be derived from the Exposure Information reports.2.5 Querying the GAEN API ::: 2 MethodologyFor each TEK and time interval we made repeated queries to the GAEN API holding the low threshold constant at 48dB and varying the high threshold from 49dB to 100dB (in 1dB steps up to 80dB, then in 5dB steps since noise tends to be higher at higher attenuation levels).", [["the GAEN API", "TREATMENT", 300, 312]]], ["By differencing this sequence of reports we can infer the attenuation duration at each individual attenuation level from 48dB through to 100dB.2.5 Querying the GAEN API ::: 2 MethodologyAt the time of our meaurement study the GAEN documentation did not precisely state how the attenuation level is calculated, nor did it give details as to how the attenuation duration is calculated.", [["our meaurement study", "TEST", 201, 221]]], ["The analysis in [9], indicated the attenuation level is calculated as PTX \u2212 PRX, where PTX is the transmit power level sent in the beacon metadata and PRX is given by a filtered RSSI For Google Pixel 2 handsets (and others) the RSSI is recorded only from beacons transmitted on one of the three radio channels used by Bluetooth LE for transmitting beacons, see [9]. measurements plus a calibration offset.", [["PTX", "CHEMICAL", 70, 73], ["PTX", "CHEMICAL", 87, 90], ["PTX", "CHEMICAL", 70, 73], ["PTX", "CHEMICAL", 87, 90], ["PTX \u2212 PRX", "SIMPLE_CHEMICAL", 70, 79], ["PTX", "SIMPLE_CHEMICAL", 87, 90], ["RSSI", "DNA", 228, 232], ["The analysis", "TEST", 0, 12], ["the attenuation level", "PROBLEM", 31, 52], ["PTX \u2212 PRX", "PROBLEM", 70, 79], ["PTX", "PROBLEM", 87, 90], ["a filtered RSSI", "TREATMENT", 167, 182], ["Google Pixel 2 handsets", "TREATMENT", 187, 210], ["the RSSI", "TEST", 224, 232], ["transmitting beacons", "PROBLEM", 335, 355], ["a calibration offset", "TREATMENT", 384, 404], ["calibration offset", "OBSERVATION", 386, 404]]], ["Google has subsequently published documentation [12] that confirms this.2.5 Querying the GAEN API ::: 2 MethodologyFor the Google Pixel 2 handsets and GAEN API version 202512001 used in our experiments PTX is -31dB and the calibration offset is -6dB.", [["PTX", "CHEMICAL", 202, 205], ["PTX", "CHEMICAL", 202, 205], ["PTX", "SIMPLE_CHEMICAL", 202, 205]]], ["Google supplied us with the calibration and offset values used for all handset models in GAEN version 202512001 and we have posted these in our online study archive [5].", [["the calibration", "TEST", 24, 39], ["offset values", "TEST", 44, 57]]], ["Note that we observed that the noise floor (the RSSI below which beacons can no longer be reliably decoded) is around -100dB in a Pixel 2, giving a maximum measureable attenuation of around 75dB i.e. above this attenuation level beacons are generally not decoded successfully and so no RSSI values are reported by Bluetooth scans.3.1 Attenuation vs Distance ::: 3 ResultsFig 3(a) plots the attenuation measured between two handsets placed at seat height in the aisle of the tram as the distance between them is varied.", [["RSSI", "PROTEIN", 286, 290], ["the RSSI below", "TREATMENT", 44, 58], ["RSSI values", "TEST", 286, 297], ["Bluetooth scans", "TEST", 314, 329], ["Attenuation vs Distance", "TEST", 334, 357], ["Attenuation", "OBSERVATION_MODIFIER", 334, 345], ["attenuation", "OBSERVATION_MODIFIER", 390, 401], ["varied", "OBSERVATION_MODIFIER", 511, 517]]], ["These measurements were taken using the standard Android Bluetooth LE scanner API (rather than the GAEN API).", [["These measurements", "TEST", 0, 18], ["the standard Android Bluetooth LE scanner API", "TREATMENT", 36, 81]]], ["This scanner API reports an RSSI value for each received beacon.", [["This scanner API", "TEST", 0, 16], ["an RSSI value", "TEST", 25, 38]]], ["Following [9] updated to reflect GAEN calibration changes pushed by Google on 13th June 2020, for the Google Pixel 2 handsets used in our experiments we map from RSSI to attenuation level using the formula -31-(RSSI-6) dB.3.1 Attenuation vs Distance ::: 3 ResultsIt can be seen that the attenuation initially increases as the distance is increased from 0.5m to 1.5m, as might be expected.", [["the Google Pixel 2 handsets", "TREATMENT", 98, 125], ["attenuation level", "TEST", 170, 187], ["the formula", "TEST", 194, 205], ["RSSI", "TEST", 211, 215], ["can be seen", "UNCERTAINTY", 266, 277], ["attenuation", "OBSERVATION_MODIFIER", 287, 298], ["initially", "OBSERVATION_MODIFIER", 299, 308], ["increases", "OBSERVATION_MODIFIER", 309, 318], ["distance", "OBSERVATION_MODIFIER", 326, 334], ["increased", "OBSERVATION_MODIFIER", 338, 347], ["0.5m to 1.5m", "OBSERVATION_MODIFIER", 353, 365], ["might be expected", "UNCERTAINTY", 370, 387]]], ["But thereafter the attenuation level stays roughly constant with increasing distance out to 2.5m.", [["the attenuation level", "PROBLEM", 15, 36], ["attenuation", "OBSERVATION_MODIFIER", 19, 30], ["roughly", "OBSERVATION_MODIFIER", 43, 50], ["constant", "OBSERVATION_MODIFIER", 51, 59], ["increasing", "OBSERVATION_MODIFIER", 65, 75]]], ["There is then a sharp rise in the attenuation at 3m.", [["a sharp rise in the attenuation", "PROBLEM", 14, 45], ["sharp", "OBSERVATION_MODIFIER", 16, 21], ["rise", "OBSERVATION_MODIFIER", 22, 26], ["attenuation", "OBSERVATION_MODIFIER", 34, 45]]], ["This corresponds to the end of a group of seats and the start of a flexible joint between two carriages.", [["joint", "ANATOMY", 76, 81], ["joint", "MULTI-TISSUE_STRUCTURE", 76, 81], ["a flexible joint", "TREATMENT", 65, 81], ["flexible", "ANATOMY_MODIFIER", 67, 75], ["joint", "ANATOMY", 76, 81]]], ["As the distance is increased further it can be seen that the attenuation starts to fall.", [["increased", "OBSERVATION_MODIFIER", 19, 28], ["attenuation", "OBSERVATION", 61, 72]]], ["The attenuation is around 52dB at 1.5m and around 60dB at 4m.3.1 Attenuation vs Distance ::: 3 ResultsThe baseline measurements in Fig 3 indicate that the radio attenuation within the tram does not simply increase with the distance between handsets.", [["The baseline measurements in Fig", "TEST", 102, 134], ["the radio attenuation", "PROBLEM", 151, 172], ["attenuation", "OBSERVATION_MODIFIER", 4, 15], ["radio attenuation", "OBSERVATION", 155, 172], ["increase", "OBSERVATION_MODIFIER", 205, 213]]], ["Although further measurements are needed to confirm this, it seems likely that this effect is due to reflections from the tram walls, ceiling and floor, all of which are made of metal and highly reflective at the Bluetooth radio frequency.3.2 Attenuation between passengers ::: 3 ResultsThe full attenuation duration data reported by GAEN API is given in the Appendix and is publicly available online [5].", [["tram walls", "ANATOMY", 122, 132], ["tram walls", "MULTI-TISSUE_STRUCTURE", 122, 132], ["further measurements", "TEST", 9, 29], ["seems likely", "UNCERTAINTY", 61, 73], ["Attenuation", "OBSERVATION_MODIFIER", 243, 254], ["Appendix", "ANATOMY", 359, 367]]], ["In this section we analyse two aspects of this data: (i) the relationship, if any, between attenuation level and distance between handsets and (ii) the magnitude of the variations in the attenuation level induced by differences in the way participants hold their handsets.3.3 Trend with distance ::: 3 ResultsFig 4 plots the mean attenuation level vs the distance between participants in the three tests.", [["participants", "SPECIES", 239, 251], ["participants", "SPECIES", 372, 384], ["the mean attenuation level", "TEST", 321, 347], ["the three tests", "TEST", 388, 403], ["attenuation", "OBSERVATION_MODIFIER", 187, 198], ["mean attenuation", "OBSERVATION_MODIFIER", 325, 341]]], ["The mean is calculated by weighting each attenuation level by the duration at that level reported by the GAEN API and then summing over all attenuation levels.", [["the GAEN API", "TEST", 101, 113], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["It can be seen that there is no clear trend in the mean attenuation level as the distance changes, with similar ranges of attenuation levels observed at all distances, except perhaps for distances below 1m where the attenuation level is more tightly clustered.3.3 Trend with distance ::: 3 ResultsThe GAEN API records the duration at each attenuation, and so effectively the full distribution of attenuation levels rather than just the mean.", [["the attenuation level", "PROBLEM", 212, 233], ["attenuation levels", "PROBLEM", 396, 414], ["can be seen", "UNCERTAINTY", 3, 14], ["no", "UNCERTAINTY", 29, 31], ["clear", "OBSERVATION_MODIFIER", 32, 37], ["trend", "OBSERVATION_MODIFIER", 38, 43], ["mean attenuation", "OBSERVATION", 51, 67], ["distance", "OBSERVATION_MODIFIER", 81, 89], ["similar", "OBSERVATION_MODIFIER", 104, 111], ["ranges", "OBSERVATION_MODIFIER", 112, 118], ["attenuation", "OBSERVATION_MODIFIER", 122, 133], ["levels", "OBSERVATION_MODIFIER", 134, 140], ["attenuation", "OBSERVATION_MODIFIER", 216, 227], ["more tightly", "OBSERVATION_MODIFIER", 237, 249], ["attenuation", "OBSERVATION_MODIFIER", 339, 350], ["full", "OBSERVATION_MODIFIER", 375, 379], ["distribution", "OBSERVATION_MODIFIER", 380, 392], ["attenuation levels", "OBSERVATION", 396, 414]]], ["We have therefore indicated the 2m distance with a vertical line in Fig 5, and attenuation durations greater than 15 minutes by the shaded areas.3.3 Trend with distance ::: 3 ResultsFor reliable detection of proximity events what one might like is that for an appropriate choice of threshold value the attenuation levels lie within the shaded area when the distance is less than 2m and outside the shaded area when the distance is greater than 2m.", [["a vertical line in Fig", "TREATMENT", 49, 71], ["attenuation durations", "TEST", 79, 100], ["vertical line", "OBSERVATION", 51, 64], ["attenuation", "OBSERVATION_MODIFIER", 79, 90], ["durations", "OBSERVATION_MODIFIER", 91, 100], ["attenuation", "OBSERVATION_MODIFIER", 302, 313], ["shaded", "OBSERVATION_MODIFIER", 336, 342], ["area", "OBSERVATION_MODIFIER", 343, 347], ["shaded", "OBSERVATION_MODIFIER", 398, 404], ["area", "OBSERVATION_MODIFIER", 405, 409]]], ["Instead, consistent with Fig 4 we see no consistent trend between attenuation duration and distance below/above 2m.3.4 Magnitude of inter-test variations ::: 3 ResultsBetween each of the three experiments the participants switch seats.", [["participants", "SPECIES", 209, 221]]], ["The seat positions themselves remain the same, only the person sitting in the seat changes, allowing us to see the impact of differences in the way that each participant uses their handset.", [["person", "SPECIES", 56, 62]]], ["For beacons transmitted from each seat position Fig 6 shows the mean attenuation level observed at the other seat positions (see the Appendix for the full attenuation duration data).", [["beacons", "PROBLEM", 4, 11], ["the mean attenuation level", "PROBLEM", 60, 86], ["mean attenuation", "OBSERVATION_MODIFIER", 64, 80], ["Appendix", "ANATOMY", 133, 141]]], ["The attenuation level observed in test 1 is plotted vs the attenuation level observed in test 2.", [["The attenuation level", "TEST", 0, 21], ["the attenuation level", "TEST", 55, 76], ["attenuation", "OBSERVATION_MODIFIER", 4, 15]]], ["It can be seen that the points are clustered around the 45\u00b0 line, but variations of \u00b110dB between the two tests are common.", [["\u00b110dB", "PROTEIN", 84, 89], ["the 45\u00b0 line", "TREATMENT", 52, 64], ["the two tests", "TEST", 98, 111], ["45", "OBSERVATION_MODIFIER", 56, 58], ["\u00b0 line", "OBSERVATION", 58, 64]]], ["Since the seating locations and environment within the tram are the same between experiments, participants have similar build and height and use the same model of handset, these variations can be attributed to differences in the way each particpant holds their handset and/or changes between tests in the way the same particpant holds their handset.", [["tram", "MULTI-TISSUE_STRUCTURE", 55, 59], ["participants", "SPECIES", 94, 106], ["tests", "TEST", 292, 297]]], ["Such substantial variations in attenuation level are obviously pertinent to the use of attenuation level for proximity detection.3.5.1 Swiss & German exposure notification rules ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsSwitzerland deployed a Covid-19 contact tracing app based on the GAEN API on 26 May 2020 [15].", [["Such substantial variations in attenuation level", "PROBLEM", 0, 48], ["proximity detection", "TEST", 109, 128], ["substantial", "OBSERVATION_MODIFIER", 5, 16], ["variations", "OBSERVATION_MODIFIER", 17, 27], ["attenuation", "OBSERVATION_MODIFIER", 31, 42]]], ["The documentation for this app states that it queries the GAEN API with low and high attenuation thresholds of t1 = 50dB and t2 = 55dB and then bases exposure notifications on the quantity ES = B1 + 0.5B2, where B1 is the attenuation duration below 50dB reported by the GAEN API and B2 is the attenuation duration between 50dB and t2 [16].", [["B1", "PROTEIN", 194, 196], ["B1", "PROTEIN", 212, 214], ["B2", "PROTEIN", 283, 285], ["the GAEN API", "TEST", 54, 66], ["low and high attenuation thresholds", "PROBLEM", 72, 107], ["t1", "TEST", 111, 113], ["t2", "TEST", 125, 127], ["B1", "TEST", 194, 196], ["high attenuation", "OBSERVATION_MODIFIER", 80, 96], ["attenuation", "OBSERVATION_MODIFIER", 293, 304]]], ["An exposure notification is triggered when ES is greater than 15 mins, see Table 1.3.5.1 Swiss & German exposure notification rules ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsGermany deployed a Covid-19 contact tracing app based on the GAEN API on 15 June 2020 [17].", [["a Covid", "TEST", 227, 234]]], ["We downloaded the detection settings from the server on 21 June 2020 and they are included in the study data repository [5], we determined that the German app follows an approach similar to the Swiss app for triggering an exposure notification, but uses values t1 = 55dB and t2 = 63dB and an exposure duration on 10 minutes.3.5.1 Swiss & German exposure notification rules ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsWe applied the Swiss and German exposure notification rules to the tram dataset.", [["t2", "TEST", 275, 277]]], ["Fig 7(a) plots the true and false positive rates for t1 = 50dB and as t2 is varied from 55dB upwards and the ES threshold varied from 10 minutes to 15 mins.", [["t1", "TEST", 53, 55]]], ["The mean rates are shown with one standard deviation indicated by the error bars.", [["The mean rates", "TEST", 0, 14], ["error bars", "OBSERVATION", 70, 80]]], ["The mean and standard deviation are obtained by a standard bootstrapping approach The dataset was resampled with replacement n = 1000 times, the exposure notification percentage calculated for each sample and then the mean and standard deviation of these n estimates calculated.", [["a standard bootstrapping approach", "TREATMENT", 48, 81], ["replacement n", "TREATMENT", 113, 126], ["the exposure notification percentage", "TEST", 141, 177], ["these n estimates", "TEST", 249, 266], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["standard deviation", "OBSERVATION", 13, 31]]], ["We selected n by calculating the mean and standard deviation vs n and selecting a value large enough that these were convergent.", [["standard deviation vs n", "PROBLEM", 42, 65]]], ["Fig 7(b) plots the true and false positive rates when t1 = 55dB.3.5.1 Swiss & German exposure notification rules ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsIt can be seen from Fig 7(a) that selecting t1 = 50dB and t2 = 55dB (the values used in the Swiss app) yields no positive detections, despite approximately 50% of the handset pairs in the tram dataset being within a 2m distance of one another.", [["Fig", "TEST", 0, 3], ["t2", "TEST", 249, 251], ["positive detections", "PROBLEM", 304, 323], ["false positive", "OBSERVATION", 28, 42]]], ["Increasing t2 to 62dB and above yields a small increase in detection rate, with true and false detection rates roughly equal (we comment further on the implications of this below).3.5.1 Swiss & German exposure notification rules ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsIt can be seen from Fig 7(b) that selecting t1 = 55dB and t2 = 63dB (the values used in the German app) there are are no detections when the threshold for ES is 15 minutes but when a threshold of 10 minutes is used, as in the app, then the true and false positive detection rates both rise to 9%.", [["a small increase in detection rate", "PROBLEM", 39, 73], ["true and false detection rates", "PROBLEM", 80, 110], ["t2", "TEST", 365, 367], ["small", "OBSERVATION_MODIFIER", 41, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["false detection", "OBSERVATION", 89, 104], ["false positive", "OBSERVATION", 556, 570], ["rise", "OBSERVATION_MODIFIER", 592, 596]]], ["Increasing t2 does not increase these detection rates.3.5.2 Italian exposure notification rule ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsItaly deployed a Covid-19 contact tracing app based on the GAEN API on 1 June 2020 [18, 19].", [["Increasing t2", "PROBLEM", 0, 13], ["these detection rates", "TEST", 32, 53], ["a Covid", "TEST", 188, 195]]], ["Fig 8(a) plots the true and false positive rates as threshold t2 is varied from 55dB upwards and the threshold for ES is varied from 10 minutes to 15 mins.", [["false positive rates", "PROBLEM", 28, 48], ["positive rates", "OBSERVATION", 34, 48]]], ["For t2 = 73dB the true and false positive detection rates are both around 50% when the threshold for ES is 15 minutes, rising to 80% when the threshold for ES is reduced to 10 minutes.", [["t2", "TEST", 4, 6], ["false positive", "OBSERVATION", 27, 41]]], ["As noted in Section 2.5, with the calibration values used in the GAEN API the maximum observable attenuation level with Google Pixel 2 handsets is around 75dB (above this level beacons are generally no longer successfully received).", [["the calibration values", "TEST", 30, 52], ["Google Pixel 2 handsets", "TREATMENT", 120, 143], ["attenuation", "OBSERVATION_MODIFIER", 97, 108]]], ["Selecting t2 = 73dB therefore means that almost the full range of possible attenuation levels will trigger an exposure notfication.", [["attenuation levels", "PROBLEM", 75, 93]]], ["High detection rates are therefore unsurprising, but the detection has little discrimination and essentially would trigger exposure notifications for all participants in our tests regardless of proximity.3.5.2 Italian exposure notification rule ::: 3.5 Exposure notification true/false positive detection rate ::: 3 ResultsFig 8(a) also shows the true and false positive detection rates for other choices of threshold t2.", [["participants", "SPECIES", 154, 166], ["High detection rates", "PROBLEM", 0, 20], ["the detection", "TEST", 53, 66], ["our tests", "TEST", 170, 179], ["the true and false positive detection rates", "PROBLEM", 343, 386], ["false", "OBSERVATION", 356, 361], ["positive detection", "OBSERVATION", 362, 380]]], ["While the detection rates are generally substantially higher than with the Swiss and German detection rules, it can be seen that the false positive rate increases almost exactly in line with the true positive rate.", [["the detection rates", "TEST", 6, 25], ["the false positive rate", "PROBLEM", 129, 152], ["false", "OBSERVATION_MODIFIER", 133, 138], ["positive", "OBSERVATION_MODIFIER", 139, 147], ["rate", "OBSERVATION_MODIFIER", 148, 152], ["increases", "OBSERVATION_MODIFIER", 153, 162], ["positive rate", "OBSERVATION", 200, 213]]], ["It can be seen that the true vs false positive curve lies close to the 45\u00b0 line (to avoid clutter we do not plot the error bars from Fig 8(a) on Fig 8(b) but the small deviation from the 45\u00b0 line is not statistically significant.).", [["the true vs false positive curve", "PROBLEM", 20, 52], ["the 45\u00b0 line", "TREATMENT", 67, 79], ["clutter", "PROBLEM", 90, 97], ["the small deviation", "PROBLEM", 158, 177], ["small", "OBSERVATION_MODIFIER", 162, 167], ["deviation", "OBSERVATION", 168, 177]]], ["That is, the detection performance is poor, and comparable to simply selecting from participants at random when making exposure notifications.4 DiscussionA limitation of this study is that it is confined to handsets using the Android operating system.", [["participants", "SPECIES", 84, 96], ["the detection performance", "TEST", 9, 34], ["this study", "TEST", 170, 180]]], ["The GAEN API is also implemented on Apple iOS devices, but Apple have severely limited the ability of testers to make measurements (each handset is limited to querying the GAEN API a maximum of 15 times a day, and Apple has no whitelisting process to relax this constraint.", [["Apple iOS devices", "TREATMENT", 36, 53], ["API", "OBSERVATION", 9, 12]]], ["Our measurement approach uses 34 queries to extract fine-grained attenuation data per pair of handset locations.4 DiscussionWe equipped participants with the same model of handset in order to remove this as a source of variability in the data and instead focus on variability caused by the radio environment and the way that people hold their handsets.", [["people", "ORGANISM", 325, 331], ["participants", "SPECIES", 136, 148], ["people", "SPECIES", 325, 331]]], ["We therefore expect that our measurements should also be applicable to a range of handsets, although this remains to be confirmed.4 DiscussionWith regard to calibration, we note that Bluetooth received signal strength is affected by several factors including (i) differences between different models/makes of handset, (ii) fluctuations in the relative orientation of handsets (even small changes can have a large impact), (iii) absorption by human bodies (especially when phone is in a pocket), bags etc, (iv) radio wave reflection from walls, floors, furniture.", [["human", "ORGANISM", 442, 447], ["human", "SPECIES", 442, 447], ["human", "SPECIES", 442, 447], ["walls", "ANATOMY_MODIFIER", 537, 542]]], ["See [14] for measurements highlighing the potential for significant impact of these factors.", [["these factors", "PROBLEM", 78, 91]]], ["A direct comparison of detection accuracy in these two datasets is unfortunately not possible since in the bus measurements all pairs of handsets were within 2m of one another and so only the rate of false negatives can be evaluated.5 ConclusionWe report on the results of a Covid-19 contact tracing measurement study carried out on a commuter tram in Dublin, Ireland.", [["detection accuracy", "TEST", 23, 41], ["a Covid", "TEST", 273, 280], ["contact tracing measurement study", "TEST", 284, 317], ["a commuter tram", "TREATMENT", 333, 348], ["not possible", "UNCERTAINTY", 81, 93], ["false negatives", "OBSERVATION", 200, 215]]], ["Our measurements indicate that in the tram there is little correlation between received signal strength and distance between handsets.", [["Our measurements", "TEST", 0, 16]]], ["We applied the detection rules used by the Italian, Swiss and German apps to our measurement data and also characterised the impact on performance of changes in the parameters used in these detection rules.", [["our measurement data", "TEST", 77, 97], ["these detection rules", "TEST", 184, 205]]], ["We find that the Swiss and German detection rules trigger no exposure notifications on our data, while the Italian detection rule generates a true positive rate of 50% and a false positive rate of 50%.", [["a false positive rate", "TEST", 172, 193]]], ["Our analysis indicates that the performance of such detection rules is similar to that of triggering notifications by randomly selecting from the participants in our experiments, regardless of proximity.Data presentation format ::: AppendixWe present the full attenuation duration data using a coloured heatmap.", [["participants", "SPECIES", 146, 158], ["Our analysis", "TEST", 0, 12], ["a coloured heatmap", "PROBLEM", 292, 310], ["full attenuation", "OBSERVATION_MODIFIER", 255, 271]]], ["We split the range of attenuation values into 2dB bins, i.e. 70-72dB, 72-74dB and so on, up to 80dB when 5dB bins are thereafter used since the data is noisier at these low signal levels.", [["2dB bins", "TEST", 46, 54], ["the data", "TEST", 140, 148], ["attenuation", "OBSERVATION_MODIFIER", 22, 33]]], ["The mapping from colours to percentages is shown on the righthand side of the plot.", [["The mapping", "TEST", 0, 11]]], ["Bins with no entries (i.e. with duration zero) are left blank.", [["no", "UNCERTAINTY", 10, 12], ["left", "ANATOMY_MODIFIER", 51, 55], ["blank", "ANATOMY", 56, 61]]], ["Where appropriate we also include a solid line in plots that indicates the average attenuation level at each transmit power level (the average is calculated by weighting each attenuation level by the duration at that level and then summing over all attenuation levels).Data presentation format ::: AppendixFor example, in Fig 9(a) the left-hand heatmap shows the attenuation durations measured between participants 1 and 4.", [["left-hand", "ANATOMY", 335, 344], ["participants", "SPECIES", 402, 414], ["a solid line in plots", "PROBLEM", 34, 55], ["the left-hand heatmap", "TEST", 331, 352], ["solid line", "OBSERVATION", 36, 46], ["average", "OBSERVATION_MODIFIER", 75, 82], ["attenuation", "OBSERVATION_MODIFIER", 83, 94], ["left", "ANATOMY_MODIFIER", 335, 339], ["hand", "ANATOMY", 340, 344], ["heatmap", "OBSERVATION", 345, 352], ["attenuation durations", "OBSERVATION", 363, 384]]], ["The attenuation spends around 60% of its time in the 74-76dB bin, with the rest of the time roughly evenly split between 62-64dB, 66-68dB, 70-72dB.", [["attenuation", "OBSERVATION_MODIFIER", 4, 15], ["spends", "OBSERVATION_MODIFIER", 16, 22]]], ["The weighted average attenuation is 70dB.Measurement data ::: AppendixFigs 9\u201311 plot the exposure information between each pair of handsets reported by the GAEN API for each of the three experiments.", [["attenuation", "OBSERVATION_MODIFIER", 21, 32]]], ["To assist with interpreting the plots the reports in each plot are ordered by increasing distance between the pairs of participants (see Fig 1(a)).", [["participants", "SPECIES", 119, 131]]], ["It can be seen that occasionally there is an increasing trend in attenuation, for example see Figs 9(c) and 11(c), but this is infrequent.", [["an increasing trend in attenuation", "PROBLEM", 42, 76], ["can be seen", "UNCERTAINTY", 3, 14], ["increasing", "OBSERVATION_MODIFIER", 45, 55], ["trend", "OBSERVATION_MODIFIER", 56, 61], ["attenuation", "OBSERVATION_MODIFIER", 65, 76]]], ["Occasionally there is a decreasing trend in attenuation, for example see Figs 9(e) and 11(d).", [["a decreasing trend in attenuation", "PROBLEM", 22, 55], ["decreasing", "OBSERVATION_MODIFIER", 24, 34], ["trend", "OBSERVATION_MODIFIER", 35, 40], ["attenuation", "OBSERVATION_MODIFIER", 44, 55]]], ["Overall, however no consistent trend is evident in the change in attenuation level with increasing distance.Measurement data ::: AppendixIn Fig 11 participants 1 and 3 place their handsets in their left trouser pocket rather than their hand.", [["left trouser pocket", "ANATOMY", 198, 217], ["hand", "ANATOMY", 236, 240], ["hand", "ORGANISM_SUBDIVISION", 236, 240], ["participants", "SPECIES", 147, 159], ["the change in attenuation level", "PROBLEM", 51, 82], ["increasing distance", "PROBLEM", 88, 107], ["no consistent", "UNCERTAINTY", 17, 30], ["trend", "OBSERVATION_MODIFIER", 31, 36], ["change", "OBSERVATION_MODIFIER", 55, 61], ["attenuation", "OBSERVATION_MODIFIER", 65, 76], ["increasing", "OBSERVATION_MODIFIER", 88, 98], ["distance", "OBSERVATION_MODIFIER", 99, 107], ["left", "ANATOMY_MODIFIER", 198, 202]]], ["Intuitively, one might expect this change to increase the attenuation level since the particpants body is now more likely to affect transmission and reception of radio signals.", [["body", "ANATOMY", 98, 102], ["attenuation", "OBSERVATION_MODIFIER", 58, 69], ["more likely", "UNCERTAINTY", 110, 121]]], ["However, comparing Fig 11(a) and 11(c) with Figs 9 and 10 it can be seen that this change does not cause any consistent change in the observed attenuation level.", [["Fig", "TEST", 19, 22], ["Figs", "TEST", 44, 48], ["change", "OBSERVATION_MODIFIER", 120, 126], ["attenuation", "OBSERVATION_MODIFIER", 143, 154]]], ["For example, comparing Figs 11(a) and 10(a) the attenuation level between participants 1 and 5 decreases from test 2 to test 3, while the attenuation level between participants 1 and 3 increases.", [["participants", "SPECIES", 74, 86], ["participants", "SPECIES", 164, 176], ["Figs", "TEST", 23, 27], ["test", "TEST", 120, 124], ["attenuation", "OBSERVATION_MODIFIER", 138, 149]]]], "34a46a44fe67be5155ee691d018273adc579550d": [["for STS.", [["STS", "DISEASE", 4, 7], ["STS", "CANCER", 4, 7], ["STS", "PROBLEM", 4, 7]]], ["There were no significant differences in the burnout rate between doctors and non-doctors (33\u22c53% vs 59\u22c53%, OR = 2\u22c591, p = 0\u22c513), and between frontline deployed staff and those who were not (28\u22c56% vs 52\u22c56%, OR 0\u22c536, p = 0\u22c541).", [["burnout", "DISEASE", 45, 52], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["Non-doctors were more likely to screen positive for STS than doctors (77\u22c58% vs 28\u22c56%, OR = 7\u22c50, p = 0\u22c5005).", [["STS", "DISEASE", 52, 55], ["vs", "TEST", 76, 78]]], ["Being deployed to the frontline did not affect the rate of STS.", [["STS", "DISEASE", 59, 62], ["STS", "CANCER", 59, 62]]], ["In our study, there were no differences in outcomes between staff deployed to the frontline and those who were not.", [["our study", "TEST", 3, 12], ["no", "UNCERTAINTY", 25, 27]]], ["Non-doctors were more likely to be afraid of contracting COVID-19 and spreading it to their families, and were more likely to screen positive for STS.", [["STS", "DISEASE", 146, 149], ["STS", "CANCER", 146, 149]]], ["The overall rate of burnout was 48\u22c59%.", [["burnout", "DISEASE", 20, 27]]], ["Even prior to this pandemic, high burnout rates of up to 50% have been reported among general surgeons.", [["burnout", "DISEASE", 34, 41], ["this pandemic", "PROBLEM", 14, 27], ["high burnout rates", "PROBLEM", 29, 47]]], ["2 The everburgeoning demands of clinical care, research pursuits, education commitments and administrative tasks have been typically met by Surgery providers at the expense of their psychological and physical health.", [["clinical care", "TREATMENT", 32, 45]]], ["Longer working hours are a known major risk factor for burnout.", [["burnout", "DISEASE", 55, 62], ["burnout", "PROBLEM", 55, 62]]], ["3 It is crucial to minimize risk factors for burnout.", [["burnout", "DISEASE", 45, 52], ["burnout", "PROBLEM", 45, 52]]], ["Careful workload management and staff rotation should be instituted with opportunities for periods of respite.", [["Careful workload management", "TREATMENT", 0, 27], ["staff rotation", "TREATMENT", 32, 46]]], ["Staged progression of workload with close monitoring of staff morale is important.", [["close monitoring", "TEST", 36, 52]]], ["Formal PPE training and familiarisation with pandemic protocols should be conducted to bolster staff confidence in infection control measures.", [["infection", "DISEASE", 115, 124], ["Formal PPE training", "TREATMENT", 0, 19], ["familiarisation", "TREATMENT", 24, 39], ["pandemic protocols", "TREATMENT", 45, 63], ["infection control measures", "TREATMENT", 115, 141], ["infection", "OBSERVATION", 115, 124]]], ["Access to mental health services, associated with reduced burnout rates, should be made available.", [["reduced burnout rates", "PROBLEM", 50, 71]]], ["5 In this pandemic of an unprecedented scale in recent memory, it is imperative to recognise the presence and implications of burnout.", [["burnout", "DISEASE", 126, 133], ["burnout", "PROBLEM", 126, 133]]]], "f2615e2f1b1e1de90023706bf99405151406bbd8": [["IntroductionViruses cause most respiratory tract infections, yet the specific infectious agent often remains unknown [1, 2] .", [["respiratory tract", "ANATOMY", 31, 48], ["IntroductionViruses", "DISEASE", 0, 19], ["respiratory tract infections", "DISEASE", 31, 59], ["tract", "ORGANISM_SUBDIVISION", 43, 48], ["IntroductionViruses", "TREATMENT", 0, 19], ["most respiratory tract infections", "PROBLEM", 26, 59], ["the specific infectious agent", "PROBLEM", 65, 94], ["respiratory tract", "ANATOMY", 31, 48], ["infections", "OBSERVATION", 49, 59]]], ["Comparison of the viral causes of infection provides a useful starting point for an understanding of illness following respiratory infection.", [["respiratory", "ANATOMY", 119, 130], ["infection", "DISEASE", 34, 43], ["illness", "DISEASE", 101, 108], ["respiratory infection", "DISEASE", 119, 140], ["infection", "PROBLEM", 34, 43], ["illness", "PROBLEM", 101, 108], ["respiratory infection", "PROBLEM", 119, 140], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 34, 43], ["infection", "OBSERVATION", 131, 140]]], ["It also provides data relevant to the development of prevention strategies.", [["prevention strategies", "TREATMENT", 53, 74]]], ["The following viruses (in no particular order) have been detected during acute respiratory infections (ARIs) [1, 2] : influenza virus (Flu), parainfluenza virus (PIV), adenovirus (ADV), picornavirus (PIC, including rhinovirus and enterovirus), respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and human coronavirus (HCoV).", [["respiratory", "ANATOMY", 79, 90], ["acute respiratory infections", "DISEASE", 73, 101], ["ARIs", "DISEASE", 103, 107], ["influenza virus (Flu), parainfluenza virus (PIV), adenovirus (ADV), picornavirus (PIC, including rhinovirus and enterovirus)", "DISEASE", 118, 242], ["respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and human coronavirus", "DISEASE", 244, 330], ["influenza virus", "ORGANISM", 118, 133], ["Flu", "ORGANISM", 135, 138], ["parainfluenza virus", "ORGANISM", 141, 160], ["PIV", "ORGANISM", 162, 165], ["adenovirus", "ORGANISM", 168, 178], ["ADV", "ORGANISM", 180, 183], ["rhinovirus", "ORGANISM", 215, 225], ["enterovirus", "ORGANISM", 230, 241], ["respiratory syncytial virus", "ORGANISM", 244, 271], ["RSV", "ORGANISM", 273, 276], ["human", "ORGANISM", 279, 284], ["metapneumovirus", "ORGANISM", 285, 300], ["hMPV", "ORGANISM", 302, 306], ["human coronavirus", "ORGANISM", 313, 330], ["HCoV", "CANCER", 332, 336], ["influenza virus", "SPECIES", 118, 133], ["parainfluenza virus", "SPECIES", 141, 160], ["respiratory syncytial virus", "SPECIES", 244, 271], ["RSV", "SPECIES", 273, 276], ["human", "SPECIES", 279, 284], ["metapneumovirus", "SPECIES", 285, 300], ["hMPV", "SPECIES", 302, 306], ["human", "SPECIES", 313, 318], ["coronavirus", "SPECIES", 319, 330], ["parainfluenza virus", "SPECIES", 141, 160], ["PIV", "SPECIES", 162, 165], ["adenovirus", "SPECIES", 168, 178], ["ADV", "SPECIES", 180, 183], ["respiratory syncytial virus", "SPECIES", 244, 271], ["RSV", "SPECIES", 273, 276], ["human metapneumovirus", "SPECIES", 279, 300], ["hMPV", "SPECIES", 302, 306], ["human coronavirus", "SPECIES", 313, 330], ["HCoV", "SPECIES", 332, 336], ["acute respiratory infections (ARIs)", "PROBLEM", 73, 108], ["influenza virus (Flu)", "PROBLEM", 118, 139], ["parainfluenza virus (PIV)", "PROBLEM", 141, 166], ["adenovirus", "PROBLEM", 168, 178], ["picornavirus (PIC", "TREATMENT", 186, 203], ["rhinovirus", "PROBLEM", 215, 225], ["enterovirus", "PROBLEM", 230, 241], ["respiratory syncytial virus", "PROBLEM", 244, 271], ["human metapneumovirus (hMPV)", "PROBLEM", 279, 307], ["human coronavirus (HCoV)", "TREATMENT", 313, 337], ["viruses", "OBSERVATION", 14, 21], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory", "ANATOMY", 79, 90], ["infections", "OBSERVATION", 91, 101], ["respiratory syncytial", "ANATOMY", 244, 265]]], ["Respiratory virus infections are diagnosed in four principal ways: virus culture, serology, immunofluorescence/antigen detection, and nucleic acid/PCR-based tests.", [["Respiratory virus infections", "DISEASE", 0, 28], ["nucleic acid", "CHEMICAL", 134, 146], ["Respiratory virus", "ORGANISM", 0, 17], ["Respiratory virus", "SPECIES", 0, 17], ["Respiratory virus infections", "PROBLEM", 0, 28], ["virus culture", "TEST", 67, 80], ["serology", "TEST", 82, 90], ["immunofluorescence/antigen detection", "TEST", 92, 128], ["nucleic acid/PCR", "TEST", 134, 150], ["based tests", "TEST", 151, 162], ["virus infections", "OBSERVATION", 12, 28]]], ["Nucleic acid tests are significantly more sensitive than the other methods described, which may have an impact on the viruses detected [1, 2] .", [["Nucleic acid tests", "TEST", 0, 18], ["the viruses", "PROBLEM", 114, 125], ["viruses", "OBSERVATION", 118, 125]]], ["Nucleic acid tests are now being multiplexed, allowing rapid simultaneous detection of many viruses [1, 2] .IntroductionIn China, several groups have reported the prevalence and clinical presentation of viral infections [3] [4] [5] , particularly those of HCoV infections by reverse transcriptase PCR (RT-PCR) assays performed on clinical specimens taken from adults with ARTIs from 2005 to 2009 in Beijing [5] .", [["specimens", "ANATOMY", 339, 348], ["viral infections", "DISEASE", 203, 219], ["infections", "DISEASE", 261, 271], ["ARTIs", "DISEASE", 372, 377], ["HCoV", "ORGANISM", 256, 260], ["reverse transcriptase", "PROTEIN", 275, 296], ["HCoV", "SPECIES", 256, 260], ["Nucleic acid tests", "TEST", 0, 18], ["rapid simultaneous detection", "TEST", 55, 83], ["many viruses", "PROBLEM", 87, 99], ["viral infections", "PROBLEM", 203, 219], ["HCoV infections", "PROBLEM", 256, 271], ["reverse transcriptase PCR", "TEST", 275, 300], ["RT-PCR", "TEST", 302, 308], ["assays", "TEST", 310, 316], ["clinical specimens", "TEST", 330, 348], ["viruses", "OBSERVATION", 92, 99]]], ["Moreover, to the best of our knowledge, there is no published report that describes the potential impact of viral agents on adults with ARTIs admitted to an ED in China.", [["ARTIs", "DISEASE", 136, 141], ["viral", "OBSERVATION", 108, 113]]], ["To directly address this situation, we screened for the presence of 13 respiratory virus in adults with ARTI admitted to Peking Union Medical College Hospital from May, 2010, to April, 2011, in an effort to gain a better understanding of the seasonality, epidemiology, and clinical profile of these viruses in a city with a population of more than 22 million.Ethics IssuesAll aspects of the study were performed in accordance with the national ethics regulations and approved by the Institutional Review Boards of the Centre for Disease Control and Prevention of China, as well as the Ethics Committee of Peking Union Medical College Hospital.", [["respiratory virus", "DISEASE", 71, 88], ["ARTI", "DISEASE", 104, 108], ["13 respiratory virus", "PROBLEM", 68, 88], ["these viruses", "PROBLEM", 293, 306], ["the study", "TEST", 387, 396], ["Disease Control", "TREATMENT", 529, 544], ["respiratory virus", "OBSERVATION", 71, 88], ["viruses", "OBSERVATION", 299, 306]]], ["Participants were recieved ''Written Informed Consent'' on the study's purpose and of their right to keep information confidential.", [["Participants", "SPECIES", 0, 12], ["the study's purpose", "TEST", 59, 78]]], ["Written consent was obtained from all participants or their guardians.Patients and SpecimensFrom May, 2010, to April, 2011, 416 nasal and throat swabs (NTS) were collected from patients with acute respiratory symptoms who had been admitted to the ED at Peking Union Medical College Hospital, Beijing, China.", [["nasal", "ANATOMY", 128, 133], ["throat swabs", "ANATOMY", 138, 150], ["respiratory", "ANATOMY", 197, 208], ["acute respiratory symptoms", "DISEASE", 191, 217], ["Patients", "ORGANISM", 70, 78], ["nasal", "ORGANISM_SUBDIVISION", 128, 133], ["patients", "ORGANISM", 177, 185], ["participants", "SPECIES", 38, 50], ["Patients", "SPECIES", 70, 78], ["patients", "SPECIES", 177, 185], ["Specimens", "TEST", 83, 92], ["nasal and throat swabs", "TEST", 128, 150], ["acute respiratory symptoms", "PROBLEM", 191, 217], ["nasal", "ANATOMY", 128, 133], ["throat", "ANATOMY", 138, 144], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["respiratory", "ANATOMY", 197, 208]]], ["Patients were provided written informed consent before specimen collection and testing.", [["specimen", "ANATOMY", 55, 63], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["specimen collection", "TEST", 55, 74], ["testing", "TEST", 79, 86]]], ["Patients over 14 years of age were selected according to a set of criteria that included respiratory symptoms, a body temperature above 37.5uC, and a normal or low leukocyte count, but not pulmonary abnormalities on radiography [4] .", [["respiratory", "ANATOMY", 89, 100], ["body", "ANATOMY", 113, 117], ["leukocyte", "ANATOMY", 164, 173], ["pulmonary", "ANATOMY", 189, 198], ["respiratory symptoms", "DISEASE", 89, 109], ["pulmonary abnormalities", "DISEASE", 189, 212], ["Patients", "ORGANISM", 0, 8], ["body", "ORGANISM_SUBDIVISION", 113, 117], ["leukocyte", "CELL", 164, 173], ["pulmonary", "ORGAN", 189, 198], ["Patients", "SPECIES", 0, 8], ["respiratory symptoms", "PROBLEM", 89, 109], ["a body temperature", "TEST", 111, 129], ["low leukocyte count", "PROBLEM", 160, 179], ["pulmonary abnormalities", "PROBLEM", 189, 212], ["radiography", "TEST", 216, 227], ["normal", "OBSERVATION", 150, 156], ["low leukocyte count", "OBSERVATION_MODIFIER", 160, 179], ["not", "UNCERTAINTY", 185, 188], ["pulmonary", "ANATOMY", 189, 198], ["abnormalities", "OBSERVATION", 199, 212]]], ["Symptoms, history of illness, results of a clinical examination and laboratory investigations, and demographic data were recorded for each patient, using a standardized form.", [["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["Symptoms", "PROBLEM", 0, 8], ["illness", "PROBLEM", 21, 28], ["a clinical examination", "TEST", 41, 63], ["laboratory investigations", "TEST", 68, 93], ["demographic data", "TEST", 99, 115]]], ["Clinical information of patients with virus infection was reviewed retrospectively from the records.", [["infection", "DISEASE", 44, 53], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["virus infection", "PROBLEM", 38, 53]]], ["Swabs were kept in viral transport medium and stored at 270uC prior to analysis.Nucleic Acid Extraction and cDNA SynthesisNucleic acid was extracted using QIAamp MiniElute Virus Spin kits (Qiagen, Mississauga, Ontario, Canada) according to the manufacturer's instructions. cDNA was synthesized from 10 mL RNA eluate using random hexamer primers and AMV Reverse Transcriptase (Promega, Madison, WI), as described previously [6] [7] [8] .Detection of Common Respiratory Viruses by RT-PCRAll samples were tested by multiple nested RT-PCR screening for common respiratory viruses infections (Table 1) , including influenza virus types A, B, adenovirus (group 1), PIC (enterovirus, rhinovirus), respiratory syncytial virus (group 2), and parainfluenza virus types 1-3 (group 3), as described previously [6] .", [["Swabs", "ANATOMY", 0, 5], ["SynthesisNucleic acid", "CHEMICAL", 113, 134], ["respiratory viruses infections", "DISEASE", 556, 586], ["influenza virus", "DISEASE", 609, 624], ["enterovirus, rhinovirus)", "DISEASE", 664, 688], ["respiratory syncytial virus", "DISEASE", 690, 717], ["parainfluenza virus", "DISEASE", 733, 752], ["SynthesisNucleic acid", "CHEMICAL", 113, 134], ["Nucleic Acid", "SIMPLE_CHEMICAL", 80, 92], ["influenza virus", "ORGANISM", 609, 624], ["B", "GENE_OR_GENE_PRODUCT", 634, 635], ["adenovirus", "ORGANISM", 637, 647], ["rhinovirus", "ORGANISM", 677, 687], ["respiratory syncytial virus", "ORGANISM", 690, 717], ["parainfluenza virus", "ORGANISM", 733, 752], ["cDNA", "DNA", 273, 277], ["influenza virus", "SPECIES", 609, 624], ["respiratory syncytial virus", "SPECIES", 690, 717], ["parainfluenza virus", "SPECIES", 733, 752], ["respiratory syncytial virus", "SPECIES", 690, 717], ["Swabs", "TEST", 0, 5], ["viral transport medium", "TREATMENT", 19, 41], ["analysis", "TEST", 71, 79], ["Nucleic Acid Extraction", "TREATMENT", 80, 103], ["cDNA SynthesisNucleic acid", "TREATMENT", 108, 134], ["QIAamp MiniElute Virus Spin kits", "TREATMENT", 155, 187], ["cDNA", "TEST", 273, 277], ["random hexamer primers", "TREATMENT", 322, 344], ["AMV Reverse Transcriptase (Promega, Madison, WI)", "TREATMENT", 349, 397], ["Common Respiratory Viruses", "PROBLEM", 449, 475], ["PCRAll samples", "TEST", 482, 496], ["multiple nested RT", "TEST", 512, 530], ["PCR screening", "TEST", 531, 544], ["common respiratory viruses infections", "PROBLEM", 549, 586], ["influenza virus types", "PROBLEM", 609, 630], ["A, B, adenovirus (group 1)", "TEST", 631, 657], ["PIC (enterovirus", "PROBLEM", 659, 675], ["rhinovirus", "PROBLEM", 677, 687], ["respiratory syncytial virus", "PROBLEM", 690, 717], ["parainfluenza virus types", "PROBLEM", 733, 758], ["Common", "ANATOMY", 449, 455], ["Respiratory Viruses", "OBSERVATION", 456, 475], ["respiratory viruses", "ANATOMY", 556, 575], ["respiratory syncytial", "ANATOMY", 690, 711], ["parainfluenza virus", "OBSERVATION", 733, 752]]], ["The analytic sensitivity of PCR or RT-PCR for detection of single virus is 10-100 molecules.", [["The analytic sensitivity", "TEST", 0, 24], ["PCR", "TEST", 28, 31], ["RT-PCR", "TEST", 35, 41], ["single virus", "PROBLEM", 59, 71]]], ["All PCR products were confirmed by sequencing.Detection of HMPV and HCoV by Real-Time RT-PCRSpecimens were tested for human metapneumovirus (HMPV) and non-SARS HCoVs (including OC43, 229E, NL63, and HKU1) by real-time RT-PCR (Table 1 ) using a TaqMan RNA-to-CT 1-Step kit (Applied Biosystems, USA) and an ABI Prism 7000 TaqMan machine (Applied Biosystems, USA), as described previously [7, 8] .", [["HMPV", "ORGANISM", 59, 63], ["HCoV", "GENE_OR_GENE_PRODUCT", 68, 72], ["human", "ORGANISM", 118, 123], ["metapneumovirus", "ORGANISM", 124, 139], ["HMPV", "ORGANISM", 141, 145], ["HCoVs", "GENE_OR_GENE_PRODUCT", 160, 165], ["OC43", "GENE_OR_GENE_PRODUCT", 177, 181], ["229E", "GENE_OR_GENE_PRODUCT", 183, 187], ["NL63", "GENE_OR_GENE_PRODUCT", 189, 193], ["HKU1", "GENE_OR_GENE_PRODUCT", 199, 203], ["PCR products", "DNA", 4, 16], ["non-SARS HCoVs", "DNA", 151, 165], ["OC43", "PROTEIN", 177, 181], ["229E", "PROTEIN", 183, 187], ["NL63", "PROTEIN", 189, 193], ["HKU1", "PROTEIN", 199, 203], ["human", "SPECIES", 118, 123], ["HMPV", "SPECIES", 59, 63], ["HCoV", "SPECIES", 68, 72], ["human metapneumovirus", "SPECIES", 118, 139], ["HMPV", "SPECIES", 141, 145], ["All PCR products", "TREATMENT", 0, 16], ["HMPV", "PROBLEM", 59, 63], ["HCoV", "TEST", 68, 72], ["human metapneumovirus", "PROBLEM", 118, 139], ["HMPV", "TEST", 141, 145], ["OC43", "TEST", 177, 181], ["NL63", "TEST", 189, 193], ["a TaqMan RNA", "TEST", 242, 254], ["CT", "TEST", 258, 260], ["an ABI Prism", "TEST", 302, 314], ["HMPV", "OBSERVATION", 59, 63]]], ["The lower limit of detection of each real-time RT PCR assay was 100 copies/20 mL, with intra-assay coefficients of variability (CVs) between 0.45% and 1.02% (n = 3), and interassay CVs of 0.68-2.24%.Statistical AnalysisAge, maximum body temperature, laboratory parameters, clinical features, and annual incidence of each virus were compared using the x 2 -test or Fisher's exact test for categorical variables, and the data sets were compared between groups using a two-tailed paired Student's ttest to obtain P values.", [["body", "ANATOMY", 232, 236], ["body", "ORGANISM_SUBDIVISION", 232, 236], ["RT PCR assay", "TEST", 47, 59], ["intra-assay coefficients", "TEST", 87, 111], ["CVs", "TEST", 128, 131], ["interassay CVs", "TEST", 170, 184], ["maximum body temperature", "TEST", 224, 248], ["laboratory parameters", "TEST", 250, 271], ["each virus", "PROBLEM", 316, 326], ["Fisher's exact test", "TEST", 364, 383], ["categorical variables", "TEST", 388, 409], ["the data sets", "TEST", 415, 428], ["P values", "TEST", 510, 518], ["lower limit", "OBSERVATION_MODIFIER", 4, 15]]], ["P,0.05 was considered significant.Viral PrevalenceOf 416 nasopharyngeal samples analysed by both multiple nested RT-PCR and real-time RT-PCR (Table 1) , 220 (52.88%) were positive for one or more agents, comprising 47.51% (86/181) males and 57.02% (134/235) females, (x 2 = 3.709; P.0.05).", [["nasopharyngeal samples", "ANATOMY", 57, 79], ["nasopharyngeal samples", "CANCER", 57, 79], ["Viral PrevalenceOf", "TEST", 34, 52], ["nasopharyngeal samples", "TEST", 57, 79], ["multiple nested RT-PCR", "TEST", 97, 119]]], ["Detection of any viral agent was significantly more common during the summer (July and August, 2010) and winter (December 2010 and January 2011) in patients aged 20-50 years old.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["any viral agent", "PROBLEM", 13, 28]]], ["As shown in Table 2Seasonal distributionTheCo-infection of respiratory virusesOf the 416 patients, 30 were co-infected with at least two respiratory viruses, with detection rates of 7.21% (30/416) of total samples and 14.63% (30/220) of positive samples.", [["samples", "ANATOMY", 206, 213], ["samples", "ANATOMY", 246, 253], ["infection", "DISEASE", 46, 55], ["respiratory virusesOf", "DISEASE", 59, 80], ["respiratory viruses", "DISEASE", 137, 156], ["patients", "ORGANISM", 89, 97], ["samples", "CANCER", 206, 213], ["patients", "SPECIES", 89, 97], ["two respiratory viruses", "PROBLEM", 133, 156], ["detection rates", "TEST", 163, 178], ["total samples", "TEST", 200, 213], ["positive samples", "PROBLEM", 237, 253], ["infection", "OBSERVATION", 46, 55], ["respiratory virusesOf", "OBSERVATION", 59, 80], ["respiratory viruses", "OBSERVATION", 137, 156]]], ["Most co-infected patients were 20-39 years of age (66.67%, 20/30), and PIC was frequently detected co-infecting virus (29.73%, 22/74) (Clinical profiles associated with FluA, ADV, PIC, and HCoV infectionThe clinical characteristics of patients with FluA, ADV, PIC, and HCoV infection are summarized in Table 3 .", [["HCoV infection", "DISEASE", 189, 203], ["HCoV infection", "DISEASE", 269, 283], ["patients", "ORGANISM", 17, 25], ["FluA", "GENE_OR_GENE_PRODUCT", 169, 173], ["patients", "ORGANISM", 235, 243], ["FluA", "GENE_OR_GENE_PRODUCT", 249, 253], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 235, 243], ["ADV", "SPECIES", 175, 178], ["HCoV", "SPECIES", 189, 193], ["ADV", "SPECIES", 255, 258], ["HCoV", "SPECIES", 269, 273], ["PIC", "PROBLEM", 71, 74], ["FluA", "PROBLEM", 169, 173], ["ADV", "PROBLEM", 175, 178], ["PIC", "PROBLEM", 180, 183], ["HCoV infection", "PROBLEM", 189, 203], ["FluA", "PROBLEM", 249, 253], ["ADV", "PROBLEM", 255, 258], ["PIC", "PROBLEM", 260, 263], ["HCoV infection", "PROBLEM", 269, 283], ["infection", "OBSERVATION", 194, 203], ["infection", "OBSERVATION", 274, 283]]], ["All patients infected with these viruses presented with respiratory infection symptoms including fever, cough, headache, sore throat, runny nose, and so on; a few also presented with diarrhoea.", [["respiratory", "ANATOMY", 56, 67], ["respiratory infection", "DISEASE", 56, 77], ["fever", "DISEASE", 97, 102], ["cough", "DISEASE", 104, 109], ["headache", "DISEASE", 111, 119], ["sore throat", "DISEASE", 121, 132], ["runny nose", "DISEASE", 134, 144], ["diarrhoea", "DISEASE", 183, 192], ["patients", "ORGANISM", 4, 12], ["throat", "ORGANISM_SUBDIVISION", 126, 132], ["patients", "SPECIES", 4, 12], ["these viruses", "PROBLEM", 27, 40], ["respiratory infection symptoms", "PROBLEM", 56, 86], ["fever", "PROBLEM", 97, 102], ["cough", "PROBLEM", 104, 109], ["headache", "PROBLEM", 111, 119], ["sore throat", "PROBLEM", 121, 132], ["runny nose", "PROBLEM", 134, 144], ["diarrhoea", "PROBLEM", 183, 192], ["infected", "OBSERVATION", 13, 21], ["respiratory", "ANATOMY", 56, 67], ["infection", "OBSERVATION", 68, 77], ["sore throat", "ANATOMY", 121, 132], ["runny nose", "ANATOMY", 134, 144], ["diarrhoea", "OBSERVATION", 183, 192]]], ["The three most common symptoms of infection with FluA were cough (82.09%), sore throat (79.10%), and headache (65.67%).", [["infection", "DISEASE", 34, 43], ["FluA", "CHEMICAL", 49, 53], ["cough", "DISEASE", 59, 64], ["sore throat", "DISEASE", 75, 86], ["headache", "DISEASE", 101, 109], ["infection", "PROBLEM", 34, 43], ["FluA", "PROBLEM", 49, 53], ["cough", "PROBLEM", 59, 64], ["sore throat", "PROBLEM", 75, 86], ["headache", "PROBLEM", 101, 109], ["three", "OBSERVATION_MODIFIER", 4, 9], ["most common", "OBSERVATION_MODIFIER", 10, 21], ["infection", "OBSERVATION", 34, 43]]], ["The most common symptoms of infection with ADV, PIC, and HCoV were headache, sore throat, and cough, respectively.", [["infection", "DISEASE", 28, 37], ["ADV", "CHEMICAL", 43, 46], ["headache", "DISEASE", 67, 75], ["sore throat", "DISEASE", 77, 88], ["cough", "DISEASE", 94, 99], ["ADV", "SPECIES", 43, 46], ["HCoV", "SPECIES", 57, 61], ["infection", "PROBLEM", 28, 37], ["ADV", "PROBLEM", 43, 46], ["PIC", "PROBLEM", 48, 51], ["HCoV", "PROBLEM", 57, 61], ["headache", "PROBLEM", 67, 75], ["sore throat", "PROBLEM", 77, 88], ["cough", "PROBLEM", 94, 99], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 28, 37], ["sore throat", "ANATOMY", 77, 88], ["cough", "OBSERVATION", 94, 99]]], ["Most infected patients were aged 20-49 years old, and slightly more were female.DiscussionRVs, a major cause of ARTIs [1] [2] [3] [4] [5] [6] [7] [8] [9] , which cause significant global human morbidity and mortality, especially in infants, are a serious health and economic burden and have become a national .", [["ARTIs [1] [2] [3] [4] [5] [6] [7] [8] [9", "CHEMICAL", 112, 152], ["ARTIs [1] [2] [3] [4] [5] [6] [7]", "CHEMICAL", 112, 145], ["patients", "ORGANISM", 14, 22], ["ARTIs [1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 112, 153], ["human", "ORGANISM", 187, 192], ["infants", "ORGANISM", 232, 239], ["patients", "SPECIES", 14, 22], ["human", "SPECIES", 187, 192], ["infants", "SPECIES", 232, 239], ["human", "SPECIES", 187, 192], ["significant global human morbidity", "PROBLEM", 168, 202], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["global", "OBSERVATION_MODIFIER", 180, 186], ["human morbidity", "OBSERVATION", 187, 202]]], ["This study provides useful information on the prevalence, clinical profiles, and epidemiology of specific viral aetiology in adults with ARTI attending an ED in China, and will contribute to the diagnosis, treatment, and prevention of ARTI in adults.", [["ARTI", "DISEASE", 137, 141], ["ARTI", "DISEASE", 235, 239], ["ARTI", "CANCER", 235, 239], ["This study", "TEST", 0, 10], ["treatment", "TREATMENT", 206, 215], ["ARTI in adults", "PROBLEM", 235, 249]]], ["We collected nasal and throat swab samples from adult patients attending an ED in Beijing, and analysed them using both multiple nested RT-PCR and real-time RT-PCR methods to detect 13 human RVs: FluA, B, RSV, PIVs 1-3, PIC, ADV, HCoVs (-229E, -OC43, -NL63, -HKU1), and hMPV.", [["nasal", "ANATOMY", 13, 18], ["throat swab samples", "ANATOMY", 23, 42], ["nasal", "ORGANISM_SUBDIVISION", 13, 18], ["throat swab samples", "ORGANISM_SUBSTANCE", 23, 42], ["patients", "ORGANISM", 54, 62], ["human", "ORGANISM", 185, 190], ["FluA", "GENE_OR_GENE_PRODUCT", 196, 200], ["B", "GENE_OR_GENE_PRODUCT", 202, 203], ["RSV", "ORGANISM", 205, 208], ["PIVs 1-3", "GENE_OR_GENE_PRODUCT", 210, 218], ["PIC", "GENE_OR_GENE_PRODUCT", 220, 223], ["ADV", "ORGANISM", 225, 228], ["HCoVs", "GENE_OR_GENE_PRODUCT", 230, 235], ["HKU1", "GENE_OR_GENE_PRODUCT", 259, 263], ["hMPV", "ORGANISM", 270, 274], ["PIC", "DNA", 220, 223], ["HCoVs", "DNA", 230, 235], ["OC43", "DNA", 245, 249], ["NL63", "DNA", 252, 256], ["HKU1", "DNA", 259, 263], ["patients", "SPECIES", 54, 62], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["RSV", "SPECIES", 205, 208], ["ADV", "SPECIES", 225, 228], ["hMPV", "SPECIES", 270, 274], ["both multiple nested RT-PCR", "TREATMENT", 115, 142], ["PCR methods", "TEST", 160, 171], ["FluA", "TEST", 196, 200], ["RSV", "TEST", 205, 208], ["PIVs", "TEST", 210, 214], ["PIC", "TEST", 220, 223], ["HCoVs", "TEST", 230, 235], ["OC43", "TEST", 245, 249], ["hMPV", "PROBLEM", 270, 274], ["nasal", "ANATOMY", 13, 18], ["throat", "ANATOMY", 23, 29], ["RSV", "ANATOMY", 205, 208], ["ADV", "ANATOMY", 225, 228], ["hMPV", "OBSERVATION", 270, 274]]], ["Of the 416 samples, 220 (52.88%) contained at least one virus, which is consistent with other studies performed worldwide (34.6-62.6%) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , but a little higher than a previous report from Beijing [4] .", [["samples", "ANATOMY", 11, 18], ["samples", "CANCER", 11, 18], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 135, 195], ["one virus", "PROBLEM", 52, 61], ["other studies", "TEST", 88, 101], ["virus", "OBSERVATION", 56, 61], ["consistent with", "UNCERTAINTY", 72, 87]]], ["This may be due to differences in detection methods, population, and/or the time the study was performed.", [["detection methods", "TEST", 34, 51], ["the study", "TEST", 81, 90], ["may be due to", "UNCERTAINTY", 5, 18]]], ["This also reminds us that in the year after influenza pandemics, the frequency distribution of these 13 respiratory viruses in adult patients in the Beijing area may increase, pending further studies.", [["influenza pandemics", "DISEASE", 44, 63], ["respiratory viruses", "DISEASE", 104, 123], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["influenza pandemics", "PROBLEM", 44, 63], ["these 13 respiratory viruses", "PROBLEM", 95, 123], ["further studies", "TEST", 184, 199], ["respiratory viruses", "OBSERVATION", 104, 123], ["increase", "OBSERVATION_MODIFIER", 166, 174]]], ["In addition, of the 416 samples, no viruses were detected in 196 (47.11%).", [["samples", "ANATOMY", 24, 31], ["viruses", "PROBLEM", 36, 43]]], ["This suggests the existence of other pathogens, such as human parvovirus [15] and human polyomavirus [16, 17] , or unknown others.", [["human", "ORGANISM", 56, 61], ["parvovirus [15]", "ORGANISM", 62, 77], ["human", "ORGANISM", 82, 87], ["polyomavirus", "ORGANISM", 88, 100], ["human", "SPECIES", 56, 61], ["parvovirus", "SPECIES", 62, 72], ["human", "SPECIES", 82, 87], ["human parvovirus", "SPECIES", 56, 72], ["human polyomavirus", "SPECIES", 82, 100], ["other pathogens", "PROBLEM", 31, 46], ["human parvovirus", "PROBLEM", 56, 72], ["human polyomavirus", "PROBLEM", 82, 100], ["pathogens", "OBSERVATION", 37, 46]]], ["Thus, further optimization of specimen collection (location, period) and detection methods may improve the detection rate.DiscussionBy comparing the patterns of detection of the four most frequently detected viruses (PIC, FluA, ADV, HCoVs), gender, and age group, we found similar detection rates in males and females, and those aged 20-49 had highest prevalence (70%), which is consistent with trends of RV infection reported previously [1] [2] [3] [4] [5] [6] [7] [8] [9] .", [["specimen", "ANATOMY", 30, 38], ["RV infection", "DISEASE", 405, 417], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 438, 473], ["ADV", "SPECIES", 228, 231], ["specimen collection", "TEST", 30, 49], ["detection methods", "TEST", 73, 90], ["the detection rate", "TEST", 103, 121], ["PIC", "TREATMENT", 217, 220], ["FluA", "TEST", 222, 226], ["RV infection", "PROBLEM", 405, 417], ["viruses", "OBSERVATION", 208, 215], ["consistent with", "UNCERTAINTY", 379, 394], ["RV", "ANATOMY", 405, 407], ["infection", "OBSERVATION", 408, 417]]], ["PICs, including rhinovirus and enterovirus, are frequently detected in patients with upper respiratory tract infections [18, 19] .", [["upper respiratory tract", "ANATOMY", 85, 108], ["rhinovirus and enterovirus", "DISEASE", 16, 42], ["respiratory tract infections", "DISEASE", 91, 119], ["rhinovirus", "ORGANISM", 16, 26], ["enterovirus", "ORGANISM", 31, 42], ["patients", "ORGANISM", 71, 79], ["upper respiratory", "ORGANISM_SUBDIVISION", 85, 102], ["tract", "ORGANISM_SUBDIVISION", 103, 108], ["patients", "SPECIES", 71, 79], ["PICs", "PROBLEM", 0, 4], ["rhinovirus", "PROBLEM", 16, 26], ["enterovirus", "PROBLEM", 31, 42], ["upper respiratory tract infections", "PROBLEM", 85, 119], ["rhinovirus", "OBSERVATION", 16, 26], ["enterovirus", "OBSERVATION", 31, 42], ["upper", "ANATOMY_MODIFIER", 85, 90], ["respiratory tract", "ANATOMY", 91, 108]]], ["A previous study showed that 50% of common cold infections are caused by rhinovirus [18] .", [["infections", "DISEASE", 48, 58], ["rhinovirus", "ORGANISM", 73, 83], ["A previous study", "TEST", 0, 16], ["common cold infections", "PROBLEM", 36, 58], ["rhinovirus", "PROBLEM", 73, 83], ["infections", "OBSERVATION", 48, 58], ["rhinovirus", "OBSERVATION", 73, 83]]], ["PIC had the highest detection rate (17.79%, 74/416), and covered all age groups.", [["PIC", "TREATMENT", 0, 3], ["highest", "OBSERVATION_MODIFIER", 12, 19]]], ["This PIC detection rate is higher than that reported elsewhere [4] , likely due to the fact that the previous study focused only on rhinovirus and enterovirus, neglecting the other PICs that may cause respiratory infection.", [["respiratory", "ANATOMY", 201, 212], ["enterovirus", "DISEASE", 147, 158], ["respiratory infection", "DISEASE", 201, 222], ["rhinovirus", "ORGANISM", 132, 142], ["enterovirus", "ORGANISM", 147, 158], ["This PIC detection rate", "TEST", 0, 23], ["the previous study", "TEST", 97, 115], ["rhinovirus", "PROBLEM", 132, 142], ["enterovirus", "PROBLEM", 147, 158], ["the other PICs", "TREATMENT", 171, 185], ["respiratory infection", "PROBLEM", 201, 222], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["may cause", "UNCERTAINTY", 191, 200], ["respiratory", "ANATOMY", 201, 212], ["infection", "OBSERVATION", 213, 222]]], ["In addition, different sample collection periods and detection methods may have contributed to the discrepancies in detection rates [10] .DiscussionThe detection rate of FluA, the most common respiratory virus, was 16.11% with significant seasonality.", [["FluA", "GENE_OR_GENE_PRODUCT", 170, 174], ["FluA", "PROTEIN", 170, 174], ["different sample collection periods", "PROBLEM", 13, 48], ["detection methods", "TEST", 53, 70], ["the discrepancies in detection rates", "PROBLEM", 95, 131], ["the most common respiratory virus", "PROBLEM", 176, 209], ["significant", "OBSERVATION_MODIFIER", 227, 238], ["seasonality", "OBSERVATION", 239, 250]]], ["Peaks appeared in winter, and no FluA was detected in June, 2010, and April, 2011.", [["FluA", "GENE_OR_GENE_PRODUCT", 33, 37], ["FluA", "PROTEIN", 33, 37], ["FluA", "PROBLEM", 33, 37], ["no", "UNCERTAINTY", 30, 32]]], ["Because this study was conducted at the end of the H1N1 pandemic, many people had recently been vaccinated and so possessed high levels of circulating antibody, likely causing a decline in infection rate.", [["infection", "DISEASE", 189, 198], ["people", "ORGANISM", 71, 77], ["circulating antibody", "PROTEIN", 139, 159], ["people", "SPECIES", 71, 77], ["this study", "TEST", 8, 18], ["high levels of circulating antibody", "PROBLEM", 124, 159], ["a decline in infection rate", "PROBLEM", 176, 203], ["circulating antibody", "OBSERVATION", 139, 159], ["likely causing", "UNCERTAINTY", 161, 175], ["decline", "OBSERVATION_MODIFIER", 178, 185], ["infection", "OBSERVATION", 189, 198]]], ["Other reports have indicated that FluA infection is interfered with by rhinovirus infection [19, 20] , which may also have decreased the detection rate.", [["FluA", "CHEMICAL", 34, 38], ["infection", "DISEASE", 39, 48], ["rhinovirus infection", "DISEASE", 71, 91], ["FluA", "GENE_OR_GENE_PRODUCT", 34, 38], ["rhinovirus", "ORGANISM", 71, 81], ["FluA infection", "PROBLEM", 34, 48], ["rhinovirus infection", "PROBLEM", 71, 91], ["infection", "OBSERVATION", 39, 48], ["decreased", "OBSERVATION_MODIFIER", 123, 132]]], ["Typing and identification of seasonal influenza virus and H1N1 influenza virus warrant further research.DiscussionEpidemiological studies have shown that more than 15% of common colds in adults are caused by human coronavirus (HCoV) [18] , with HCoV-229E and -OC43 being the most common [18] .", [["influenza virus", "DISEASE", 38, 53], ["influenza virus", "DISEASE", 63, 78], ["colds", "DISEASE", 178, 183], ["seasonal influenza virus", "ORGANISM", 29, 53], ["H1N1 influenza virus", "ORGANISM", 58, 78], ["human coronavirus", "ORGANISM", 208, 225], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 245, 254], ["seasonal influenza virus", "SPECIES", 29, 53], ["H1N1 influenza virus", "SPECIES", 58, 78], ["human", "SPECIES", 208, 213], ["coronavirus", "SPECIES", 214, 225], ["seasonal influenza virus", "SPECIES", 29, 53], ["H1N1 influenza virus", "SPECIES", 58, 78], ["human coronavirus", "SPECIES", 208, 225], ["HCoV", "SPECIES", 227, 231], ["Typing", "TEST", 0, 6], ["seasonal influenza virus", "PROBLEM", 29, 53], ["H1N1 influenza virus", "PROBLEM", 58, 78], ["Epidemiological studies", "TEST", 114, 137], ["common colds in adults", "PROBLEM", 171, 193], ["HCoV", "TEST", 245, 249], ["OC43", "PROBLEM", 260, 264], ["seasonal influenza virus", "OBSERVATION", 29, 53]]], ["The detection rate was 11.78% in this study, significantly higher than in previous reports [5] .", [["The detection rate", "TEST", 0, 18], ["this study", "TEST", 33, 43], ["higher", "OBSERVATION_MODIFIER", 59, 65]]], ["All four non-SARS HCoVs (-OC43, -229E, -NL63, and -HKU1) were detected, the highest being HCoV-229E (9.38%), which differs from the data of Ren and coworkers [5] .", [["HCoVs", "GENE_OR_GENE_PRODUCT", 18, 23], ["HKU1", "GENE_OR_GENE_PRODUCT", 51, 55], ["HKU1", "DNA", 51, 55], ["HCoV-229E", "SPECIES", 90, 99], ["All four non-SARS HCoVs", "TEST", 0, 23], ["OC43", "TEST", 26, 30], ["NL63", "TEST", 40, 44], ["HCoV", "TEST", 90, 94]]], ["This was likely due to different detection methods or the peak in HCoV-OC43 infection every 2-3 years [21] .", [["infection", "DISEASE", 76, 85], ["HCoV-OC43", "CELL", 66, 75], ["HCoV-OC43", "SPECIES", 66, 75], ["different detection methods", "PROBLEM", 23, 50], ["the peak in HCoV", "PROBLEM", 54, 70], ["OC43 infection", "PROBLEM", 71, 85], ["likely due to", "UNCERTAINTY", 9, 22], ["peak", "OBSERVATION_MODIFIER", 58, 62], ["OC43 infection", "OBSERVATION", 71, 85]]], ["The two HCoVs identified most recently, HCoV-NL63 and HCoV-HKU1 [22, 23] , had low detection rates (,1%), similar to HCoV-OC43, but markedly lower than that of HCoV-229E.DiscussionADV, an important pathogen in infants, was also detected frequently (11.3%) in this study.", [["HCoV-229E", "CHEMICAL", 160, 169], ["DiscussionADV", "CHEMICAL", 170, 183], ["HCoVs", "GENE_OR_GENE_PRODUCT", 8, 13], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 40, 49], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 54, 63], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 117, 126], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 160, 169], ["infants", "ORGANISM", 210, 217], ["HCoVs", "PROTEIN", 8, 13], ["HCoV", "PROTEIN", 40, 44], ["HCoV", "DNA", 54, 58], ["infants", "SPECIES", 210, 217], ["HCoV-229E", "SPECIES", 160, 169], ["The two HCoVs", "TEST", 0, 13], ["HCoV", "TEST", 40, 44], ["HCoV", "TEST", 54, 58], ["HKU1", "TEST", 59, 63], ["low detection rates", "PROBLEM", 79, 98], ["HCoV", "TEST", 117, 121], ["OC43", "PROBLEM", 122, 126], ["HCoV", "TEST", 160, 164], ["this study", "TEST", 259, 269], ["OC43", "OBSERVATION", 122, 126], ["markedly", "OBSERVATION_MODIFIER", 132, 140], ["lower", "OBSERVATION_MODIFIER", 141, 146]]], ["HMPV, which usually infects children [24, 25] , was detected in 2.16% of adult patients in this study.", [["HMPV", "ORGANISM", 0, 4], ["children", "ORGANISM", 28, 36], ["patients", "ORGANISM", 79, 87], ["children", "SPECIES", 28, 36], ["patients", "SPECIES", 79, 87], ["HMPV", "SPECIES", 0, 4], ["HMPV", "PROBLEM", 0, 4], ["this study", "TEST", 91, 101]]], ["The etiological significance of HMPV infection in adult ARTI patients requires further study.", [["HMPV infection", "DISEASE", 32, 46], ["ARTI", "DISEASE", 56, 60], ["HMPV", "ORGANISM", 32, 36], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["HMPV", "SPECIES", 32, 36], ["HMPV infection", "PROBLEM", 32, 46], ["further study", "TEST", 79, 92], ["HMPV", "OBSERVATION_MODIFIER", 32, 36], ["infection", "OBSERVATION", 37, 46]]], ["PIVs were detected only infrequently (0.96%), markedly lower than in previous reports [4] .", [["PIVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PIVs", "TREATMENT", 0, 4], ["markedly", "OBSERVATION_MODIFIER", 46, 54], ["lower", "OBSERVATION_MODIFIER", 55, 60]]], ["Several factors may account for this disparity: we detected mainly PIV1-3, but PIV4 was in reality the most common virus; or the PIV-4 infection rate increased in recent outbreaks of ARTIs [26] .", [["infection", "DISEASE", 135, 144], ["ARTIs", "DISEASE", 183, 188], ["PIV1-3", "GENE_OR_GENE_PRODUCT", 67, 73], ["PIV4", "GENE_OR_GENE_PRODUCT", 79, 83], ["PIV-4", "ORGANISM", 129, 134], ["PIV4", "TREATMENT", 79, 83], ["the most common virus", "PROBLEM", 99, 120], ["the PIV", "TREATMENT", 125, 132], ["4 infection rate", "PROBLEM", 133, 149], ["may account for", "UNCERTAINTY", 16, 31]]], ["In addition, PIV causes mainly LRTIs, but samples in this study were mainly collected from patients with URTIs.", [["samples", "ANATOMY", 42, 49], ["LRTIs", "DISEASE", 31, 36], ["URTIs", "DISEASE", 105, 110], ["LRTIs", "PATHOLOGICAL_FORMATION", 31, 36], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["PIV", "TREATMENT", 13, 16], ["mainly LRTIs", "PROBLEM", 24, 36], ["this study", "TEST", 53, 63], ["URTIs", "PROBLEM", 105, 110], ["PIV", "OBSERVATION", 13, 16], ["mainly", "OBSERVATION_MODIFIER", 24, 30], ["LRTIs", "OBSERVATION", 31, 36]]], ["RSV, another important viral agent in infants and young children, was not detected in this study.DiscussionOf the 220 positive patients with RV infection, 30 were infected with more than one viral agent, 27 of which represented coinfections and 3 of which were triple-infections.", [["RSV", "DISEASE", 0, 3], ["RV infection", "DISEASE", 141, 153], ["coinfections", "DISEASE", 228, 240], ["infections", "DISEASE", 268, 278], ["RSV", "ORGANISM", 0, 3], ["infants", "ORGANISM", 38, 45], ["children", "ORGANISM", 56, 64], ["patients", "ORGANISM", 127, 135], ["infants", "SPECIES", 38, 45], ["children", "SPECIES", 56, 64], ["patients", "SPECIES", 127, 135], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["this study", "TEST", 86, 96], ["RV infection", "PROBLEM", 141, 153], ["coinfections", "PROBLEM", 228, 240], ["triple-infections", "PROBLEM", 261, 278], ["viral agent", "OBSERVATION", 23, 34], ["RV", "ANATOMY", 141, 143], ["infection", "OBSERVATION", 144, 153], ["coinfections", "OBSERVATION", 228, 240], ["infections", "OBSERVATION", 268, 278]]], ["Twenty-two PICpositive patients were co-infected with FluA, ADV, 229E, PIV, HKU1, or FluB.", [["patients", "ORGANISM", 23, 31], ["FluA", "GENE_OR_GENE_PRODUCT", 54, 58], ["229E", "GENE_OR_GENE_PRODUCT", 65, 69], ["PIV", "GENE_OR_GENE_PRODUCT", 71, 74], ["HKU1", "GENE_OR_GENE_PRODUCT", 76, 80], ["FluB", "GENE_OR_GENE_PRODUCT", 85, 89], ["FluA", "PROTEIN", 54, 58], ["HKU1", "PROTEIN", 76, 80], ["FluB", "PROTEIN", 85, 89], ["patients", "SPECIES", 23, 31], ["ADV", "SPECIES", 60, 63], ["FluA", "TREATMENT", 54, 58], ["PIV", "TREATMENT", 71, 74], ["HKU1", "PROBLEM", 76, 80], ["FluB", "PROBLEM", 85, 89], ["co-infected", "OBSERVATION", 37, 48]]], ["Rhinovirus is a major etiological agent of URTIs, and is implicated in 25-70% of co-infections in hospitalized patients [18] .", [["Rhinovirus", "CHEMICAL", 0, 10], ["URTIs", "DISEASE", 43, 48], ["co-infections", "DISEASE", 81, 94], ["URTIs", "CANCER", 43, 48], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus", "PROBLEM", 0, 10], ["URTIs", "PROBLEM", 43, 48], ["co-infections", "PROBLEM", 81, 94], ["URTIs", "OBSERVATION", 43, 48]]], ["Therefore, further identification and typing of PIC is [1, 2, [4] [5] [6] [7] 18] , patients infected with the four most frequently detected viruses (FluA, ADV, PIC, HCoVs) presented with obvious symptoms of respiratory infection, including headache, sore throat, cough, runny nose, chills, and coryza.", [["respiratory", "ANATOMY", 208, 219], ["[1, 2, [4] [5] [6] [7] 18", "CHEMICAL", 55, 80], ["respiratory infection", "DISEASE", 208, 229], ["headache", "DISEASE", 241, 249], ["sore throat", "DISEASE", 251, 262], ["cough", "DISEASE", 264, 269], ["runny nose", "DISEASE", 271, 281], ["chills", "DISEASE", 283, 289], ["PIC", "CHEMICAL", 48, 51], ["PIC", "SIMPLE_CHEMICAL", 48, 51], ["[1, 2, [4] [5] [6] [7] 18", "SIMPLE_CHEMICAL", 55, 80], ["patients", "ORGANISM", 84, 92], ["FluA", "GENE_OR_GENE_PRODUCT", 150, 154], ["PIC", "GENE_OR_GENE_PRODUCT", 161, 164], ["nose", "ORGANISM_SUBDIVISION", 277, 281], ["patients", "SPECIES", 84, 92], ["ADV", "SPECIES", 156, 159], ["further identification", "TEST", 11, 33], ["PIC", "TEST", 48, 51], ["FluA", "TEST", 150, 154], ["PIC", "PROBLEM", 161, 164], ["obvious symptoms", "PROBLEM", 188, 204], ["respiratory infection", "PROBLEM", 208, 229], ["headache", "PROBLEM", 241, 249], ["sore throat", "PROBLEM", 251, 262], ["cough", "PROBLEM", 264, 269], ["runny nose", "PROBLEM", 271, 281], ["chills", "PROBLEM", 283, 289], ["coryza", "PROBLEM", 295, 301], ["infected", "OBSERVATION", 93, 101], ["viruses", "OBSERVATION", 141, 148], ["respiratory", "ANATOMY", 208, 219], ["infection", "OBSERVATION", 220, 229], ["sore throat", "ANATOMY", 251, 262], ["cough", "OBSERVATION", 264, 269], ["runny nose", "ANATOMY", 271, 281], ["chills", "OBSERVATION", 283, 289], ["coryza", "ANATOMY", 295, 301]]], ["Except for chills and diarrhoea (P.0.05), the clinical characteristics of ARTIs caused by these four viruses differed slightly.", [["chills", "DISEASE", 11, 17], ["diarrhoea", "DISEASE", 22, 31], ["ARTIs", "DISEASE", 74, 79], ["ARTIs", "CANCER", 74, 79], ["chills", "PROBLEM", 11, 17], ["diarrhoea", "PROBLEM", 22, 31], ["ARTIs", "PROBLEM", 74, 79], ["these four viruses", "PROBLEM", 90, 108], ["chills", "OBSERVATION", 11, 17], ["diarrhoea", "OBSERVATION", 22, 31], ["ARTIs", "OBSERVATION", 74, 79], ["viruses", "OBSERVATION", 101, 108]]], ["Headache was associated with PIC, ADV, and HCoV infection.", [["Headache", "DISEASE", 0, 8], ["ADV", "CHEMICAL", 34, 37], ["infection", "DISEASE", 48, 57], ["HCoV", "GENE_OR_GENE_PRODUCT", 43, 47], ["ADV", "SPECIES", 34, 37], ["HCoV", "SPECIES", 43, 47], ["Headache", "PROBLEM", 0, 8], ["PIC", "PROBLEM", 29, 32], ["ADV", "PROBLEM", 34, 37], ["HCoV infection", "PROBLEM", 43, 57], ["infection", "OBSERVATION", 48, 57]]], ["Cough was significantly more common in influenza patients; and sore throat, cough, rhinorrhoea, nasal symptoms were more common in those infected with PIC, which were in line with previous reports [2, 6, 18] .", [["sore throat", "ANATOMY", 63, 74], ["nasal", "ANATOMY", 96, 101], ["Cough", "DISEASE", 0, 5], ["influenza", "DISEASE", 39, 48], ["sore throat", "DISEASE", 63, 74], ["cough", "DISEASE", 76, 81], ["rhinorrhoea", "DISEASE", 83, 94], ["patients", "ORGANISM", 49, 57], ["throat", "ORGANISM_SUBDIVISION", 68, 74], ["nasal", "ORGANISM_SUBDIVISION", 96, 101], ["patients", "SPECIES", 49, 57], ["Cough", "PROBLEM", 0, 5], ["influenza", "PROBLEM", 39, 48], ["sore throat", "PROBLEM", 63, 74], ["cough", "PROBLEM", 76, 81], ["rhinorrhoea", "PROBLEM", 83, 94], ["nasal symptoms", "PROBLEM", 96, 110], ["PIC", "TREATMENT", 151, 154], ["influenza", "OBSERVATION", 39, 48], ["sore throat", "ANATOMY", 63, 74], ["nasal", "ANATOMY", 96, 101]]], ["Molecular assays are useful for diagnosis of RTIs, because it is often difficult even for the experienced clinician to pinpoint the aetiological agent based only on clinical information.", [["RTIs", "DISEASE", 45, 49], ["Molecular assays", "TEST", 0, 16], ["RTIs", "PROBLEM", 45, 49]]], ["Thus, etiological research may facilitate physicians' appropriate antibiotic use, and will provide useful information for surveillance and control of ARTIs [27] .DiscussionIn summary, we conducted a comprehensive analysis of the potential impact of 13 RVs in adults with ARTIs admitted to an ED in Beijing.", [["ARTIs", "DISEASE", 150, 155], ["ARTIs", "DISEASE", 271, 276], ["surveillance", "TEST", 122, 134], ["a comprehensive analysis", "TEST", 197, 221]]], ["Our study is original and unique in several aspects.", [["Our study", "TEST", 0, 9]]], ["First, to the best of our knowledge, it is the first use of sensitive, real-time RT-PCR assays targeting all four HCoVs and hMPV in adults with ARTIs in China.", [["hMPV", "DISEASE", 124, 128], ["ARTIs", "DISEASE", 144, 149], ["HCoVs", "GENE_OR_GENE_PRODUCT", 114, 119], ["hMPV", "ORGANISM", 124, 128], ["hMPV", "SPECIES", 124, 128], ["PCR assays", "TEST", 84, 94], ["hMPV", "PROBLEM", 124, 128], ["hMPV", "OBSERVATION", 124, 128], ["ARTIs", "OBSERVATION", 144, 149]]], ["Compared to the reports of Ren et al. [4, 5] regarding adult ARTIs which specimens collected from the same hospital (Table 4 ), the detection rates of several aetiological agents (hMPV, total HCoVs, HCoV-229E, and HCoV-HKU1) in this study were significantly higher (P,0.05,the data were compared between groups of specimens for virus detected using a Student's t-test), although the reasons for this require further investigation.", [["specimens", "ANATOMY", 73, 82], ["specimens", "ANATOMY", 314, 323], ["hMPV", "ORGANISM", 180, 184], ["HCoVs", "GENE_OR_GENE_PRODUCT", 192, 197], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 199, 208], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 214, 223], ["HCoV", "PROTEIN", 199, 203], ["HCoV", "PROTEIN", 214, 218], ["hMPV", "SPECIES", 180, 184], ["HCoV-229E", "SPECIES", 199, 208], ["adult ARTIs", "PROBLEM", 55, 66], ["the detection rates", "TEST", 128, 147], ["hMPV", "TEST", 180, 184], ["total HCoVs", "TEST", 186, 197], ["HCoV", "TEST", 199, 203], ["HCoV", "TEST", 214, 218], ["this study", "TEST", 228, 238], ["the data", "TEST", 273, 281], ["specimens", "TEST", 314, 323], ["virus", "PROBLEM", 328, 333], ["a Student's t-test", "TEST", 349, 367], ["further investigation", "TEST", 408, 429], ["ARTIs", "OBSERVATION", 61, 66]]], ["The second unique aspect of this study is the identification of four leading viral agents (PIC, FluA, ADV, and HCoVs) and associated clinical profiles in adults with ARTIs admitted to the ED.", [["ARTIs", "DISEASE", 166, 171], ["PIC", "GENE_OR_GENE_PRODUCT", 91, 94], ["FluA", "GENE_OR_GENE_PRODUCT", 96, 100], ["ADV", "GENE_OR_GENE_PRODUCT", 102, 105], ["HCoVs", "GENE_OR_GENE_PRODUCT", 111, 116], ["ADV", "SPECIES", 102, 105], ["this study", "TEST", 28, 38], ["viral agents", "TREATMENT", 77, 89], ["PIC", "TREATMENT", 91, 94], ["FluA", "TEST", 96, 100], ["ADV", "PROBLEM", 102, 105], ["viral agents", "OBSERVATION", 77, 89]]], ["To the best of our knowledge, this is the first report of the potential impact of four viruses (PIC, FluA, ADV, and HCoVs) as causes of ARTIs in adults admitted to an ED in China.", [["ARTIs", "DISEASE", 136, 141], ["PIC", "GENE_OR_GENE_PRODUCT", 96, 99], ["FluA", "GENE_OR_GENE_PRODUCT", 101, 105], ["ADV", "GENE_OR_GENE_PRODUCT", 107, 110], ["HCoVs", "GENE_OR_GENE_PRODUCT", 116, 121], ["ARTIs", "PATHOLOGICAL_FORMATION", 136, 141], ["ADV", "SPECIES", 107, 110], ["four viruses", "PROBLEM", 82, 94], ["PIC", "TREATMENT", 96, 99], ["FluA", "TEST", 101, 105], ["viruses", "OBSERVATION", 87, 94], ["ARTIs", "OBSERVATION", 136, 141]]], ["The main limitation of the study is that we did not evaluate other recently identified viruses (such as bocavirus, WU, and KI virus) or atypical aetiologies.", [["bocavirus", "GENE_OR_GENE_PRODUCT", 104, 113], ["KI virus", "ORGANISM", 123, 131], ["KI virus", "SPECIES", 123, 131], ["the study", "TEST", 23, 32], ["viruses", "PROBLEM", 87, 94], ["bocavirus, WU, and KI virus", "PROBLEM", 104, 131], ["atypical aetiologies", "PROBLEM", 136, 156], ["main", "OBSERVATION_MODIFIER", 4, 8], ["limitation", "OBSERVATION_MODIFIER", 9, 19], ["viruses", "OBSERVATION", 87, 94], ["atypical", "OBSERVATION_MODIFIER", 136, 144]]]]}